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Abstract 
In the last decades, the proportion of the tattooed population has been increasing all 
over the world, particularly in the young generations. Concerns about the possible health 
problems associated to tattoos and permanent make up (PMU) have also grown together 
with the number of tattoo/PMU applications and removals. 
The Council of Europe Resolution (CoE ResAP)(2008)1 [1], on requirements and criteria 
for the safety of tattoos and permanent make-up, is a non-binding internationally 
recognised benchmark that was taken as a reference for the development of national 
legislation adopted in a number of European countries. 
The European Commission launched the 18-month project "Tattoos - Permanent Make-
up" with the aim of collecting data about the use, the ingredients, the European Union 
(EU) market and the possible health problems associated to tattoo and permanent 
make-up inks.1 
This project is divided into 4 Work Packages: 1) preparatory work; 2) state of play; 3) 
assessment and update of the CoE ResAP(2008)1; 4) conclusions. The reports on Work 
Packages 1 and 2 [2, 3] are available at http://bookshop.europa.eu/. 
The present report is the outcome of Work Package 3 which aims to gather data about 
adverse health effects and complications linked to tattoo/PMU application and/or 
removal, risk perception and communication, data gaps and research needs, as well as 
to evaluate the lessons learned from the experience in implementing the 
recommendations of the CoE ResAP(2008)1. 
The information was collected through the following sources. (1) Two questionnaires 
were developed: one addressed to dermatologists on adverse health effects and the 
other one to national authorities on complications, experience with the CoE 
ResAP(2008)1, risk perception and communication, data gaps and research needs. They 
were sent to all EU Member States and European Free Trade Association (EFTA) 
countries and to 36 dermatologist associations in Europe with the request to circulate 
among their members. 14 Member States and 19 dermatologists filled-in the 
questionnaires. (2) A systematic review of the literature from 2003 on was carried out 
according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-
Analysis) methodology. (3) The outcome of the meetings of the Consumer Safety 
Network Subgroup Tattoos and Permanent Make-up was taken into account. 
The main findings show that: 
It is not possible to conclude on an exact incidence of adverse health effects following 
tattoo/PMU applications. The majority of tattoo/PMU recipients report minor short-term 
discomfort and complaints during the wound healing process following the tattoo 
application. This could be confused with other more serious complications and makes the 
accurate calculation difficult.  
Short term complications, such as skin infections, may appear some days after the 
tattoo placing, or within weeks, for allergic reactions. In the long run chronic 
inflammatory dermatoses may develop, sometimes after decades.  
The precise frequency of microbiological (mainly bacterial, more rarely viral) 
contamination through inks, tools or procedures used in the tattoo application remains 
unknown, though it has been generally estimated at up to 5% of the tattoo-recipients in 
the case of bacterial infections. 
                                           
1 Administrative Arrangement 33617 "Tattoos - Permanent Make-up", signed by the Directorate General Joint 
Research Centre (DG JRC), Unit I.1 Chemical Assessment and Testing, and the Directorate General Health and 
Consumers (DG SANCO), Unit B.3 Product and Service Safety, as from 1st January 2015 Directorate General 
Justice and Consumers (DG JUST), Unit E.3 Product and Service Safety. 
  
 
2
The vast majority of tattoo/PMU adverse reactions are due to delayed and unpredictable 
hypersensitivity, involving allergy and/or autoimmunity. Direct causal relationship 
between tattooing and (skin) cancer has been so far neither proved nor excluded. 
However, tattoos may blur and hence delay a melanoma diagnosis. They can also 
interfere with diagnosis imaging, and should be avoided in patients with prior cardiac, 
blood or autoimmune pathologies, inter alia. 
Similarly, also the process of tattoo removal is associated with side effects. The modern 
removal techniques, based on the use of Q-switched lasers, have improved the safety, 
efficiency and selectivity of the removal procedure, still side effects might occur, 
especially when incorrect parameters are applied to the laser device. The frequency of 
skin pigmentation disorders following laser therapy have been encountered in 5-15% of 
patients. 
Henna based preparations are not permanently injected in the skin and therefore they 
cannot be considered as tattoos. However, as the use of henna for temporary body 
decoration has become also widespread it has been included in this report for 
completeness. Henna has been used for centuries for body painting and it is generally 
well tolerated. When p-phenylendiamine (PPD) is added to make the painting darker, 
side effects due to sensitisation to PPD have been reported in the literature. 
The majority of the national authorities who replied to the questionnaire indicate that, in 
order to improve the safety of tattoo/PMU inks and practices, it would be necessary to 
update the list of recommendations in the CoE ResAP(2008)1. In particular, suggestions 
were put forward to include additional substances to the negative lists and to modify 
and/or introduce new limits. Other suggestions were to add new labelling requirements, 
such as the period of maximum durability after opening, to envisage the compilation of a 
register of complaints and to include information on the ink and tool sterilisation 
methods. Furthermore, several Member States pointed out the need to establish Good 
Manufacturing Practices for tattoo/PMU inks, to control products sold on-line, to establish 
compulsory training for tattooists, to enhance the collaboration among manufacturers 
and authorities and to ban backyard tattooing. 
Risk communication has been addressed by means of information campaigns targeted to 
various audiences and using a variety of means in nine Member States, out of the twelve 
who filled-in this section of the questionnaire. Beside this, national authorities generally 
agreed on the need to organise further actions to reach tattooists and potential clients, 
particularly adolescents, to give them the correct instruments to be able to take an 
informed decision. Actually risk perception is based on the information given by the 
tattooist (e.g. via an informed consent form), or received through parents or friends, or 
read in mass media and internet. In addition, some studies estimated the level of 
knowledge of possible health risks among students, either school or university ones. In 
general, infectious risks were better known that non-infectious ones, even though the 
level of knowledge was in many cases only superficial and, for example, not specifically 
linked to the transmittable agents of possible infections or to the various possible non-
infectious risks. These evidences support the need of further additional information 
campaigns. 
Data gaps and research needs were identified, such as development of guidelines for risk 
assessment of tattoo/PMU products, harmonised analytical methods, data on normal 
usage of and exposure to tattoo inks, including their characteristics (physical-chemical 
properties, chemical composition, ingredients' purity and concentration). In order to 
carry out a risk assessment of tattoo/PMU inks, data are missing on absorption, 
distribution, metabolism and excretion (ADME) of ingredients, including migration in the 
body of pigments and their (photo)-degradation products, DNEL (Derived No Effect 
Level), as well as chemical and toxicological properties of ingredients. Moreover, several 
authors considered that, although costly, prospective cohort studies should be conducted 
to investigate the association between tattoos and (skin) carcinogenesis. 
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1. Introduction  
The worldwide trend of increasing popularity for tattoos and Permanent Make-Up (PMU) 
applications among the total population has led to a parallel rise in health related 
complications [4-6]. Although a number of surveys, national reports and papers have 
become more and more available, a clear insight into the extent and frequency of 
adverse reactions remains difficult. 
In 2003, the Directorate General Joint Research Centre (DG JRC) of the European 
Commission (EC), on behalf of DG Health and Consumers (SANCO), prepared a 
document describing the state of play in terms of prevalence of tattooing and piercing 
practices in the European Union (EU), chemicals involved, review of health effects and 
risks and regulatory review, which included recommendations on the safety of tattoos, 
body piercing and related practices in the EU such as risk assessment on ingredients, the 
development of a negative/positive list of substances and the use appropriate labelling 
[7]. In the same year, the safety of tattoo/PMU inks and practices was addressed by the 
Council of Europe in a resolution (CoE ResAP(2003)2) [8], which included several 
requirements about the chemical composition of tattoo/PMU inks, the labelling and 
safety assessment of these products, as well as the hygiene and information necessities. 
In 2008, an updated version of the resolution was published [9]. Since 2003, a number 
of Member States and EFTA countries adopted legislations which use the 
recommendations in the CoE resolutions as reference. 
Since 2003, the state of play has changed significantly due to several factors, the most 
relevant being: the increasing prevalence of tattooed population; the new legislative 
framework in place; the enlargement of the EU; and the wider online availability of 
tattoo/PMU inks compared to 2003. Consequently, an updated evaluation of the situation 
related to the safety of tattoo/PMU inks and practices become needed. 
 
1.1. Tattoos and Permanent Make-up Project  
In April 2014, the Consumer Safety Network (CSN) Subgroup Tattoos and Permanent 
Make-up (CSN-STPM) was established by DG SANCO as a subgroup of the CSN. The first 
meeting of this subgroup was held on 23th June 2014 with representatives from 14 
EU/EFTA national authorities, tattooists, ink manufacturers, consumer groups, medical 
professionals, the Council of Europe, etc. At the end of September 2014, DG JRC was 
entrusted by DG SANCO with the project on "Tattoos - Permanent Make-up".  
The main goal of this 18-month project is to gather all the available information to 
describe the up-to-date situation and to understand what the current problems are, 
which their size is and how they can be addressed to improve the safety of tattoo/PMU 
inks and practices. This Work Package 3 focused on the collection of information 
regarding the adverse health effects linked to tattoo/PMU applications and removal, the 
experience gained by the European countries with the CoE ResAP(2008)1, the risk 
perception and communication and the data gaps and research needs. 
This project is divided into 4 Work Packages: 
1. Preparatory work: regulatory framework and analytical testing methods [2] 
2. State of play: current trends in tattoo practices, prevalence, data on inks market 
and composition of tattoo/PMU inks, post marketing surveillance [3] 
3. Assessment and update of the CoE ResAP(2008)1: including adverse health 
effects, lessons learned from the experience in implementing the 
recommendations of the CoE ResAP(2008)1, risk perception and communication, 
data gaps 
4. Conclusions. 
The results of Work Package 1 showed large differences in the regulatory framework 
across the Member States, together with a lack of harmonised analytical methods. Work 
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Package 2 concluded that around 12% of the European population has at least one 
tattoo and more than 20% in the United States. Regarding tattoo and PMU inks 
composition, colorants are the main ingredients, while additives, by-products and 
impurities are also present. According to market surveillance actions and studies carried 
out by the Member States, the CoE ResAP(2008)1 recommendations concerning e.g. 
primary aromatic amines, polycyclic aromatic hydrocarbons and metals are not always 
respected by the inks available on the European market. 
This report covers the results of Work Package 3, which include: 
• CSN-STPM meeting discussions 
• Adverse health effects linked to tattoo/PMU applications 
• Adverse health effects linked to tattoo removals 
• Adverse health effects linked to henna-based temporary tattoos 
• Experience with the CoE ResAP(2008)1 
• Risk perception and communication 
• Data gaps and research needs. 
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2. Methodology 
The data were gathered from various sources: 
1. the responses to two questionnaires sent to national authorities and 
dermatologist associations (Annexes II, III and IV); 
2. a literature review, performed according to the guidelines "Preferred Reporting 
Items for Systematic reviews and Meta-Analysis" (PRISMA) [10], which included 
also national reports (References chapter); 
3. and the discussions at the 9th November 2015 Consumer Safety Network 
Subgroup Tattoos and Permanent Make-up meeting (Annex I). 
 
2.1. Questionnaires 
Two different questionnaires were developed to collect information: one targeted 
specifically to dermatologists and the other one to competent authorities (see Annex II). 
Questions 
a) For dermatologists, the questions were focused only on health effects: 
o complications following a tattoo/PMU application or removal (including skin and 
systemic symptoms and their frequency and severity, proportion of people with 
previous skin diseases, including allergy, allergic skin reactions, other 
inflammatory reactions, cutaneous/regional/systemic infections and tumours); 
o correlations between health complications and certain tattoo 
characteristics/parameters (number of tattoos/patient, tattoo sizes, gender/age, 
colours, localisation). 
b) For competent authorities, the queries covered a wider range of topics: 
o health effects (frequency of different health issues amongst people having 
undertaken tattoos/PMU applications or removals and factors correlated to 
higher frequency of medical complications); 
o experience gained with the CoE ResAP(2008)1 (in terms of chemical, labelling, 
hygiene/sterility and other requirements); 
o risk communication and perception (information campaigns, information on risk 
perceived by the general public, signature of a prior informed consent); 
o data gaps identification (research or technical development to improve the 
safety of tattoo/PMU inks and practices). 
Distribution 
Both questionnaires were sent to the 28 EU Member States' plus the 4 EFTA countries' 
authorities (through the Consumer Safety Network by DG JUST). MS were invited to 
distribute the dermatologist questionnaire among dermatologist associations in their 
country, who had to further circulate it among their members. This dermatologist 
questionnaire was also sent by DG JRC to 31 dermatologist associations from 24 
countries, inviting them to share it with their members (Table 2.1). 
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Table 2.1: List of dermatologist associations involved in the survey. 
 
 
Responses 
a) Nineteen dermatologists from 6 countries replied on health effects (Annex IV): 4 BE, 
5 DE, 5 DK, 1 FI, 3 NL, 1 SE.  
 
b) 14 Member States completed the questionnaire developed for them (Annex III): BE, 
BG, CZ, DE, DK, ES, FI, FR, IT, NL, RO, SE, SI, SK. Replies from national authorities 
covered (Figure 2.1): 
o health effects: 6 answers (BE, ES, FI, FR, NL, SE) 
o CoE ResAP(2008)1: 12 replies (BE, CZ, DE, DK, ES, FI, FR, IT, NL, SE, SI, SK) 
o risk perception and communication: 12 answers (BE, CZ, DE, DK, ES, FI, FR, IT, 
NL, SE, SI, SK) 
o data gaps and research needs: 10 replies (CZ, DE, DK, ES, FR, IT, NL, SE, SI, 
SK). 
 
 
 
 
 
Country Dermatologists associations
AT Österreichischen Gesellschaft für Dermatologie und Venerologie 
BE Union Professionnelle de Dermatologie et Vénérologie Belge 
European Academy of Dermatology and Venerology (BE, CH offices)
BG Bulgarian Dermatological Society 
CH Schweizerische Gesellschaft für Dermatologie und Venerologie 
CY Cyprus Society of Dermatology and Venereology
CZ Czech Dermatovenereology Society 
DE Deutsche Dermatologische Gesellschaft 
European Society of Contact Dermatitis
DK Nordic Dermatology Association (DK, FI, SE)
EE Estonian Society for Dermatovenereologists 
FI Finnish Dermatological Society 
FR Société Française de Dermatologie 
HR Croatian Dermatovenereological Society of the Croatian Medical Society
HU Hungarian Dermatological Society 
IE Irish Association of Dermatologists 
IT Associazione Italiana Dermatologi Ambulatoriali
Associazione Dermatologi Ospedalieri Italiani
Associazione Italiana Dermatologia e Cosmetologia
Società Italiana di Laser in Dermatologia
LI Lithuanian Association of Dermatovenereologists
LT Association of Dermato-Venereologists of Latvia 
MT Maltese Society of Dermatology and Venereology
NL Nederlandse Vereniging voor Dermatologie en Venereologie 
PL Polish Society for Aesthetic Dermatologists 
Polish Dermatological Society 
PT Portuguese Society of Dermatology and Venereology
RO Societatea Romana de Dermatologie 
SE Swedish Society for Dermatology and Venereology 
UK British Association of Dermatologists
British Society for Medical Dermatology 
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Figure 2.1: Rate of MS responses to the questionnaire. 
 
Limitations impacting on conclusions 
Despite the large number of dermatologists reached by the questionnaire, the rate of 
responses was very low. Among the 19 dermatologists who replied, 15 reported less 
than 15 patients per year with tattoo complications and 4 up to 150. Similarly, only 6 
competent authorities filled-in the questionnaire section related to health effects, and 
among them just Belgium and The Netherlands reported on the individual complications. 
Relatively to health effects, these facts strongly limited the representativeness of the 
exercise and prevented the possibility to draw sound conclusions. For this reason, the 
chapter regarding adverse health effects is essentially based on the literature review. 
 
2.2. Literature 
The PRISMA approach [10] for the literature review was used. The overall objective was 
to collect the available relevant information on adverse health effects and risk perception 
linked to tattoos/PMU application/removal published after 2003, not included in the 
previous JRC report of the same year [11]. The literature search was conducted in 
PubMed and Scifinder data bases. 
The preliminary results were processed using the following exclusion/inclusion criteria: 
• years included 2004-2015; 
• key words present in abstract and title; 
• removal of duplicates; 
• filtering for relevance to health effects of tattoos, PMU or henna; 
• focus on more than one case studies. 
Search strategy 
The inclusion search criteria used a combination of the following keywords with tattoo(s) 
or tattooing: adverse health effects/reactions, (skin) allergy, (skin) infections, risks, 
diseases, safety, laser, epidemiology and toxicology. 
For permanent make-up, 42 references were found and combined with the same key 
words. On the resulting references, the exclusion criteria before 2004 and no patents 
lead to a final number of 5 articles.  
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For risk perception, tattoos were searched in combination with perception, attitudes, 
knowledge, experiences and awareness. A final number of 61 abstracts of publications 
were read to select 6 relevant articles for inclusion in the report. 
PRISMA flow diagram and final results 
The approach followed for adverse health effects is illustrated in Figure 2.2, where the 4 
steps of the flow diagram are represented (identification, screening, eligibility and 
inclusion). 
Following the identification of the articles using the above mentioned key words, the first 
screening excluded patents, publications before 2004, some languages (Japanese, 
Chinese, Polish and Russian) and documents classified as historical, dissertation, 
biography, commentary and conference.  
In the eligibility step the abstracts were reviewed, according the following relevance 
criteria: 1) reviews, recent books and national reports; 2) clinical trials and 3) other 
papers. The pertinence to the objective of the study was checked, and preference was 
given to studies reporting more than one case. 
The selected papers were read and used in the preparation of this report (see 
References).  
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4) Historical, dissertation, biography commentary, conference 
n = 1034 
 
 
Figure 2.2: PRISMA flowchart on adverse health effects of tattoos. 
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3. Work Package 3: Assessment and update of the CoE 
ResAP(2008)1 
A meeting of the CSN-STPM was held at the JRC in Ispra (Varese, Italy) on 9th November 
2015 to discuss the issues to be tackled in Work Package 3. 24 participants were 
present, representing 11 Member States, plus Switzerland, and a number of 
stakeholders, such as dermatologists, professors from academia, representatives from 
tattoo artists', ink manufacturers' and consumers' associations. 
The aim of the meeting was to share information and try to discuss conclusions and 
recommendations on the following topics: adverse health effects linked to tattoo/PMU 
applications and removal, experience with the CoE ResAP(2008)1 [9], risk perception 
and communication, data gaps and research needs. 
The discussion was preceded by a number of presentations on the above mentioned 
topics, as well as by an overview of the literature and replies to the questionnaires. 
The minutes, agenda and list of participants to this meeting are reported in Annex I. 
 
3.1. Adverse health effects linked to tattoo/PMU applications 
As the popularity of the body art phenomenon has been steadily increasing over the last 
decades, a wide range of medical side-effects of both tattoos and permanent make-up 
applications and removal are nowadays encountered by physicians, essentially 
dermatologists. 
These associated adverse reactions can be acute or chronic according to the delay after 
the tattoo/PMU application.  
At short term, accompanying the inevitable wound healing process that takes place 
already during the tattoo session, immediate complications may arise within days in the 
case of skin bacterial infection, or within weeks, for allergic reactions. 
In the long run we may assist, sometimes after years or decades, at persistent 
inflammatory reactions and delayed hypersensitivity with chronic dermatosis. (Skin) 
tumour development has been incriminated, but it has been neither proved nor 
excluded.  
There are different types of tattoos. According to the practitioner, they are classified as 
amateur or professional. Cosmetic tattoos, also known as PMU, are used to resemble 
make-up. Iatrogenic or medical tattoos are mainly carried out by physicians for 
diagnosis or therapeutic purposes. Finally traumatic tattoos may be provoked by 
accidents and explosions, where exogenous elements enter the human skin and colour it 
in an indelible way. 
The following findings take stock of the previous JRC reports published in 2003 [7, 11] 
and are mainly based on a literature research carried out from 2004 onwards. 
 
Frequency of secondary effects 
The real incidence of tattoo reactions is currently unknown, according to many authors, 
such as Kluger [12] or Desai [13]. 
To establish the true nature of these lesions, a biopsy is mandatory, because there is no 
clear-cut correspondence between clinical aspects and histopathological findings. From 
October 2008 to June 2015, Serup [14] diagnosed and treated 493 tattoo complications. 
In 292 tattoo reactions, histopathological findings show a predominance of inflammatory 
patterns (70%), followed by granulomatous reactions (21%, among which 7% of the 
sarcoidal-type). 
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Serup [15] distinguishes between on one hand "discomfort" or "complaints", which are 
mild by nature, experienced by 42% of tattooed individuals [16], and more severe 
reactions qualified as "complications" for which the patient would normally consult a 
physician.  
In a US study on 300 tattooed individuals [6], 10.3% (31 out of 300) reported adverse 
tattoo reactions; of which 13 (4.3% of total participants) were acute (pain, itching, 
swelling) and 18 (6%) lasted beyond 4 months. Høgsberg [17], analysing complaints 
from 154 Danish tattoo-recipients in 2013, found 15% of minor acute effects (redness, 
swelling, itching) within 3 months after tattooing, and 27% of symptoms (predominantly 
plaque elevation and itching related to sun exposure in the majority of cases, 58%) 
persisting beyond 3 months, mainly in black and red tattoos.  
According to the Klügl [18] survey performed over the Internet among German-speaking 
tattooed persons in 2010, 67% of the 3411 responders complained spontaneously over 
acute dermal symptoms (which could be merely inconveniences, in fact). This figure, is 
comparable to the 76% of bleeding complaints amongst tattoo-recipients, cited by 
Carney [19], but much higher than the incidence of acute minor symptoms signalled by 
many authors (see below). In Klügl's study, after one month persistent effects were 
mentioned by 9% of tattooed customers, 6% locally and 3% on a systemic level 
(dizziness, headache or nausea). Yet life-threatening situations remain exceptional. 
Overall, Klügl himself admitted the limitations of his study, as "people with health 
problems may be more willing to participate in such a survey" and Wenzel [20] 
challenged the reliability of these responses given without validation by a physician. 
Precise data on the extent and frequency of adverse reactions are not available so far. 
Probably because, in case of minor symptoms, tattoo recipients prefer rather return to 
their tattooist than consult a physician. Actually, only 1.6% of the Klügl study tattooed 
people showing health problems did so. As Kluger [12] put it "Dermatologists deal with 
two types of tattooed patients: most often those desiring tattoo removal and, more 
rarely, patients presenting with cutaneous reactions associated with tattoos". This is 
particularly true in the case of PMU applications, where the most common complications 
and patients' dissatisfaction result from "misapplication of the pigment, pigment 
migration, and pigment fanning" [21]. 
These psycho-social consequences, even though frequent, will not be further treated in 
the present document, neither will be the psychiatric impact of chronic pain and itching. 
On the contrary, the aftermath and sequels of tattoo removal are considered in chapter 
3.2. 
Categories of medical complications 
In addition to the minor inflammatory symptoms accompanying necessarily the tattooing 
act itself, adverse reactions to tattooing and PMU can be divided into two main 
categories according to the transmissible character of the adverse effects (infectious vs. 
non-infectious complications). The non-infectious reactions may be of allergic nature or 
not. Many authors, like Kaatz [22], use the words "coincidental diseases", regrouping 
both the underlying dermatoses reactivated or triggered by tattooing ("concomitant 
diseases" such as sarcoidosis, amongst other auto-immune pathologies), and tumours 
arising within a tattoo. 
Furthermore, tattoos may interfere in some cases with diagnosis, disrupt various 
imaging exams and hamper medical procedures and treatments. In addition, patients 
with specific clinical status or pre-existing pathologies should be warned against placing 
a tattoo. 
The relative frequencies of these various pathologies have been so far hardly estimated 
due to lack of epidemiologic studies. According to Serup's data on 405 sick tattooed 
patients treated in a specialised dermatologic clinic between October 2008 and June 
2015 [14], 12% of adverse reactions are of infectious nature (at local, regional or 
systemic level, induced mostly by bacteria), while the bulk of the non-infectious 
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reactions (the remaining 88%) consists mainly (65%) of inflammatory nature (allergic or 
not). It has to be noted that no skin cancer originating from a tattoo was observed 
among these 493 adverse reactions, even though 1 case of invading Basal Cell 
Carcinoma (BCC) from surrounding skin has been reported. Yet these figures have to be 
taken with caution, as details about the selection modalities of these patients are not 
available ("recruitment bias"), making their representativeness questionable. With that 
respect, it is remarkable that 14% of the complications listed are attributed to amateur 
tattooing (meaning tattoos performed by non-professional tattooist), 80% to 
professional tattooing and 2% to PMU. 
 
3.1.1. Acute aseptic inflammation 
As the tattoo procedure consists of the skin layers' breach, the needle prick trauma to 
vessels is inevitably associated with a superficial bleeding, which normally fades away 
within a week without any specific medical care. Individuals getting a tattoo experience 
immediate discomfort, swelling and erythema during the procedure and the days after, 
together with transient bleeding and lymphadenopathy. This acute inflammatory reaction 
of variable intensity remains in principle aseptic, unless cases of bacterial contamination. 
During the healing phase lasting 1 to 4 weeks, a superficial crusting and induration takes 
place in the tattooed area and patients may complain about pain, itching, blistering and 
burning sensation, like after sun exposure.  
Reactions such as itching, tenderness, pain or fluid discharge occur normally in all 
tattooed individuals, as they are inherent to the needle injury and the intradermal 
injection of foreign substances with subsequent histamine release, which may trigger a 
general flush. These so-called “complications” are part of the natural history of tattoos. 
Consequently, results of self-report questionnaires from tattooed individuals are difficult 
to interpret and statistics about their prevalence are highly variable, not only because of 
the methodological bias, but also due to the confusion, by the respondents, between real 
complications and symptoms that are almost always present during the wound healing 
phase. While the Klügl on-line survey [18] with 3411 responders mentioned figures of 
67%, other authors come with much lower complication rates calculated on smaller 
groups. 
Laumann [23] reported that 15 out of 120 tattooed people (12.5%) developed medical 
problems within two weeks after tattooing. 
Antoszewski [24] wrote that 31% of the 416 interviewed tattooed recipients experienced 
complications, including mainly pruritus (21.6%) and bleeding (7.7%). 
Hutton Carlsen [16] counted 60 tattooed persons out of 144 (42%) who expressed 
complaints (mainly swelling and itching), of which 31 (52%) sun-related, especially with 
black, red and blue tattoos. Symptoms may disappear immediately or last several 
weeks. Problems not related to sun exposure included "swelling after consumption of 
alcohol or tomatoes", "acne-like changes", tenderness, itching, etc. 
Høgsberg's 2013 study on 154 Danish tattoo recipients showed that 27% of them had 
chronic discomfort, especially in black and red tattoos, with itching and skin elevation as 
main symptoms.  
On a sample of 493 tattoo reactions, Serup's 2015 study [14] , reported the following 
prevalence for various symptoms according to patients' history (more than one symptom 
could be associated to one tattoo reaction): 80% swelling, 65% itching, 30% pain, 24% 
scaling, 20% redness, 19% wounds, 17% photosensitivity, 7% scar tissue and 2% 
thermal/alcohol/hash mechanic deterioration. 
The gradation of severity is also a matter of subjectivity and might vary from one 
individual to the other. In the abovementioned German internet survey of 2010 [25] the 
adverse effects have been described as "negligible" by 31.4% of the respondents 
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reporting complications, "slight" by 49.8%, "moderate” by 16.2%, “intense” by 2.1% 
and “very intense” by 0.6%. Differential evaluation of bleeding during tattooing might 
explain discrepancies in “slight bleeding" reported from 7.7% up to 76% of the tattooed 
individuals.  
The Klügl survey [25] showed slight more frequent skin reactions to coloured tattoos 
(83.%) than to black tattoos (80%), calculated on the total of replies that could be 
multiple. It has to be noted, however, that the majority of tattoos are black.  
Serup [26], reported also soft tissue lymph oedema, together with a pigmentation of the 
surrounding skin (pigment drift) and sometimes of regional lymph nodes. He further 
mentioned papular or nodular thickening and elevation in certain tattooed areas, as a 
result of ‘pigment overload’ with injection of too much ink. In addition he described 
tattoo-related pain in the segment of the radial nerve i.e. hand, fore-arm and arm [15]. 
Apart from these local symptoms, a systemic contact dermatitis with generalised rash 
can occur in in previously sensitised persons to, in particular, nickel and also to other 
metals or preservatives (e.g. parabens, methylisothiazolinone), if these substances are 
present as trace element and impurities. If limited to the tattooed area, this allergic 
reaction can be confounded with the wound healing process and also misdiagnosed as a 
bacterial infection. 
Generalised allergic reactions, e.g. to methylisothiazolinone, can also be induced by the 
use of local products (cleaning products, liquid soaps, body lotions for aftercare, etc.); 
the same is true for some topical antibiotics and antiseptics. 
 
3.1.2. Infectious risks 
The source of infection may be the tattooist, the instruments, the ink or the tattooed 
individual himself. Infections may occur if tattoo instruments are not properly sterilized 
and from tattoo inks microbiologically contaminated at manufacturing phase or after the 
opening of the bottle, due to deficient hygienic conditions and e.g. by diluting inks with 
non-sterile water. Infection can further take place during the healing phase of a tattoo. 
The risk of blood borne transmission is low in registered parlours respecting the hygiene 
requirements. Fungal or parasitic contaminations have only been reported in historical or 
exotic cases. 
By applying standard hygiene measures for both instruments and inks, professional 
tattooists and established PMU providers can minimize the risk of infections. 
Various studies were carried out on sealed tattoo/PMU inks to evaluate the 
microbiological contamination. Høgsberg [27] analysed 58 samples and found an ink 
contamination rate of 10%, Health Canada [28] 20% (3/15), Kaatz [22] 37% (3/8) and 
Bäumgartner [29] 44% (17/39). 
 
3.1.2.1. Bacterial infections 
Skin infections in the form of papulo-pustules provoked usually by pyogenic strains, such 
as staphylococcus aureus or streptococcus, may appear quickly within the first few days 
after the tattoo procedure. Both acute superficial pyogenic infections, such as folliculitis, 
impetigo or ecthyma, and deep regional pyogenic infections, like furunculosis, erysipelas 
and cellulitis of the entire limb, are seldom [12], while systemic involvement and life-
threatening outcome (by gangrene, osteomyelitis, epidural abscesses, septicaemia, toxic 
shock syndrome, etc.) remains exceptional under correct hygienic circumstances. 
Infective endocarditis has been mostly documented in patients getting extensive and 
repeated tattoos [30]. As a preventive measure every customer suffering of heart 
valvular diseases should be refrained from undergoing a tattoo procedure without a prior 
antibiotic prophylaxis, because of the potential risk of bacterial endocarditis [31].  
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Cutaneous superficial infections have been scarcely described by the medical literature, 
but the number of publications has increased in recent years, probably due to better 
clinical identification or improvements in mycobacterial testing. In his review Wenzel  
[20] considered 122 publications which included 280 patients. The published cases were 
classified into the following three categories: 1) granulomatous, lichenoid or 
hypersensitivity allergic reactions; 2) infections; 3) tumours, which represented 34.3%, 
53.9% and 11.8% of cases, respectively.  
Yet the real frequency of cutaneous infections remains difficult to estimate [32], as in 
minor cases the patients go rather to see their tattooist than a physician and this is not 
recorded in medical statistics. Laux [33], estimates the rate of bacterial infections at 1-
5% of the tattoo-recipients. Klügl's survey [18] indicated that 0.5% of tattoo 
respondents had pus-filled skin areas, especially at extremities. Bacterial contamination 
is clearly influenced by the hygienic conditions of the tattoo shop equipment and tools, 
and by the ink sterility. Tattoos performed in dubious hygienic settings by inexperienced 
amateurs with poor instrumentation and inks of unknown origin or composition, present 
obviously more risks than procedures carried out by trained professionals in licensed 
tattoo parlours, or aesthetician shops in the case of PMU, for which bacterial infections 
are rare [34].  
According to some authors, these enhanced disinfection measures might have facilitated 
in the last years the development of commensal (coli bacteria) and opportunistic germs, 
such as pseudomonas or Non Tuberculosis Mycobacteriae (NTM). These pathogenic 
bacteria could be either present in unopened tattoo ink bottles [35] or in unsterile tap 
water used to dilute black inks in order to obtain different grey shades [36, 37]. 
Incubation of NTM infections after tattooing varies from 3 days to 1 month, with the 
development of unspecific itchy erythematous papulo-nodules, pustules or lichenoid 
plaques on the grey lines of the tattoo. The responsible pathogens of these suppurated 
(or tuberculoid) granulomatous patterns (sometimes pseudoepitheliomatous hyperplasia-
like, see below) are usually Mycobacterium chelonae or Mycobacterium abscessus. 
Special concern has also been expressed for emerging outbreaks of Community 
Acquired-Methicillin-Resistant Staphylococcus Aureus (CA-MRSA), essentially by nose 
secretions of asymptomatic carriers, who could be as numerous as 50% of the 
individuals in some US communities, whilst in Germany they account for some 20% of 
the population [38] . Since grey colour of tattoos is often involved, the influence of 
diluting tap water has been evoked as well [20] 
The CDC reported the outbreaks of CA-MRSA in the states of Kentucky, Ohio, and 
Vermont [39]. These outbreaks were traced back to unlicensed tattooists operating in 
unsanitary facilities. 
Quality control measures ensuring sterile inks are hence clearly needed, together with 
more stringent hygiene practices in tattoo parlours. However as Conaglen [36] noted, 
"Any such interventions must balance the benefits of stricter controls with the risks of 
alienating the tattoo industry or increasing tattoo prices as these, in turn, could increase 
the prevalence of illegal tattooing with potentially grave public health consequences". 
Last but not least, linked to the increased use of topical antibiotics for mild infections 
following a tattoo, there is the theoretical risk of germs developing resistance against 
some antibiotics. 
 
3.1.2.2. Viral infections 
Isolated cases of viral warts caused by the human papilloma virus (HPV) or molluscum 
contagiosum (MCV) transmitted during the tattoo process or due to the presence of HPV 
in the tattoo ink have been observed [20] after an incubation period of 2 weeks to 10 
years, but these events rarely take place within professional settings.  
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The fact that these verrucae are sometimes restricted to one tattoo ink colour, namely 
black, and that they might appear from 1 month to 10 years after the tattoo procedure 
have lead Kluger [40] to consider these viral reactions as a Köbner phenomenon (see 
below the section on coincidental diseases) on pre-existing skin lesions. UV exposure 
and sunburn 2.5 years after tattooing can represent another latent HPV triggering factor 
[41]. 
Blood-borne viruses of Hepatitis B (HBV) or C (HCV) may provoke serious systemic 
pathologies, such as hepatic failure, and several authors investigated the association 
among hepatitis and tattooing with conflicting findings. 
Tohme [42] considered that there is no increased incidence of hepatitis C from tattooing 
in low-risk adults when sterile equipment is used. Mataix [43] mentioned that the HCV 
risk factor from tattooing is epidemiologically statistically irrelevant. Other authors 
mainly attributed the risk of getting hepatitis B or C to an inadequate hygienic 
environment [13, 32, 44] and Kluger [32] referred to home (or prison-) made tattoos, 
as well as to tattoos performed in unregulated settings as source of risks.  
Analysing data from the Italian Surveillance System (SEIEVA) for acute viral hepatitis in 
the period 1997-2002, Mariano [45] suggested that tattooing plays a causal role in the 
transmission of acute hepatitis C (adjusted OR = 5.6, 95% CI 2.8 – 11.0). Tattooing was 
also associated to hepatitis B (adjusted OR = 1.7, 95% CI 1.0 – 3.1;). This study, 
however, did not indicate where the tattooing procedure had taken place (professional 
shops vs. home tattooing). 
Carney [19] carried out a survey on 3871 patients, 1930 of which with chronic HCV 
infection. Tattooing resulted being associated with HCV infection (OR = 3.81, 95% CI 
3.23 – 4.49). The same was true on a smaller sample of patients (1886, of which 465 
HCV-positive patients) without traditional risk factors, such as drug injection and blood 
transfusion prior to 1992 (OR = 5.71, 95% CI 3.75 – 7.11). 
Urbanus [46] performed a study on 434 individuals with multiple tattoos and/or 
piercings in The Netherlands, excluding possible confounding factors such as present or 
past drug users and men who have sex with men. There was neither a correlation with 
the number of tattoos, nor with the body surface area covered by tattoos. He concluded 
that "in low HBV/HCV-endemic countries where strict hygiene guidelines for tattoo and 
piercing practices have been implemented, like in the Netherlands, tattoo and piercing 
practices are not associated with HBV/HCV infection". The Dutch experience over the last 
years, reflected his paper, shows that a correct sterilisation of tattoo material and 
enforcement of robust hygiene guidelines by tattoo professionals in controlled premises 
prevents effectively virus transmission during the tattoo application. Exchange of good 
practices on this topic between the different countries is crucial for the eradication of 
blood-borne contamination. 
In 2012 and 2010, Jafari [47, 48] published two systematic literature reviews and 
meta-analyses that evidenced a statistically significant association between tattooing 
and risk of transmission of hepatitis B and C, respectively (hepatitis B, odd ratio (OR) = 
1.48, 95% confidence interval (CI) 1.30 – 1.68; hepatitis C, OR = 2.74, 95% CI 2.38 – 
3.15). Higher odd ratios were calculated in the case of high risk behaviour groups. In 
addition, results suggested a stronger association between tattoos made in non-
professional parlours and hepatitis C (pooled OR 2.80 based on 4 studies) compared to 
those made in professional studios (pooled OR 1.28 based on 4 studies). He also 
estimated that, in countries with tattoo prevalence of 8% in the general population, 6% 
of the hepatitis C infections are related to tattooing, and that risk increases with the 
number of tattoos and surface area of the tattoo.  
Serup [26] considered that the threat of HBV/HCV transmission through tattooing is 
overlooked since hepatic failure may take decennia to develop. 
Recent epidemiologic unpublished SEIEVA findings (2010-2014) showed strong 
association between placing a tattoo and acute B- or C-hepatitis, without proving a 
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formal causality between the two events, in the age group of 15 to 54 years old. 
Subjects who had placed a tattoo in the last 6 months had a significant and almost 
double risk of acute B- or C-hepatitis as compared to subjects without a tattoo (B, 
adjusted OR=2.1, CI at 95% 1.4-3.1; C, OR=2.2 with CI at 95% 1.1-4.4). Klügl [25] 
calculated a post-tattoo hepato-seroconversion rate of 0.6% against the total number of 
tattooed people showing any kind of adverse reaction. 
As far as other viruses are concerned, Kluger [32] could only find one documented case 
of a herpes rash within a tattoo 3 days after the application. However, it was not proved 
that the cause was direct contamination and it has to be noted that latent herpes 
simplex and herpes zoster infections are known to be also reactivated through the 
tattooing procedure [22]. 
In his review, Kluger [32] also reported one possible case of AIDS contamination 
concerning 2 men who in 1988 received tattoos in prison with unsterilized needles used 
previously for other inmates. The risk remains thus theoretical, also because 
transmission of the HIV virus needs a massive and prolonged body fluid contact, which is 
unlikely to happen during a standard tattooing session, in contrast to HBV/HCV viruses, 
which require only a small inoculum to infect a person.  
 
3.1.3. Non-Infectious risks 
These types of complications comprise the allergic/hypersensitivity reactions and the 
coincidental diseases, who are both unpredictable and may occur years after the tattoo 
application. These coincidental pathologies may be further subdivided into concomitant 
underlying dermatoses, reactivated or triggered by tattooing, and cutaneous tumours 
developing within a tattoo.  
 
3.1.3.1. Allergic reactions 
The medical literature mentions hypersensitivity as the most common reaction to tattoos 
and PMU inks. These allergic manifestations are predominantly linked to coloured 
tattoos, and more specifically to red inks, in particular for lichenoid reactions (see 
below). Allergic reactions to black tattoo pigment are also rarely reported [49]. 
Older reports mentioned allergy to metals such as mercury sulphide (red pigment, 
cinnabar), chromium (green), cobalt (blue), cadmium (yellow) or magnesium (purple), 
but this view may have become partly obsolete, as nowadays inks are largely based on 
organic pigments and have eliminated some of these metals, except as impurities [49]. 
Nevertheless, metals such as chromium, cobalt and nickel are still present not only as 
impurities; some heavy metals, e.g. copper and titanium, are present as nanoparticles; 
and iron oxides are present in many PMU colours (such as in red, brown, pink and black 
inks (causing problems with Magnetic Resonance Imaging exams). As seen earlier, nickel 
contamination can, in already sensitive individuals, trigger a widespread rash the first 
days after the tattoo/PMU placement. Preservatives such as parabens can induce the 
same generalised eczema, sometimes after 8 weeks [14]. 
Notwithstanding this shift from metal salts towards organic dyes and pigments, allergic 
reactions are still more frequent with red tattoos, possibly due to primary aromatic 
amines (PAA)-containing azodyes. Modern inks' composition is highly variable, even 
among similar-coloured pigments, in addition to organic substances they may often 
contain, compounds or elements such as cadmium selenide, ferric hydrate, aluminium, 
titanium, carbon, barium, copper and strontium. Titanium oxide are one of the least 
reactive white pigments with no described allergic reaction [50]. A recent Danish study 
[51] found nickel, as a trace element or in higher amounts, on all the 61 tattoo inks 
analysed. Allergies to green and light-blue pigments are less common, often related to 
chromium, aluminium or chloride cobalt additives [50]. However, even though 
granulomatous reactions to chromium, mercury, cobalt, and magnesium have been 
  
 
16
described, Serup [26] points out that apparently tattooing is not a clinically important 
allergy inducer to nickel and chromium VI, despite the presence of nickel in almost all 
tattoo inks, considering unlikely that allergy to nickel can explain chronic tattoo 
reactions, usually developing after months or years. 
The difficulty to identify the culprit allergy-eliciting ink constituent is related, on the one 
hand, to the widely unknown composition of these low-purity industrial products and, on 
the other hand, to the often negative outcome of epi-cutaneous patch tests, especially 
with the granulomatous and lichenoid types of reactions. In the period 2009 – 2013, 
Serup [52] performed patch tests on 90 patients with non-infectious chronic tattoo 
reactions, whose results were negative. He suggested that chronic sensitisation is not 
elicited by an allergen directly present in the tattoo ink, but rather through metabolites 
produced in months or years probably due to haptenisation, i.e. the intra-dermis 
formation of a hapten, possibly helped by external factors such as light exposure. This 
slow haptenisation hypothesis and the possible pigment degradation, forming for 
example primary aromatic amines through photochemical cleavage of azo pigments 
upon sunlight exposure, could also explain why the results of patch tests were also 
negative in patients who had experienced concomitant reactions in another hitherto 
tolerated tattoo of the same colour as the reacting one. In its 2012 survey, [51] the 
Danish Environmental Protection Agency, sustained that "Complex allergic reactions in 
the body mediated by tattooing in the form of widespread reactions in the vascular 
system, vasculitis, and in the form of iritis in the eye, also after tattooing, can be 
induced through an allergic reaction by a pigment protein complex and allergic reactions 
to tattoo colours are not obligatory limited to a simple chemical substance as mediator". 
The onset of the inflammation is unpredictable, and can happen from immediately after 
tattooing up to 45 years later [53]. The duration is equally unpredictable, as the 
hypersensitivity reaction may last for ever. 
Clinical aspect is non-specific, ranging from isolated pruritus to pseudo-tumoral wart 
[53]. Symptoms, which may disappear spontaneously or after decades, include itchy 
papulo-nodules, tenderness, swelling and induration. Papulo-nodular forms are especially 
noted with black tattoos and black linings. Ulceration, necrosis and hyperkeratosis are 
primarily encountered in red tattoos or red nuances [26]. Plaque elevation is typically 
seen in red, occasionally in blue/green [26].  
The development of allergy to latex proteins originating from the tattooist’s gloves and 
introduced into the skin via the needle has been reported [26]. Serious complication 
may arise, with a risk of life-threatening anaphylaxis upon further exposure to latex. 
Sensitised persons can immediately elicit anaphylactic shock when they get into contact 
with latex particles either by a new tattooing session or by another direct contact with 
latex containing articles. Latex particles from the tattooist’s gloves can also provoke 
delayed type allergy causing hand eczema affecting the tattooist. 
The histopathological findings refer traditionally to "lichenoid, granulomatous, or 
pseudolymphomatous" patterns, but these labels are imprecise, may overlap in the same 
biopsy without strict correlation to a clear clinical image, and should not be applied to 
distinguish various tattoo reactions. Consequently authors often opt for a histological 
pattern (e.g. ‘granulomatous type IV inflammation’) without specifying a clinical 
diagnosis [20]. The following manifestations are hence not specific, and attempt to 
classify them reveals challenging. 
 Acute or chronic eczematous dermatitis presents usually as an itchy and 
scaly erythema in sensitized patients following any topical application during the 
healing phase, e.g. antibiotics, disinfectants, or by contact with gloves' latex, etc. 
The papulovesicular rash is typically localized at the tattoo site, but can 
secondarily spread as an urticarius to the whole body. These hypersensitivity 
reactions involve predominantly red pigments though black pigments also might 
be involved sometimes. Generalised erythema multiforme after localised allergic 
dermatitis from dark henna tattoo has been described [54]. 
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Paraphenylenediamine has been designated as the contact dermatitis-triggering 
substance in "black henna" temporary tattoos [13].  
 
 Photosensitivity following sun exposure affects, preferentially on light-exposed 
parts like face and hands, about 20% of tattoo recipients [55]. Høgsberg reported 
symptoms from acute swelling and itching to chronic nodulo-papules, lasting for 
months in 16% of the 154 tattooed Danes interviewed. 
Hutton Carlsen [16] performed a survey on 144 tattooed sunbathers, of which 
21.5% experienced complaints linked to sun exposure. The major symptoms 
were swelling, itching/stinging/pain and redness. Photosensitivity was reported by 
20/133 recipients bearing black tattoos, 14/45 for red, 1/8 for pink, 1/9 for 
orange, 1/5 for purple, 7/25 for blue, 2/31 for green, 1/10 for white and 4/25 for 
yellow tattoos (multiple replies were allowed). Black tattoos were responsible for 
the larger number of complaints, but in percentage (versus the number of tattoos 
of that colour) red tattoos were predominant. The onset may vary from few 
second to the following day lasting from minutes up to several weeks. The 
authors suggested that the formation of reactive oxygen species (ROS) in tattoos 
exposed to sunlight could cause symptoms with pain, discomfort and itching as 
well as signs, primarily manifested as redness and swelling. 
Some pigments (e.g. phthalocyanines) contained in the tattoo inks can act as 
photosensitizers [18]. Some purple pigments are photoreactive and lose their 
colour after prolonged exposure to light, but it remains to be confirmed whether 
manganese may cause granulomatous allergic reactions in some purple tattoos 
[50]. Rare cases of light-induced reactions resembling discoid lupus 
erythematosus have been associated with pigments contained in red inks [33]. 
 
 Lichenoid (papules or plaques) and granulomatous (firm indurated nodules) 
pruritic lesions are generally confined to the red portion of the tattooed area. The 
lichenoid type is the most frequently reported pattern [56], and can sometimes 
generalise [57]. It is historically linked with mercuric sulphide (cinnabar) used in 
red inks, but modern organic pigments, and Lawsonia inermis extracts of 
temporary henna tattoos have also been implicated [49].  
Kaatz wrote that the majority of the granulomatous inflammations are of foreign 
body type, but an allergic origin, like in the lichenoid forms, is also possible [22]. 
Allergy reactions of the granulomatous type, with eczema and inflammation, are 
probably related to aluminium, present in almost all tattoo inks. However it is still 
unclear if these reactions are purely allergic or involve an immunotoxic 
component, as aluminium-induced granulomas may be linked to sarcoidotic lung 
pathologies (see below) in predisposed individuals [51]. 
Greens and blues made of copper pthalocyanine pigments are more stable than 
those containing cobalt or chromium pigments, and as such least likely to elicit 
allergy [50]. Setlur [58] reported the death of a patient from desquamative 
interstitial pneumonia upon foreign body reaction to his tattoo. Sweeney [59] 
cited a case of uveitis occurring simultaneously with a skin reaction possibly 
secondary to cobalt-containing tattoo pigments. 
Less commonly, these granulomatous reactions present sarcoidal type (especially 
associated with iron oxides and blue pigments). Both forms, lichenoid and 
granulomatous, may coexist in the same patient [60]. Serup [14] does not 
consider as allergic the papulo-nodular skin deposits of black pigment, but as a 
common foreign-body encapsulation phenomenon, which at histology manifests 
as sarcoidal type granuloma, evoking rather a systemic reaction pattern. Setlur 
[58] cited the case of a patient with a known sensitivity to metallic jewellery, who 
developed a sarcoidal granuloma in black pigment only, despite the presence of 
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turquoise colour that was also part of the tattoo but uninvolved by the 
granulomatous reaction.  
Some granulomatous/lichenoid reactions may be confused clinically and 
histologically with sarcoidal or lichen planus manifestations (both hypertrophic 
and atrophic forms), and in some cases constitute an early manifestation of these 
systemic underlying pathologies (see below). The same holds true for lupus-like 
lichenoid patterns, potentially associated to the systemic lupus erythematosus.  
According to both Simunovic and Wood, granuloma annulare- and necrobiosis 
lipoidica-like reactions are rare [57, 61]. Tuberculoid granulomatous reactions to 
ferric oxide and chromium salts used in eyebrow permanent make up may mimic 
inoculation diseases such as cutaneous tuberculosis or leprosy [49], which have 
virtually disappeared among Western non immunosuppressed citizens.  
 
 Lymphomatoid reddish indurated nodulo-papules and plaques, sometimes 
pruritic, and much similar to cutaneous lymphomas at clinical and histologic 
examination, though without malignant evolution in the vast majority of cases 
(80-90% of reported cases [62]), have been rarely described, mainly within the 
red parts of the tattoos (79% of the 19 cases listed by Marchesi [62]), but also 
associated with blue, green and black pigments. The incubation period varies 
from a few weeks to 42 years. Pseudolymphomatous infiltrates, which are 
thought to be a delayed reaction to chronic antigen stimulation-albeit without 
conclusive patch-test, are not always confined to the tattooed area. A case of 
malignant transformation of a long-standing pseudolymphomatous tattoo reaction 
into a cutaneous lymphoma has been reported [57]. 
 
 Pseudoepitheliomatous hyperplasia (PEH) appears rarely as verrucous 
nodules or plaques, within weeks or months after tattooing. They are difficult to 
distinguish from tumours, hence skin biopsy is advisable, as they can also be 
linked to various infections [13].  
The end stage of these chronic inflammatory tattoo reactions, if untreated, may take the 
clinical aspect of fibrosis, with scarring or even keloid formation, in what has been 
described as sclerodermatous or morphea-like pathologies, to be distinguished from the 
isomorphic phenomenon (see next paragraph) arising in patients prone to connective 
tissue diseases [57]. Thum Chee [49], cited 2 cases of pruritic morphea-like tattoo 
reaction developing in indurated multi-coloured tattoo (one of them restricted to the red 
area of the tattoo), without any systemic of scleroderma or morphea. Even though prior 
trauma (like vaccination) has been evoked in morphea etiopathogenesis, Thum Chee 
considered that the link between tattooing and morphea/scleroderma had not yet been 
demonstrated. Post-tattoo ocular involvement has also been reported by Ostheimer [63] 
(bilateral uveitis in all 7 patients with elevated and indurated black tattoos on various 
locations, e.g. arms, chest and abdomen), and by Kaatz [22] (concomitant retinal 
vasculitis and cystoid macular oedema). 
 
3.1.3.2. Underlying Dermatoses reactivated by tattooing 
"Coincidental diseases", regroup both the underlying dermatoses 
triggered/reactivated by tattooing ("concomitant diseases" such as sarcoidosis and other 
auto-immune pathologies), and tumours arising incidentally within a tattoo. 
The isomorphic phenomenon has been originally reported by Köbner in 1872, who 
described a psoriasis-like eruption developing within a tattoo of a psoriatic patient, and 
may occur between 1 week and decades after the skin trauma (typically within 10-20 
days). This flaring of known skin disease into the tattoo through "Köbnerisation", 
sometimes decades after tattoo application, is relatively frequent, especially in 
immunodepressed patients, but does not adhere to strict rules. This isomorphic response 
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may concern, further to psoriasis, various other chronic dermatoses such as lichen 
planus/sclerosus, cutaneous lupus erythematosus, atopic dermatitis, sarcoidosis, 
pyoderma gangrenosum, vitiligo, and cutaneous vasculitis.  
Though these severe reactions are poorly understood [14], tattoo putative clients known 
to suffer from such chronic pathologies should be warned against tattooing, which might 
precipitate their underlying disease. Furthermore, tattooing might reactivate latent 
herpes infections. 
The influence of tattooing on sarcoidosis, an autoimmune disease affecting 10 to 20 
per 100000 persons (irrespectively if they are tattooed or not) [64], is a matter of a 
controversy [22], and remains as enigmatic as the etiology and pathogenesis of the 
disease itself [65]. This author is convinced that immunosensitivity towards specific 
tattoo pigments plays a role, especially in patients treated with interferon (four of such 
sarcoidal reactions have been reported by Simunovic [57]. Sarcoidosis has been labelled 
as one of the great dermatologic masqueraders. Ethnic susceptibility, together with 
environmental factors, have been suggested by Selim [66], as contributors to the 
etiology of the disease. He considered a challenge the correct diagnosis of sarcoidosis as 
its clinical presentation varies greatly. 
Sarcoid reactions have been noticed on old scars, skin traumas sites and around 
embedded foreign material, including decorative and cosmetic tattoos. However, 
sarcoidosis belongs to category IV (poor or questionable trauma-induced processes), 
according to the Boyd-Nelder classification of the Köbner phenomenon. Granulomatous 
skin reaction, even of the non sarcoidal type, may reveal the systemic sarcoidosis in 25-
30% of latent patients. This may happen from some weeks after the trauma, up to 45 
years later. Quoting Kluger [64], "The tattoo is most likely the target of sarcoidosis, 
rather than its cause".  
Lesions consist mainly of asymptomatic, itchy or sometimes tender papules, nodules, 
plaques or infiltrations on the tattoos, with sometimes scaling, ulcers or blisters. 
Reviewing literature for sarcoidotic skin reaction to tattoos/PMU, Kluger [64] found 59 
cases of sarcoidosis on tattoos, 8 on PMU and 8 cases of association of granulomatous 
tattoo reaction and uveitis. The cases with lesions confined to the tattooed area were 
twice as numerous as those where the nodules were present outside the tattoo, on other 
scars, or elsewhere on the skin. Moreover, a large male predominance was observed.. 
Granulomatous reaction to tattoos, even of the not sarcoidal pattern, may reveal or 
complicate systemic sarcoidosis. Cases of skin sarcoidosis restricted to one color of the 
tattoo might be sarcoidal hypersensitivity reaction to the tattoo pigment or the first and 
often unique symptom of a systemic sarcoidosis microscopically difficult to distinguish 
from foreign-body granuloma. Red and black tattoos were most often affected, but other 
colours (blue-in particular in case of systemic involvement, green and brown) were also 
reported. In the majority of patients with multi-coloured tattoos, skin reaction was 
confined to a single tattoo pigment, but several colours were simultaneously involved 
amongst 40% of cases. 84% of patients with multiple tattoos had more than one tattoos 
affected as well. Systemic involvement, defined as extra cutaneous manifestations of 
sarcoidosis, was found in 70% of cases, of which 69% had involvement of mediastinal 
lymph nodes and 46% parenchymal sarcoidosis. As there was no follow-up in most of 
the published cases, it is unknown whether the remaining 30% had developed systemic 
manifestations in the following years [64]. Lo Schiavo [67], estimated the rate of later 
generalisation of cutaneous sarcoidosis in a tattoo site at 74% of patients.  
Thum Chee [49], mentions the development of psoriatic arthritis within a week of 
appearance of skin lesions. Generalized flare-up has been observed after tattooing, but a 
true link remains uncertain [12]. 
It is challenging to determine if a lichenoid eruption following a tattoo represents a 
generalized lichenoid tattoo reaction or a true lichen planus. Other anecdotal cases of 
lichen sclerosus and atrophicus, perforating granuloma annulare (commonly with red 
pigments), perforating collagenosis occurring in red tattoos, Darier’s disease (genetic 
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Keratosis follicularis), erythema multiforme and scleroderma-like reaction restricted to 
the red parts of a tattoo have also been reported [12, 57, 61]. 
Thum Chee [49] reported a case of skin lupus erythematosus lesions developing 3 
weeks after a black tattoo, and progressing beyond the tattooed areas. The term 
“cutaneous lupus erythematosus–like tattoo reaction” has been used for vacuolar 
interface dermatitis and perivascular inflammation involving an old tattoo in a patient 
lacking signs of systemic lupus erythematosus. Several cases of discoid lupus 
erythematosus–like lesions have been reported to occur in patients with systemic lupus 
erythematosus, on the red areas of the tattoo, sometimes 15 years after [12, 22, 43, 
49].  
Reviewing literature Thum Chee [49], reported only 4 cases of cutaneous vasculitis 
complicating a tattoo between 10 days to 28 years after the procedure, one of them on 
the red part of a tattoo (cited by Setlur [58]). Lesions appeared first on the tattoo and 
then extended further on the non-tattooed skin. As mentioned by Kluger [32], the role of 
ink in the pathogenesis of vasculitis is difficult to prove.  
Pyoderma Gangrenosum (PG) is a rare complication of tattooing, particularly on the 
lower extremities, and has been described in only two patients, one of whom had an 
underlying blood cancer [57]. PG-like ulcers might be also elicited by bacterial infections. 
A less commonly form, morphea, has also been described [44]. 
 
3.1.3.3. Tumours 
The potential carcinogenic effects of tattoo inks remain unclear, both at skin and 
systemic levels. The tattoo inks injected in the dermis contain several chemicals, such as 
pigments, additives, plus impurities and degradation products, some with intrinsic 
carcinogenic properties (like polycyclic aromatic hydrocarbons and aromatic amines). 
Nevertheless, the causal link between the tattooing procedure and neoplasm formation 
has so far neither been established nor excluded due, on one hand, to the long latency 
of carcinogenesis and, on the other hand, to its multifactorial character.  
Some theories suspect that trauma, scars or cutaneous chronic reaction to foreign 
material may elicit the development of tattoo-related skin tumours [59]. 
Kluger [68] extensively reviewed the literature over the 40 last years, and found only 50 
cases of cutaneous tumours on tattoos: 23 cases of squamous-cell carcinoma (SCC) and 
keratoacanthoma (the distinction is often challenging), 11 cases of basal-cell carcinoma 
(BCC), and 16 cases of melanoma. Compared to the dozens of millions of tattooed 
individuals, and to the 2-3 millions of skin cancers per year [14, 26], the number of 
cutaneous neoplasms arising in tattoos seems negligible, making in the opinion of Kluger 
the association between the two events purely coincidental. As far as tattoo ink 
composition is concerned, Kluger [68] wrote that "it is unknown so far, whether 
polycyclic aromatic hydrocarbons in black tattoo inks contribute to carcinogenic risk for 
individuals with tattoos", adding that most of the investigations on detected carcinogenic 
chemicals are in-vitro studies, while it remains unclear whether some of these 
substances can cause health problems when tattooed in the skin. 
Multiple malignant melanomas, BCCs, or SCCs occurring on a single tattoo have been 
never described. Recent findings showed that patients who develop skin neoplasms on 
tattoos are younger and have a shorter delay since tattoo placement. At the same time, 
skin cancer in general affects nowadays younger people than it used to be in the past, 
perhaps due to the fashion of sunbathing and use of UV lamps. And as simultaneously 
tattooing is getting more popular among youngsters as well, having a coincidental 
malignancy on a tattoo becomes more likely. Kluger added that the increase in reported 
cases of keratoacanthomas (KA) and pseudoepitheliomatous hyperplasia (PEH) on 
tattoos may reflect a true incidence hike or just a better recognition or bias in publishing 
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trendy complications. In the opinion of Kluger [40], previous concerns of epidermal 
carcinomas following lumbar puncture through lower back tattoos are outdated. 
The majority of the published cases of melanoma and BCCs occurred on dark coloured 
tattoos, while SCCs, keratoacanthomas, and benign pseudoepitheliomatous hyperplasia 
were more frequent within red tattoos [68].  
The tumour onset ranged from 1 month to 55 years following the tattoo. 
 
Pseudoepitheliomatous Hyperplasia 
Rapidly growing after tattooing (between 1 week and few months), albeit benign lesion, 
it presents as nodules, large verrucous plaques or ulcerated lesions, mostly confined to 
red areas. It can be associated with various infectious, inflammatory or neoplastic 
processes, and its clinical and histologic features are hard to differentiate from KA or 
verrucous carcinoma [57]. Kluger in his review reported 10 cases in the last 40 years 
[68]. 
 
Keratoacanthoma and Squamous Cell Carcinoma 
Keratoacanthomas are considered by some physicians malignant SCCs, whereas others 
debate about its malignancy [68]. Biopsy does not always contribute to differentiate 
precisely between PEH, KA and SCC; but time lag after tattoo may help to distinguish 
KA, which grow usually within a week to a year and resolve spontaneously over some 
months [14], from SCC, whose first reported case occurred on a 21‑year-old tattoo [12]. 
Red tattoo ink was associated with 9 out of 11 (82%) of the keratoacanthomas 
diagnosed in 8 patients [50]. According to Kazandjieva [69], there is not any specific 
proof for a causative link between tattoos and SCC. 
 
Basal cell carcinoma 
BCC has been rarely found to appear after trauma, for example in surgical scars [20]. In 
the case documented by Serup [14] the basal cell carcinoma originated in the adjacent 
non-tattooed skin and overgrew secondarily the tattoo. 
 
Malignant melanoma 
Both benign nevi and malignant melanoma can arise de novo in a tattooed area. While 
in-depth risk analyses did not reveal tattooing as a significant risk factor for the 
development of malignant melanoma [22], it can certainly delay its diagnosis and 
treatment.  
 
Non-Hodgkin lymphoma 
One case of B-cell lymphoma was reported in a patient with a long history of 
pseudolymphoma (a benign lymphocytic infiltration) on tattoos on both arms, the 
lymphoma developed on both tattooed and non-tattooed areas. Two additional reported 
cases of cutaneous lymphoma have been reconsidered as pseudo lymphoma [68]. 
Additionally, Kluger [68] cited some other anecdotal cases of rare skin malignant lesions, 
for which a true link with the tattooing event is highly speculative; these included two 
cases of dermatofibrosarcoma protuberans (Darier-Ferrand) occurring 1 and 2 years 
after tattooing, and a leiomyosarcoma which appeared 9 years after tattooing.  
Baker [70] reported one case of dermatofibrosarcoma protuberans (uncommon, locally 
aggressive cutaneous tumour of intermediate grade malignancy) arising in a tattoo. 
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To conclude, the fact that a causal link between tattooing and cancers has not yet been 
established does not rule out the risk, but it seems negligible, probably a coincidence. 
Belgian and Danish authorities [51, 71] have drawn the same conclusions. 
Monitoring and reporting side effects, together with epidemiological studies in the long 
run, is needed to demonstrate the causative nature of the connection between these two 
events, if any. 
 
3.1.4. Medical diagnostic and treatment interference 
Tattoo pigment deposition in the dermis may mask the pattern of dermatoses arising in 
the tattooed area, and in particular hamper dermatoscopic surveillance of pre-existing 
naevi with the risk of delaying the diagnostic of their potential malignant transformation 
into a melanoma.  
These pigments stemming from dark tattoo inks may also lead to a false diagnosis of 
melanoma, and subsequent unnecessary stress linked to surgical excision. Similarly, 
dark pigments migrating to regional lymph nodes draining the tattooed area may mimic 
metastatic invasion of a sentinel lymph node by a melanoma; however, new 
immunohistochemical techniques are now able to differentiate the two types of 
pigmentation. 
Metal (in particular iron)-containing inks may interfere with the quality of the diagnostic 
imaging techniques, such as Magnetic Resonance Imaging (MRI) and Positron Emission 
Tomography (PET) scan exams and give false-positive mammographies. 
Rarely tingling and burning sensation during MRI exams has been reported, especially 
with red and black tattoos [22, 72]. The role of ferric oxides in this effect has been 
reported [73]. 
Lumbar tattoos may also complicate spinal anaesthesia, e.g. in obstetrics, but the 
potential risks of such a procedure are still under debate with different opinions 
expressed by various authors [40]. 
 
3.1.5. Contra-indications to tattooing 
Some underlying clinical status may render the tattooing procedure problematic with 
regard to possible clinical complications, and, as such, should contra-indicate tattoo 
procedures. 
The area to be tattooed should be free of pre-existing naevi and other pigmented 
lesions. The tattoo recipient should have no past history of melanoma or atypical mole 
syndrome. 
Known allergies to nickel, latex, and other substances may be reactivated and 
hypersensitivity reactions triggered. Post-tattoo healing process may reveal problematic 
in patients suffering from eczema. 
As for any other intervention individuals suffering from haemophilia or presenting other 
coagulation disorders (thrombopenia, von Willebrand disease, etc.), including those 
patients taking medications with possible haemorrhagic side-effects, should seek consent 
from their doctor before undergoing any tattoo procedure [57]. 
Pre-existing cardiac diseases, in particular valvulopathy, increase the risk of bacterial 
endocarditis with potential life-threatening consequences [31]. Antibiotic coverage is 
recommended prior these patients undergo a tattoo/PMU procedure.  
In certain patients, predisposition to chronic autoimmune dermatoses (sarcoidosis, lupus 
erythematous, etc.) or treatment with interferon might trigger the skin disease to 
localise within a tattoo, sometimes many years after the application [57].  
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Years after the tattoo procedure, chronic skin disorders, such as psoriasis or lichen, 
might reactivate and induce a rash within the tattoo (Köbner phenomenon) [12]. 
Tattooing on the edge of a vitiligo lesion may trigger its extension [4]. Prior latent 
infection with herpes virus could precipitate the reawakening of the lesions. 
There is no data supporting additional risks to the foetus or mother ascribed to tattooing 
during pregnancy. However, it is generally recommended to avoid tattoo application 
while pregnant or breast feeding [44]. 
Patients with known pre-existing Pyoderma Gangrenosum should be strongly advised 
against tattooing, particularly on the lower extremities [57]. 
 
3.2. Adverse health effects linked to tattoo/PMU removal 
As the number of decorative tattoo and permanent make-up has been increasing during 
the last years, also the demand for their removal became greater. Actually, Karsai 
reported that the number of new tattoos has remained at a static rate while the number 
of removal requests is constantly growing [74], thus explaining the increasing number of 
tattoo studios offering such services. Motivations for tattoo removal include regrets 
(tattoo as a youthful folly or carried out under the influence of alcohol or drugs), 
aesthetic reason or medical problems [75]. Similarly to tattoo application, tattoo removal 
practice is not free from risks and adverse effects.  
The early removal procedures consisted of destructive methods which entailed the 
mechanical stripping of layers of skin until the ink was no longer visible. Practices such 
as salabration and dermabrasion have been used for decades as the method of choice 
for tattoo removal. These destructive modalities often resulted in permanent scarring, 
serious inflammation, loss of normal skin pigment, residual tattoo and infections. Then 
surgical and chemical procedures (trichloroacetic acid and the so called glycolic acid 
mixture, made of lactic, tartaric, malic and glycolic acid) became of routinely use as well. 
Despite surgical excision replaces the tattoo with a surgical scar, it is still considered 
nowadays the best choice for people having strong allergic reaction to their tattoos. 
Chemical procedures do not completely remove the tattoo and have the disadvantages 
of being quite painful, and leading to depigmentation and hypertrophic scars. 
Nevertheless, such methods are still sporadically used nowadays, as they are cheap and 
may be sometimes managed at home. 
Thermal procedures have also been used. Electrocautery, infrared coagulation, argon 
lasers, and CO2 lasers are some examples. As already mentioned for mechanical 
methods, also these thermal procedures almost always leave a scar and, moreover, very 
often lead to incomplete tattoo removal.  
Despite all their side effects and the lack of selectivity, argon and CO2 lasers represented 
the first attempts of selective tattoo removal and foretold the modern age of Quality-
switched (Q-switched or QS) ruby (694 nm), alexandrite (755 nm) and Nd:YAG (532 and 
1064 nm) lasers which represent, since early 90s, the gold standard for tattoo removal 
[76, 77]. 
Although Q-switched lasers have made tremendous steps in advancing the safe and 
efficient removal of tattoos, both temporary and permanent side effects might still occur, 
especially when incorrect parameters such as pulse duration and light intensity are 
applied to the laser device [49, 76, 78-80].  
In the following paragraphs the most frequent adverse effects reported in the literature 
linked to the use of Q-switched lasers are presented. 
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3.2.1. Thermally induced acute inflammation 
Blistering is reported being one of the major transient effects of epidermal thermal 
damage induced by removal treatments. According to some authors [77, 81, 82], this 
side effect is expected in most cases and is linked both to incorrect parameters applied 
to the laser device and to an unexpectedly high level of absorption of laser energy by 
epidermal melanin. When the light intensity is too low or the pulse duration is too long 
(in the range of milliseconds), pigments in the skin are heated up rather than destroyed 
and the heat is conducted to the adjacent tissues causing injuries [78, 82]. Melanin 
plays a fundamental role as it competes for laser light absorption at certain wavelength 
(mostly the one of QS Ruby and the lowest wavelength of Nd:YAG). This may manifest 
acutely as blistering and skin sloughing and later as pigment disorders (namely 
hypopigmentation), especially in individuals with a darker skin type [81]. This is the 
reason why authors emphasise the importance of sun avoidance before the removal. In 
most cases, bulla formation is avoidable by strictly attaining to the post-treatment 
indications (elevate and ice the treated area) and, in any case, complete healing of the 
affected areas can be achieved following sterile aspiration, non-disruption of the roof of 
the blister, application of a petrolatum ointment, and dressing [83].  
Local development of crusting is an additional effect caused by epidermal thermal 
stress [72, 74, 75, 78, 79, 81, 84]. As in the case of blistering phenomenon, crusting 
requires 7-10 day of appropriate post-intervention care that aims at optimising the 
cosmetic outcome. Despite the advent of modern Q-switched laser therapy drastically 
reduced the development of scars with respect to the earlier procedures, the formation 
of permanent scars is still possible when the type of laser and/or applied conditions are 
not correct and the damage is deeper. In case of particularly resistant tattoos (multi-
coloured tattoo containing iron oxide or titanium dioxide), which require a more intense 
treatment for removal, it is more likely to develop permanent scars [72, 74]. Again in a 
study conducted by Wenzel [78], 10 out of 12 individuals treated with improper device 
or light parameters developed hypertrophic scars.  
Another transient effect of laser removal is erythema formation and/or pinpoint 
bleeding. These effects are due to photo acoustic damage of dermal capillary walls as a 
result of the high peak of laser energy. This promotes extravasation of blood into the 
surrounding tissue. Erythema is reported healing after few days from the laser treatment 
with adequate cooling [82, 84]. The literature reports one case [78] of long lasting 
erythema associated to the use of a device operating in the millisecond domain (long 
pulsed). 
Additional acute effects include scaling, induration and fibrosing. Transient textural 
changes may also be observed and are reported self-resolving in 1-2 months [84]. 
 
3.2.2. Allergic reactions 
Similarly to what may happen during tattoo application, hypersensitivity reactions have 
been described following their laser removal. In this case it is not only the original dye 
that triggers a reaction, but also its degradation products that are considered as new 
antigens scattered by laser treatment [33, 44, 69, 76, 85]. 
After tattoo removal, local allergic reactions have been noticed mostly in red (e.g. 
presence of mercury), green (presence of chromium) and blue (presence of cobalt) 
parts; at the same time, photo allergic reactions have been described in the case of 
yellow cadmium based pigments [13]. Khunger and co-workers reported on local allergic 
reactions, observed in particular in the presence of red and yellow pigments and 
manifesting in the form of pruritic papules, nodules or scaly plaques. Red and yellow inks 
may be responsible of photo allergic reactions as well [86]. 
Unfortunately, many authors agree on the fact that a generalised allergic reaction could 
be potentially initiated by the systemic release of ink fragments taken up and 
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transported via the lymphatic system [69, 76, 77]. For this reason, patients who had 
developed allergic reaction at the time of tattoo placement should be particularly aware 
of the risk they come across removal. 
Systemic allergic reactions may occur immediately after the treatment; however in 
2007, Bernstein reported at least one case when an anaphylactic reaction occurred 1 
hour after treatment of the tattoo. In order to avoid any allergic reaction, some 
practitioners suggest the use of oral corticosteroids and antihistamines before and during 
the laser session and one day after the procedure [69]. 
 
3.2.3. Pigmentary disorders 
Pigmentary disorders are the most common side effects of non-ablative laser therapies, 
and numerous reports of paradoxical darkening, hyperpigmentation and 
hypopigmentation following a QS laser treatment are reported in the literature. 
Specifically, the main reason of hypopigmentation has been attributed to the presence 
of epidermal melanin, which is known to compete for laser light absorption especially at 
certain wavelengths. This interaction eventually leads to the destruction of melanocytes, 
according to the same mechanism that applies to tattoo pigments. As a chromophore, 
melanin is able to absorb energy throughout the whole range at which QS lasers operate 
with peaks of absorption lying in the ultraviolet range and decreasing at the longest 
wavelengths. Operating with Nd:YAG laser, at its highest wavelength (1064 nm), would 
minimise the risk of hypopigmentation, because absorption capacity of melanin at long 
wavelengths is minimum [74]. Nevertheless, some colours such as red, yellow and 
orange require 532 nm wavelength to be removed and side absorption by melanocytes 
with consequent hypopigmentation is unavoidable. The role of melanin as a competing 
chromophore explains why patients with darker skin types, or tanned, tend to be 
particularly at risk of unwanted pigmentary changes [77, 82]. Most of the time, the loss 
of melanin pigment is transient, but it may persist up to years or even become 
permanent especially after repeated treatments [13, 76, 82, 84]. The incidence of 
permanent hypopigmentation in different studies has been estimated to be up to 10% of 
the studied population [13, 74, 76]. Time of onset is reported being 4-6 weeks up to 
several months after treatment [77, 82].  
Hyperpigmentation is considered a result of an increased UV sensitivity of the skin 
after laser irradiation. Again, it is related to the patient’s skin type, with darker skin 
being more prone. The incidence is 5-10% of the population who underwent QS lasers, 
with higher occurrence in individuals subject to multiple laser treatment, and it is 
considered a transient effect [74, 76, 82, 84]. Because of this enhanced UV sensitivity, 
individuals who have received gold salts for diseases such as rheumatoid arthritis should 
be approached with caution because the use of gold salts and exposure to UV light 
sources is known to induce chrysiasis (permanent alteration of skin pigmentation due to 
deposition of gold and triggered by UV radiation). In addition, individuals already subject 
to chrysiasis should avoid QS lasers in order not to worsen hyperpigmentation disorders 
[81].  
An additional pigmentary disorder that is frequently observed after QS lasers treatment 
is a paradoxical darkening that takes place especially during the removal of 
multicolour tattoos. This phenomenon is strongly linked to the chemical composition of 
some colours. In particular, authors agree on identifying some metal oxides, present in 
pigments, as responsible of this side effect. Titanium dioxide, which is contained in white 
inks and is often used to add brilliance to other tattoo inks is the responsible of 
darkening when light colours are present [49, 72, 76, 77, 81]. The same complication 
can appear in tattoos containing iron pigments often used in flesh-toned colours for 
permanent make- up [72, 76, 77]. Thum Chee [49] explains the darkening encountered 
in the presence of these colours with the reduction of ferric oxide to jet black ferrous 
oxide. Kent [81] reports on a study involving 184 patients who underwent QS laser 
removal of non-black tattoos. 33 out of 184 individuals experienced a colour shifts, 
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ranging from mild greying to complete blackening of the white, flesh-coloured, red, 
brown, yellow and crimson parts of their tattoos. As already mentioned, patients should 
be informed that darkening of the tattoo can be permanent and additional laser sessions 
might be needed to completely remove the pigment [33, 49, 72, 77, 79, 81].  
 
3.2.4. Concerns about unpredictable systemic risks 
Up to date, the only evidence of systemic reactions found in the literature and linked to 
laser tattoo removal came from an internet survey launched in 2014 by Klein [75] where 
headache was reported by 6% of a population of 157 individuals, dizziness was 
described by 4%, vomiting by 1%, and fever by 1%. These systemic reactions persisted 
up to 5 weeks in 66% of participants, 6–9 weeks in 7% of people, and in 4% side effects 
persisted more than 10 weeks.  
Nevertheless, some concerns have been expressed for the potential toxicity of the 
products arising from the photodecomposition of pigment during the laser session. Kent 
[81] focused the attention on the fact that laser induced cleavage of azo-containing 
tattoo pigments results in decomposition products known to be carcinogenic and 
cytotoxic when distribute throughout the body. The same concern has been expressed 
by several authors [68, 72, 80, 84], but so far these chemical changes have not been 
proven in vivo and there are no epidemiological clinical data supporting an alarming 
increase in skin cancers [13, 68]. Nevertheless, some in vitro studies revealed that UV 
and laser induced photochemical cleavage of commonly used tattoo pigments (Red 22, 
Red 9) yields 2-methyl-5-nitroaniline, a suspected carcinogenic compound, 2, 5-
dichloroaniline and 4-nitro-toluene, which are known for being toxic [74, 80]. Yet, 
previous investigations on potential toxicity of 3,3''–dichlorobenzidine, also used in 
tattoo inks, revealed light-induced genotoxicity in some human cell lines [79].  
 
3.2.5. Pre-treatment counselling: feasibility, expectations and outcomes 
Authors agree on the need of a thorough pre-treatment counselling advising with regard 
to realistic expectations and possible side effects [33, 75, 77, 87]. Patients should be 
informed that, due to the possibility of developing pigmentary disorders, the procedure 
may not lead to the complete removal of the tattoo, especially, as widely discussed, in 
the presence of certain colours or skin type [33, 49, 72, 79, 81]. 
Patients should be also advised that several laser sessions are required for the complete 
removal of a tattoo. Williams [87] reports 4-6 sessions for removing an amateur tattoo 
and even more that 12 for a professional and multi-coloured one. Interval between 
treatments may range between 6 and 12 weeks, thus meaning that years may be 
required for the complete removal. In addition, and for the same reason, patients should 
be aware of the economic impact of removal operation. Given the number of removal 
sessions, it may result in a final cost much higher than the application itself. 
Finally, a person who decides to undergo a removal treatment should know that the 
procedure might be painful. In a survey launched on the internet by Klein [75], 47% of 
the 157 participants stated that laser therapy was much more painful than tattooing and 
33% stated that pain levels were similar. Pain persisted in 11.2% (59) cases after 
treatment. This is the reason why a number of authors agree on the need of using a 
topical anaesthetic before the treatment [77, 81, 82]. 
The initial consultation is not only important for the patient, but it is the moment for the 
physician to carry out a scrupulous skin examination in order to evaluate the suitability 
of the laser removal procedure. In the presence of hidden suspicious nevus or 
malignancy, laser treatment should be withheld until further investigations are carried 
out. Again, in the presence of dermatological reactions or skin infections, treatment 
should be postponed and the infections treated [74, 76, 77, 81, 88]. 
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Some authors also highlight the problem arising in the presence of traumatic tattoos that 
may embed combustible material. In this case there is a concrete risk of re-ignition 
during the laser treatment. This event would lead to significant scarring [77, 81]. 
 
3.2.6. Future perspectives 
Improper laser parameters are one of the main sources of adverse effects related to QS 
laser removal. For instance, lasers operating in the domain of milliseconds (10-3 
seconds) are known heating up pigments rather than destroying them with consequent 
damage of adjacent tissues. In other words, when compared to the proper use of 
nanosecond (10-9 seconds) pulses, the pigment particles in the skin are heated up a 
million times longer than necessary. Therefore, excessive heat is conducted from the hot 
pigment particle to the adjacent dermis thus originating thermal damage. 
Laser with shorter pulse duration are currently being tested. Pulses in the picoseconds 
(10-12 seconds) range have the advantage of targeting pigment particles more 
effectively, with more efficient delivering of energy minimising unwanted interaction with 
surrounding tissues. In a 2014 article, Freedman [89] reviewed the published data 
pertaining to the clinical reports of picosecond laser devices, including Nd:YAG, 
Titanium: Sapphire, a novel 758 nm/500 picosecond model, alexandrite and a 
picosecond infrared laser (PIRL). Comparing these new devices with analogue 
nanosecond lasers, authors were able to demonstrate that picosecond lasers generate 
greater clearance of black tattoos at lower energy and have a greater depth of 
penetration, when all other parameters are held constant.  
In addition, a new tattoo ink easier to be removed was made available in the United 
States in 2009 [77, 81]. These new inks contain encapsulated bioresorbable dyes in 
polymethylmethacrylate beads in which additional pigments are also present with the 
aim of absorbing specific wavelengths and to facilitate the capsule rupture under laser 
irradiation thus making the removal easier. This procedure has the additional advantage 
of using pigments which may be too small in size to be used in a conventional tattoo ink, 
as they would be swept away by the body because of the small size.  
A last possibility to facilitate the removal is working on the optical properties of the skin 
with the aim of facilitating the access of the laser light into the dermis. Reducing the 
light scattering caused by the presence of dermal collagen by using topical and injected 
solutions, such as glycerol, glucose and dimethylsulfoxide, should make the tattoo 
removal more efficient while decreasing side effects [77]. Nevertheless, it must be 
mentioned that, intradermal injection of chemicals resulted in tissue necrosis and 
scarring, making this option not really considerable [81].  
 
3.3. Adverse health effects linked to henna-based temporary 
tattoos  
This chapter has been included for completion purposes. The practice of decorating the 
skin with henna based preparations is wide spread; however, this is not a tattoo because 
it is not meant to be permanent and it does not involve needles. In fact, the henna is 
applied by brushes or special pens on the skin and not injected. Due to its non-invasive 
nature, the health risks associated to henna-based temporary tattoos are milder and less 
frequent with respect to permanent tattooing. 
In the EU, henna is considered a cosmetic product and therefore shall fulfil the 
requirements of the EC Regulation 1223/2009 on cosmetic products [90]. 
Henna is a powder obtained from the dried leaves and stalk of a plant (Lawsonia 
Inermis). To create the henna preparation, a paste is made out of this powder, by 
adding water or oil and additional (often secret) ingredients to enhance the darkening 
effect. Natural henna is also known as "red henna", because of the typical reddish-brown 
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colour generated by the interaction between the pigment contained in the henna powder 
(lawsone, CI 75480, Natural Orange 6) and the skin keratin.  
The practice of decorating the skin of hands and feet with henna-based dyes has been 
widely diffuse in Islamic and Hindu cultures in the Arab, African and Indian world for 
thousands of years. In the past decades, a revisited mode of henna application, the so-
called temporary black henna tattoo has become fashionable in western cultures as well. 
It is usually applied to young people and children in holiday resort areas and in 
attraction parks, at festivals and fairs by street artisans. Black henna is the combination 
of red henna and PPD (p-phenylenediamine), which is used to accelerate the dyeing and 
drying process, to strengthen and darken the colour, to enhance the design pattern of 
the tattoo and to make the tattoo last longer (3 to 4 weeks).  
According to the revised literature, most of reported side effects after henna tattooing 
are allergic reactions or sensitisation to one of its components. 
As for red henna, its sensitising potential can be considered negligible. Moreover, despite 
the large number of people who have been exposed to natural henna at some time in 
life, immediate-type allergy to red henna preparations has been reported rarely [91, 92]. 
In the sporadic cases described, the actual allergen remained unknown and most of the 
studies cannot definitely exclude the presence of aromatic amines [92].  
On the contrary, several cases of allergic reaction to black henna, in the form of localized 
or generalized contact dermatitis, hypertrophic or keloid scars, have been reported in 
the literature [49, 91, 92].  
Induction of allergic reactions can take as long as 7 to 20 days, but it can be shorter (24 
to 48 hours) if the patient has had previous exposure to the allergen. Normally, these 
types of reactions do not leave any permanent effect, as they completely heal if treated 
with the proper topical medicaments. In rare cases, permanent post-inflammatory 
dyschromic changes may occur. 
Principal responsible for this type of adverse reactions is PPD, which is known to be a 
powerful antigen [49, 91-93]. Nevertheless, Calogiuri and colleagues reported the 
presence of other contaminants in henna preparations, such as thiurams and latex cross-
reactive proteins, as well as nickel, cobalt and mercury, which may induce contact 
allergy as well. 
At the same time, PPD has a very strong sensitising potential and may be responsible of 
the developing of threatening allergic reactions in response to a subsequent contact to 
the allergen. Kneilling [94] examined nine patients who developed severe allergic 
reactions in response to permanent black hair dye. Seven out of nine patients reported 
having temporary black henna tattoo 3–7 years prior to the use of the permanent hair 
dye, which resulted in a strong inflammation at the site of the tattoo. All of the seven 
patients resulted positive to patch test using 1.0%, 0.5% and 0.1% PPD. 
According to the cosmetic regulation, PPD may only be used in hair colorants and only 
up to a maximum of 2% when applied to the hair. Therefore, the presence of PPD in so-
called ‘black henna’ temporary tattoos is illegal in the EU. 
 
3.4. Experience with the CoE ResAP (2008)1 
A questionnaire developed for the national authorities was sent to the 28 Member States 
of the European Union plus the 4 EFTA countries (CH, IC, LI and NO) through the 
Consumer Safety Network. Fourteen Member States (BE, BG, CZ, DE, DK, ES, FI, FR, IT, 
NL, RO, SE, SI and SK) answered, though not all of them replied to each section of the 
questionnaire. The section on the experience with the CoE ResAP(2008)1 and the 
suggestions for updating its requirements was divided in five parts (in parenthesis the 
number of MS who replied): chemical (5), labelling (11), register of complaints/side 
effects and pre-marketing authorisation (11), hygiene/sterility (5) and other (10).  
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This chapter presents the outcome related to this section of the questionnaire, 
integrated with discussions held by the CSN-STPM. The whole set of answers is reported 
in Annex III.  
 
3.4.1. Chemical requirements  
The recommendations of the CoE ResAP(2008)1 with regards to chemical substances 
that should not be part of tattoo/PMU products are listed: in its Tables 1-3 [1]; in the 
Directive 95/45/EEC [95] on specific purity criteria concerning colours for use in 
foodstuffs; in Annexes II and IV (column g) to EC Reg. 1223/2009 on cosmetic products 
[90]; and in Annex VI (Table 3.1) to EC Reg. 1272/2008 on classification, labelling and 
packaging of substances and mixtures (CLP regulation) [96], limited to the substances 
classified as carcinogenic, mutagenic and reprotoxic, CMRs, in categories 1A, 1B and 2. 
Table 1 of the CoE ResAP(2008)1 reports a list of 27 aromatic amines which should 
neither be present in tattoos and PMU products nor released from azo-colorants in 
concentrations that are technically avoidable according to good manufacturing 
procedures.  
Some Member States suggested modifications to this Table. In particular, Italy pointed 
out that, in order to help the implementation of these requirements, limit(s) should be 
established for the listed aromatic amines. This proposal was welcomed by the experts of 
the CSN-STPM. In addition, the Italian competent authority considered that aniline, 2-
ethoxyaniline and N-isopropyl-N'-phenyl-1,4-phenylendiamine should be added. Also 
Spain and Denmark proposed to add aniline and the Danish competent authority 
suggested a limit of 10 ppm for this compound. 
As shown in Table 3.1, actually the CoE ResAP(2008)1 already recommends not to use 
aniline in tattoo/PMU products, because it is listed in Annex II of the cosmetic regulation 
and because it is classified carcinogen and mutagen (category 2) in Annex VI, Table 3.1 
of the CLP regulation. The inclusion of aniline in Table 1 of the CoE ResAP(2008)1, which 
takes into consideration just aromatic amines, could make this recommendation more 
visible for enforcement laboratories and manufacturers. 
 
Table 3.1: Aromatic amines that could be evaluated for inclusion in Table 1 of the CoE ResAP(2008)1. 
 
 
The CoE ResAP(2008)1 recommends not using in tattoo/PMU inks the 35 colorants listed 
in its Table 2. Germany, Italy and Spain, as well as stakeholders from CSN-STPM, 
proposed to add a number of colorants to this list (see Table 3.2). Actually, pigments 
green 7, blue 15, red 5 and 181 should not be present in hair dye products. Pigments 
yellow 1, yellow 3 and green 7 should already not be contained in tattoo products, as 
they are listed in Annex IV (with use limitations) of the cosmetic regulation. In addition, 
tattoo inks should not include solvent yellow 14 as it is both classified carcinogen and 
mutagen (category 2) and it is mentioned in Annex II of the cosmetic regulation. 
 
 
 
Substances CAS 
number DK ES IT Annex II
Reference 
number Table 3.1 Index number
Classification (CMR, 
Skin/Eye Irrir./Sens.)
aniline 62-53-3 X (10 ppm) X X
X (its salts and its 
halogenated and 
sulphonated 
derivatives
22 X 612-008-00-7   Carc. 2, Muta. 2, Eye Dam. 1, Skin Sens. 1
aromatic amines set limits
2-ethoxyaniline 94-70-2 X
N-isopropyl-N'-phenyl-
1,4-phenylenediamine 101-72-4 X Skin Sens. 1
EC Reg 1223/2009 EC Reg 1272/2008
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Table 3.2: Colorants that could be evaluated for inclusion in Table 2 of the CoE ResAP(2008)1. 
 
 
Table 3.3: Aromatic amines that could be formed from azo pigments with indication of their 
classification. 
 
 
It has to be noted that, out of the eight monoazo pigments that the experts from the 
CSN-STPM would like to be banned in tattoo/PMU inks, pigment red 17, yellow 1, yellow 
2, yellow 5, yellow 74 and solvent yellow 14 could, by reductive cleavage of the azo 
CI Generic Name CAS 
number
CI 
number Colorant class DE ES IT
Annex II                 
(ref. number)
Annex IV 
(column g) 
(ref. number)
Table 3.1                         
(index number)
Classification (CMR, 
Skin/Eye Irrir./Sens.)
Pigment Blue 15 147-14-8 74160 phthalocyanine X
X  (1367)           
(when used as a 
substance in hair 
dye products)
Pigment Green 7 1328-53-6 74260 phthalocyanine X
X (1369)         
(when used as a 
substance in hair 
dye products)
X (107)                
(not to be used 
in eye products)
Pigment Red 5 6410-41-9 12490 monoazo X X
X (1347)                 
(and its salts 
when used as a 
substance in hair 
dye products)
Pigment Red 17 6655-84-1 12390 monoazo X X
Pigment Red 181 2379-74-0 73360 indigoid X X
X (1365)          
(when used as a 
substance in hair 
dye products)
Pigment Violet 1 1326-03-0 45170:2 xanthene X X
Pigment Yellow 1 2512-29-0 11680 monoazo X X
X (4)                     
(not to be used 
in products 
applied on 
mucous 
membranes)
Pigment Yellow 2 6486-26-6 11730 monoazo
Pigment Yellow 3 6486-23-3 11710 monoazo
X (5)                     
(not to be used 
in products 
applied on 
mucous 
membranes)
Pigment Yellow 5 4106-67-6 11660 monoazo
Pigment Yellow 74 6358-31-2 11741 monoazo X X
Solvent Yellow 14 842-07-9 12055 monoazo X X (1107) X (611-056-00-6) Carc. 2, Muta. 2, Skin Sens. 1
CI Generic Name Aromatic amine CAS 
number
CoE 
ResAP 
(2008)1 
Table 1
EC Reg 1223/2009          
Annex II                            
(Ref number)
EC Reg 1272/2008 Table 3.1                 
(Index number) 
Classification (CMR, 
Skin/Eye Irrir./Sens.)
5-nitro-o-toluidine 99-55-8 X X (1195) X (612-210-00-5)                           (Carc. 2)
o-toluidine 95-53-4 X X (32) X (612-091-00-X)                              (Carc. 1B, Eye Irrit. 2)
Pigment Yellow 1 aniline 62-53-3
X (22) (its salts and its 
halogenated and 
sulphonated 
derivatives)
X (612-008-00-7 )                  
(Carc. 2, Muta. 2, Eye Dam. 1, 
Skin Sens. 1)
Pigment Yellow 2 p-chloroaniline 106-47-8 X X (612-137-00-9)                            (Carc. 1B, Skin Sens. 1)
Pigment Yellow 5 aniline 62-53-3
X (22) (its salts and its 
halogenated and 
sulphonated 
derivatives)
X (612-008-00-7 )                  
(Carc. 2, Muta. 2, Eye Dam. 1, 
Skin Sens. 1)
Pigment Yellow 74 o-anisidine 90-04-0 X X (708) X (612-035-00-4)              (Carc. 1B, Muta. 2)
Solvent Yellow 14 aniline 62-53-3
X (22) (its salts and its 
halogenated and 
sulphonated 
derivatives)
X (612-008-00-7 )                  
(Carc. 2, Muta. 2, Eye Dam. 1, 
Skin Sens. 1)
Pigment Red 17
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bond or by break of an amide link, form the carcinogenic aromatic amines reported in 
Table 3.3. According to the CoE ResAP(2008)1, these aromatic amines should not be 
present in these products. In addition, Cui [97] reported that pigment yellow 74 can, 
under light irradiation, decompose to o-acetoacetanisidide (CAS 92-15-9), 2-
(hydroxyimine)-N-(2-methoxyphenyl)-3-oxobutanamide (CAS 42056-95-1) and N,N'-
bis(2-methoxyphenyl)urea (CAS 1226-63-7), which could be further degraded to o-
anisidine, classified carcinogen and/or mutagen in categories 1A, 1B or 2. 
In a meeting of the CSN-STPM, a representative of TIME (Tattoo ink manufacturers in 
Europe) declared that for pigment green 7, which is in negative lists mentioned in the 
CoE ResAP(2008)1, nowadays there is not a better alternative. 
The Norwegian representative considered that pigments that are not allowed in hair dyes 
or as colorants (i.e. that are not in the positive list of Annex IV to the cosmetic 
regulation) should also be banned in tattoo products. 
As already discussed for aromatic amines, the inclusion of additional colorants in Table 2 
of the CoE ResAP(2008)1, which should already not be present in tattoo/PMU inks, would 
most probably simplify the work of enforcement laboratories and manufacturers. 
In addition, taking into account the fact that azo colorants have been proven to degrade, 
in the skin and under light irradiation, to the aromatic amines used in their production 
and that the analytical methods used to quantify the aromatic amines released by azo 
colorants are not vey reproducible, in order to improve the safety of inks the group 
considered more effective to ban all azo colorants that by reductive cleavage may form 
aromatic amines classified as CMRs. 
A number of competent authorities also made suggestions for amendments of Table 3 of 
the CoE ResAP(2008)1, on maximum allowed concentrations for impurities in tattoo/PMU 
products; however, there was no consensus  on the necessary modifications. 
Concerning organic impurities, Denmark suggested to increase the limit from 0.005 to 
0.2 ppm, Italy considered that it is necessary to set individual limits for the most toxic 
polycyclic aromatic hydrocarbons (PAHs) and The Netherlands would like to specify 
which PAHs should be measured, relatively to the cumulative limit of 0.5 ppm which 
applies to the sum of PAHs. 
Speaking about elements, four Member States expressed the need to establish a limit for 
nickel (ES, IT, NL and SI), with Italy proposing the value of 0.5 ppm. Italy also 
suggested to decrease the limits for arsenic, cobalt, lead and antimony, as reported in 
Table 3.4; however, at the same time, Denmark proposed to increase the limit for lead. 
Finally, Italian competent authority considered important to label the product if it 
contains cobalt, would welcome the establishment of different limits for tattoo and PMU 
products and wondered if the limit for barium is based on recent toxicological data. 
In a meeting of the CSN-STPM, a representative of TIME proposed 5 ppm as limit to be 
established for the content of nickel, while a Swedish expert suggested adding strontium 
on the basis of its presence in some inks. 
In summary, there is a general consensus among experts for suggestions for revision of 
Tables from 1 to 3 of the CoE ResAP(2008)1, even if more in-deep discussions are 
needed, in particular on the establishment of new limit values. 
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Table 3.4: Suggestions for possible revision of Table 3 of the CoE ResAP(2008)1. 
 
 
Several national competent authorities would welcome the establishment of a positive 
list of colorants allowed to be used in tattoo/PMU products (BE, DE, IT, FI, NL, SE, SI, 
SK) and the harmonisation of analytical methods (BE, DE, DK, ES, IT, NL, SE, SI, SK). 
The preparation of a single list of chemicals that should not be present in tattoo/PMU 
inks was considered negatively by Germany and Sweden and positively by Belgium, 
France, Italy and Slovenia, even if France considered it difficult to achieve. 
Other proposals mentioned by respondents were: 
• to establish for chemicals (e.g. preservatives) in tattoo/PMU inks the same purity 
limits applicable to the drugs for injection in the body (BE); 
• to establish guidance values for technically unavoidable amounts (DE); 
• to establish a positive list for preservatives (NL); 
• to come to a European consensus on the status of tattoo removal products (FR). 
 
3.4.2. Labelling requirements  
In this part of the questionnaire the national competent authorities were requested to 
indicate what changes in the labelling recommendations would improve the safety of 
tattoo/PMU inks compared to those currently mentioned by the CoE ResAP(2008)1. 
Among the possible additional labelling requirements suggested in the questionnaire, 
there was a general consensus on the need to add the period of maximum durability 
after opening (PAO), the storage conditions, the product type (ink for tattoo or PMU) and 
health warnings. Seven countries were also in favour of having a compulsory 
quantitative composition label. On the contrary, Member States had different views on 
the benefit to include in the label the production date, the distributor's address and the 
indication of the sterilisation method used for the inks. 
Furthermore, Denmark and Italy proposed to add the batch number, Slovakia the 
symbol of minimum durability, while Italy was in favour of a label written in the national 
language of the country where the product is sold. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Substance CAS 
number
CoE ResAP 
(2008)1 
Table 3
DK ES IT NL SI
benzo[a]pyrene 50-32-8 0.005 ppm ↑ limit (0.2 ppm)
PAHs 0.5 ppm set individual limits for most toxic PAHs Specify which PAHs has to be measured 
As 2 ppm ↓ limit (0.2 ppm)
Co 25 ppm ↓ limit (5 ppm)
add in the labelling "Contains cobalt; 
may cause an allergic reaction" 
Cu soluble 25 ppm define what is intended for soluble Cu
Ni
as low as 
technically 
achievable
set limit set limit (0.5 ppm) set limit set limit
Pb 2 ppm ↑ limit (10 ppm) ↓ limit (1 ppm)
Sb 2 ppm ↓ limit (1 ppm)
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Table 3.5: Suggestions for possible additional labelling requirements. 
 
 
3.4.3. Register of complains/side effects and pre-marketing 
requirements 
A large majority of respondents (ten) considered useful the compulsory compilation of a 
register of complaints and side effects and only Slovenia was not favourable. French 
experts highlighted that this obligation already exists in France and some others 
suggested possible practical approaches. 
On the contrary, opinions diverged on the proposal to set up a pre-marketing 
authorisation for tattoo/PMU inks; five Member States were in favour and four against. 
While Spain informed that this approach is already implemented in its territory, Belgium 
thought that the fulfilment of the requirements should be enough to guarantee the 
safety of these products, Germany considered the compulsory safety assessment carried 
out by manufacturers, importers or person responsible for the placing on the market the 
right solution and Sweden highlighted the role of public authorities in guiding companies 
to fulfil the requirements. 
 
Table 3.6: Suggestions for possible additional safety requirements. 
 
 
3.4.4. Hygiene/sterility requirements 
In the part related to hygiene/sterility requirements, the options available in the 
questionnaire were four: the specification of ink or tool sterilisation method, of premises' 
Proposed modification BE DE DK ES FI FR IT NL SE SI SK
PAO Y Y Y
Y                          
(with indication 
sterility 
assured for x 
applications)
Y
Y                         
(present in 
national 
legislation)
Y Y
Y                                   
(with indication of 
conditions to be 
satisfied)
Y                              
(only for 
multiple-use 
packaging)
Quantitative composition label Y N
Y                                 
(not for < 1% 
unless skin 
sensitizer; use 
international 
nomenclature)
Y Y
Y                         
(present in 
national 
legislation)
Y Y
Production date Y N
indicate expiry 
date with the 
wording "May 
not be used 
after ..."   
Y Y Y N
Storage conditions Y
Y                 
(if specific 
conditions)
Y                          
(if necessary) Y Y
Y                         
(present in 
national 
legislation)
Y Y Y Y
Product type Y Y Y Y
Y                         
(to avoid 
injection of 
drawing inks)
Distributor's address Y N N Y Y
Y                         
(present in 
national 
legislation)
Y
Y 
(preferably 
phone 
number)
N N
Health warnings Y
Y                    
(useful in 
case of 
allergy)
Y Y
Y                  
(maybe in a 
separate 
document)
Y                           
(about allergic 
reactions, 
phototoxicity, other 
health effects)
Sterilisation method used Y N N Y N
Batch number Y Y
Label in the national language Y
Symbol of minimum durability Y
Proposed modification BE CZ DE ES FI FR IT NL SE SI SK
Register of complains/side effects Y Y Y
Y                          
(with a 
questionnaire)
Y                              
(notification 
similar to what 
foreseen by 
art. 23 of 
cosmetic 
regulation)
Y                         
(present in 
national 
legislation)
Y
Y                         
(side-
effects to 
be included 
in an 
informed 
consent 
document)
Y                           
(requirements 
for reporting 
side-effects 
should be 
discussed 
first)
N
Y                              
(similar to 
cosmetics)
Pre-marketing authorisation of inks
N                             
(respected 
requirements 
should be 
enough)
N                                          
(compulsory safety 
assessment made by 
manufacturers, 
importers or person 
responsible for the 
placing on the market)
Y                         
(present in 
national 
legislation)
N Y Y
N                             
(authorities 
should guide 
companies 
how to fulfil 
law)
Y Y
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disinfection method and the use of single dose containers. As reported in Table 3.7, five 
and four national competent authorities would be in favour of making compulsory the 
indication of the ink and tool sterilisation methods, respectively. Three and two 
respondents considered important to specify premises' disinfection methods and to use 
single dose containers, even though other highlighted that it is not practical for 
tattooists. 
Slovakia proposed the establishment of good application practices for tattooists. 
In a meeting of the CSN-STPM, a representative of TIME proposed to fix a maximum 
limit of 100 colony forming units (cfu) for a tattoo/PMU ink to be considered safe. 
 
Table 3.7: Suggestions for possible additional hygiene/sterility requirements. 
 
 
3.4.5. Other proposals 
Among the other proposals mentioned in the questionnaire, several Member States 
pointed out the need to establish Good Manufacturing Practices for tattoo/PMU inks, to 
carry out market surveillance on products sold on the web, to establish compulsory 
training for tattooists, to enhance the collaboration among manufacturers and authorities 
and to ban backyard tattooing (8, 6, 6, 5, 5 and 4 positive replies, respectively). 
It is worth noticing that to set up compulsory training for tattooists, compliance with 
national legislations should be assured. For instance in Germany, a request should be 
presented to the Federal Ministry for Economic Affairs and Energy by the social partners. 
Additional proposals put forward by respondents or discussed during CSN-STPM 
meetings were: 
• to increase controls on imported products (BE); 
• to set up more comprehensive and binding legislation (CZ); 
• to set up working group to validate ink sterilisation methods (IT); 
• to establish minimum age limit (IT); 
• to make safety assessment of inks compulsory; 
• to prepare guidelines for risk assessment of tattoo/PMU products; 
• to develop harmonised hygiene guidelines; 
• to ban illegal sales of "start-kits". 
 
 
 
 
 
 
 
Proposed modification DK ES FR IT SK
Specify ink sterilisation method Y Y Y
Y                        
(identification of the 
most effective method 
is needed)
Y
Specify tool sterilisation method
Y 
(already 
existing)
Y
Y                                         
(reference could be 
done to the sterilisation 
method used for 
medical devices)
Y
Specify premise disinfection method Y Y
Use single dose containers Y Y Y                                                                 (preferentially)
Good application practices for tattooists Y
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Table 3.8: Additional suggestions. 
 
 
3.5. Risk perception and communication  
This chapter presents the outcome related to the section of the questionnaire developed 
for the national authorities related to risk perception and communication, as well as a 
summary of what can be found in the literature on these issues.  
 
3.5.1. Answers to questionnaire 
Nine Member States informed that they had organised information campaigns in their 
countries, either at national (six) or at local level (three); while three of them reported 
that they had not. Various audiences were taken into consideration, including the 
general public, tattoo artists and studios, students, young people, prisoners, consumers, 
physicians and school teachers. The means used ranged from printed materials (reports, 
brochures, posters, newsletters, advertisements) to media coverage (newspapers and 
magazines, press releases, radio, TV), events held, such as conference and seminars, 
internet and social networks. 
In the opinion of the majority of respondents and of experts of the CSN-STPM, additional 
information campaigns would help to improve the safety of tattoo/PMU and should be 
addressed to tattoo artists, potential clients and general public. Belgium and Slovenia 
highlighted the importance of targeting young students as well, to help them creating an 
educated opinion and making an informed choice. 
 
 
 
 
 
 
 
Additional requirements BE CZ DE ES FI FR IT SE SI SK
Control products sold on the web
Y                        
(fakes 
and 
unsafe 
origin)
Y                        
(market surveillance 
should include web 
sales)
Y
Y                        
(difficult it 
can be done 
only at 
national 
level)
Y                                             
(to prevent the sale of 
fake inks)
Y
Enhance collaboration 
manufacturers/authorities Y Y Y Y
Y                           
(pre-
authorisation)
Ban backyard tattooing Y Y Y Y Y
Establish list of recognised tattooists Y
Y                                             
(institution of national 
register of professional 
tattooists on the basis 
of an European 
standard)
Y                                             
(existing 
based on the 
notification to 
open the 
business)
Y
Compulsory training for tattooists Y
(need has to be 
presented to the 
Federal Ministry for 
Economic Affairs 
and Energy by the 
social partners), ES 
(existing regional 
certification)
Y                         
(present in 
national 
legislation)
Y                                   
(harmonised at EU 
level)
Y Y
Set up Good Manufacturing Practices for inks Y Y Y Y
Y                         
(present in 
national 
legislation)
Y Y
Y                                             
(prepare 
EN 
standard)
Increase control on imported products Y
Set up more comprehensive and binding 
legislation Y
Set up working group to validate ink 
sterilisation methods Y
Establish minimum age limit
Y                                             
(forbidden under 14 
years old, 14-18 with 
informed consent of 
parents)
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Table 3.9: Information campaigns carried out. 
 
 
Table 3.10: Possible additional information campaigns. 
 
 
Six national competent authorities (DE, ES, FR, NL, SE and SK) informed that they had 
no information regarding the risk perception of the general and/or the tattooed 
population. Italy considered that the risk perception is based on the awareness of prior 
aggravating medical conditions and of possible risks, among which those of infections 
and disease transmission. No one indicated, as important elements on which risk 
perception can be based on, the awareness of risks related to the choice of tattooists 
(professional or not), the safety of premises and tools, in terms of sterility and hygiene, 
or the permanency and risks associated to removal options. 
According to the replies received from Belgium, Italy and Slovenia, the main sources of 
information for people, on which risk perception is based on, are parents, friends, media 
and internet. None of the respondents indicated physicians as consultation source for 
potential clients to form an opinion and, strangely, the same happened for tattooists, 
which on the contrary are mentioned in the literature as being the ones mostly taken 
into consideration. 
To the question on whether clients of parlours had to sign a compulsory prior informed 
consent, Italy replied yes, seven Member States replied no (CZ, DE, DK, FI, FR, NL and 
SE); even though in Finland, The Netherlands and Sweden it is recommended and in 
France compulsory information needs to be given to the clients. The information 
available or requested in the prior informed consent includes: an inquiry about client's 
health status, possible risks/complications, post-treatment instructions, what to do in 
case of problems and removal treatments, comprising risks. 
 
 
Information campaigns carried out BE DE DK ES FI FR IT NL SE SI
National level
Y                        
(report, 
dermatology 
newsletter, 
website)
Y Y Y Y
Y                        
(radio, reports, 
press release, 
advices)
Local level Y Y Y
Targeted to general public Y Y Y Y
Targeted to tattoo artists/studios Y Y                                             (newsletter)
Targeted to students Y Y
Targeted to prisoners Y
Targeted to young population Y                        (18-35 years old )
Y                        
(14-25 years old)
Targeted to consumers Y
Targeted to physicians and school teachers Y
Brochures Y Y Y Y                                             (in preparation)
Posters Y Y
Advertisements
Y                        
(on homepage 
and bus stops)
Newspapers/magazines Y Y Y Y Y
Radio
Y                        
(interview with 
dermatologists)
Y
TV
Y                        
(interview with 
dermatologists)
Y Y
Events held Y Y Y
Internet and social networks Y Y Y Y                        (Facebook) Y
Possible additional information campaigns BE CZ DE ES FR IT NL SE SI SK
Targeted to tattoo artists Y Y Y Y Y Y Y Y
Targeted to potential clients Y Y Y Y Y Y Y
Targeted to general public Y Y Y Y Y Y Y Y Y
Targeted to students
Y                           
(15-18 
years old)
Y                                             
(in primary 
schools)
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Table 3.11: Risk perception in terms of awareness and sources of information. 
 
 
Table 3.12: Information provided or requested in the prior informed consent. 
 
 
3.5.2. Literature 
Generally, considering the increasing prevalence of tattooing, particularly among youths, 
authors agree on the need of proper information related to tattoo/PMU-related risks. 
For instance, Mudedla [98] highlighted the need to warn the public, tattoo artists, ink 
and pigment manufacturers and health care professionals about potential for non-
tuberculous mycobacterium skin infections after tattooing. Carney [19] pointed out the 
necessity to organise information campaigns to raise awareness about the danger of 
transmitting blood borne infections, such as HCV, regardless of the venue of placement. 
To limit the risk of hepatitis transmission, Jafari [48] considered essential educational 
programs for tattoo parlour owners and tattoo artists, as well as regular and 
unscheduled inspection of tattoo parlours. In their opinion, information campaigns 
should be targeted to young people and prisoners, representing the population most 
likely to get tattoos and with the highest prevalence of hepatitis C, respectively. 
Furthermore, they considered tattoo artists should be obliged to keep records of their 
clients and to report any adverse effects related to tattoos to health authorities. Young 
people were identified as the most important target of information campaigns also by 
the Belgian Superior Health Council [71], who noted that not only adverse health effects 
linked to tattoos, but also to their removal should be explained. In their internet survey 
in German-speaking countries (sample 3411 tattooed participants), Klügl [18] reported 
that 37% of respondents declared to have been informed about the content and the 
safety of the tattoo colorants by their tattooists; however 41% were disinterested in the 
chemicals injected in their skin. Moreover, surprisingly about 33% of participants 
considered safe the injection of tattoo colorants in the human body, despite the fact that 
websites of public authorities, such as the German Federal Institute for Risk Assessment 
(BfR) and the US Food and Drug Administration (FDA), did not state this. 
In the literature only few papers consider risk perception in relation to tattoo/PMU 
practices and usually these studies considered the risk perception related to body art 
practices, including also piercing. 
As reported in Table 3.13, six studies were conducted in Italy [99-104] on young high 
school or university students, in various cities and regions, one in Canada [105] on high 
school students and one in Denmark [106] on a representative sample of Danish 
population. They were all based on anonymous questionnaires usually related to 
demographics, knowledge of health risks and personal experience with tattooing and 
body piercing. 
Awareness of BE IT SI
Prior aggravating medical conditions Y
Possible risks Y
Risks of infection and disease transmission Y Y
Sources of information
Parents Y Y
Friends Y
Media Y Y Y
Internet Y Y Y
BE ES FI IT NL SI
Inquiry about client's health status Y Y Y Y
Possible risks/complications Y Y Y Y Y Y
Post-treatment instructions Y Y Y Y Y
What to do in case of problems Y (sometimes) Y
Removal treatments, including risks Y Y
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The tattoo prevalence was in the range of 6.3-31.7%. When reported, the mean age at 
first tattoo was below 18 years old and the percentages of adolescents who got a tattoo 
before 15 and 18 years old were 32% in the Canadian survey and 48% in the Cegolon's 
paper, respectively. The prevalence of young people interested in getting a tattoo was in 
the range 25-57%. 
36-90% of respondents declared to be aware of infectious risks related to body art 
practices (considering both piercing and tattooing), however the percentages of those 
able to identify hepatitis B and C viruses and HIV among the transmittable agents were 
much lower (3.5-60%) in particular for hepatitis, thus supporting the idea that 
information campaigns are needed. 
In general, non-infectious risks associated to body art practices were less known that the 
infectious ones and the level of awareness ranged from 26 to 65%. Again, a more in-
deep analysis of this knowledge in the Italian studies showed that only 2-5% of 
respondents were able to identify allergies, bleeding and cysts as non-infectious risks. 
The tattooists or piercers were reported as being the main source of information on 
possible risks, followed by another person and the informed consent, which was signed 
by 7-31% of Italian respondents. Unpublished data from a recent survey performed by 
the Italian Institute of Health, in 2014-2015 on 7608 persons aged 12-75+ years old, 
showed that 50.8% of tattooed people signed the informed consent, 22.3% did not 
remember and 26.8% did not sign. Apart from the high school students in Naples, 
interviewed by Gallè [101, 102], in general a high percentage of students, both high 
school and university, referred to an authorised operator to get their body art practiced 
(66-90%) and more than 70% observed the use of sterile/disposable instruments. 
Complications were reported in 7-23% of cases among the pupils having at least one 
body art modification. It has to be highlighted that in the survey conducted by Quaranta 
[103] a significant percentage (9%) of people who got their body art practiced by an 
authorised centre developed complications. 
 
Table 3.13: Risk perception related to body art practices. 
 
2006, Deschesnes 2010, Cegolon 2010, Sidoti
Based on anonymous questionnaire anonymous questionnaire anonymous questionnaire
Sample 2145 high school students 4277 secondary school students 1200 undergraduate university students
Country Canada (Quebec) Italy (Veneto region) Italy
Tattoo prevalence 7.7% 6.3% 31.7%
Mean age at first tattoo 32.1% before 15 years old 48% before 18 years old
Interested in getting a tattoo 47.2% 53.1% (M) - 39.4% (F)
Aware of health risks associated to body art practices 
Aware of infection risks related to body art practices 54.4% 36.5%
Able to identify hepatitis B and C viruses and HIV among the 
transmittable agents
Able to identify tetanus among the transmittable agents
Aware of non-infectious risks  associated to body art practices 26%
Able to identify allergies, bleeding and cysts as non-infectious risks
Informed about the risks before undergoing the practice
Source of information - tattooist or piercer
Source of information - another person
Source of information - informed consent
Signed informed consent
Body art practiced by an authorised operator 90.4% for their first tattoo 63.5% considered it important
Observed the use of sterile/disposable instruments 
Knowledge of hygienic norms 72.3%
Complications
Seek medical advice in case of infections 73.6% in case of complications
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3.6. Data gaps and research needs 
In this chapter, the answers of the ten national authorities who replied to the section of 
the questionnaire related to data gaps and research needs are reported, together with 
some suggestions found in the literature and raised during the discussions held in the 
meetings of the Consumer Safety Network Subgroup on Tattoos and Permanent Make-
up.  
 
 
 
 
 
 
2011, Quaranta
Based on anonymous questionnaire anonymous questionnaire anonymous questionnaire
Sample 9322 high school students 3610 university students 1598 university freshmen 
Country Italy (Naples) Italy (Naples) Italy (Bari and Naples)
Tattoo prevalence 11.3% 24.5% 10%
Mean age at first tattoo 14.8 years 17.6 years 17.5 years
Interested in getting a tattoo 42.5% 25.3%
Aware of health risks associated to body art practices 24.7% 57.1%
Aware of infection risks related to body art practices 79% 87% 90%
Able to identify hepatitis B and C viruses and HIV among the 
transmittable agents 3.5% 15% 34% - 38% - 60%
Able to identify tetanus among the transmittable agents 34%
Aware of non-infectious risks  associated to body art practices 46% 59% 65%
Able to identify allergies, bleeding and cysts as non-infectious risks 2% 3%
Informed about the risks before undergoing the practice 74%
Source of information - tattooist or piercer main source main source 52%
Source of information - another person 29%
Source of information - informed consent 19%
Signed informed consent 6.9% 15.3% 31%
Body art practiced by an authorised operator 27% 66.5%
Observed the use of sterile/disposable instruments 27.9% 70.3%
Knowledge of hygienic norms
Complications 7% 7% 13% (9% of those treated in an authorised centre)
Seek medical advice in case of infections
2011, Gallè
2012, Gallè 2013, Majori 2013, DK YouGov
Based on anonymous questionnaire anonymous questionnaire anonymous questionnaire
Sample 3132 university freshmen 2712 high school students 
Country Italy (Bari) Italy (Veneto region) Denmark
Tattoo prevalence 19.8% 6.4% 20% (15-34 yeals old)
Mean age at first tattoo 17 years 37% before 20 years old
Interested in getting a tattoo 38.7% 57.4% 34% (15-34 yeals old)
Aware of health risks associated to body art practices 
Aware of infection risks related to body art practices 84.4% 81.6%
Able to identify hepatitis B and C viruses and HIV among the 
transmittable agents 4.1% 50% 34% hepatitis, 29% HIV
Able to identify tetanus among the transmittable agents
Aware of non-infectious risks  associated to body art practices 59.2%
Able to identify allergies, bleeding and cysts as non-infectious risks 5.4%
48% allergic reactions, 37% chronic 
swelling, 35% chronic inflammation, 
33% photosensitivity, 19% cancer, 
15% lump/node formations
Informed about the risks before undergoing the practice
Source of information - tattooist or piercer 57.9%
45% no information, 11% chronic 
swelling, 11% allergy, 6% chronic 
inflammation, 4% lump/node 
formations, 2% cancer
Source of information - another person
Source of information - informed consent
Signed informed consent
Body art practiced by an authorised operator 72.1% 88%
Observed the use of sterile/disposable instruments 75.9%
Knowledge of hygienic norms
Complications 23.4% (58.7% non-infectious)
12% (7% ptotosensitivity, 3% chronic 
swelling, 1% hepatitis, 1% allergy, 
1% lump/node formations, 1% 
chronic inflammation)
Seek medical advice in case of infections 30% 16% (in case of complications)
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Table 3.14: Data gaps and research needs. 
 
 
A majority of the respondents considered that, to improve the safety of tattoo/PMU inks 
and practices, guidelines for risk assessment are needed, as well as the development 
and harmonisation of analytical methods, the collection of data on normal usage of and 
exposure to tattoo inks (surface of application, body area, colour, population group), a 
better knowledge of inks' physical-chemical properties (stability and shelf-life), chemical 
composition, purity, and ingredients' concentration. The lack of harmonised analytical 
methods had been already flagged in the report on the first Work Package of the project 
[2] and in the questionnaire, the Italian experts proposed the following priority list: 1) 
heavy metals; 2) aromatic amines; 3) polycyclic aromatic hydrocarbons and 
benzo(a)pyrene. The Danish authority highlighted the importance to collect data on the 
amount of inks applied for tattoos and PMU. 
Considering the risk assessment of tattoo/PMU inks' ingredients, about half of the 
respondents identified the following data gaps and research needs: absorption level, 
distribution, metabolism and excretion (ADME) of ingredients, including pigments 
migration in the body and photo-degradation (top priority in the opinion of the Dutch 
authority); the derivation of No Adverse Effect Level (NOAEL); data on the purity level, 
impurities, auxiliaries, stability (to UV, laser, enzymes, bacteria) and cleavage products 
of ingredients; data on the following properties of ingredients: corrosion, irritation (skin, 
mucous membranes), phototoxicity, immunotoxicity (sensitisation, photo-sensitisation, 
etc.), in vitro genotoxicity, including test of cleavage products and photo-genotoxicity. 
In addition, the German experts highlighted the urgent need of research on biokinetics 
of tattoo inks and their ingredients in the human body, opinion shared also by the 
Belgian authority, who referred also to nanoparticles [71]; while the Dutch experts 
mentioned the necessity to collect more information about adverse reactions linked to 
tattoo application and removal. 
CZ DE DK ES FR IT NL SE SI SK
Better knowledge of inks' chemical 
composition and purity, ingredients' conc. Y Y Y Y Y Y
Better knowledge of inks' physical-chemical 
properties Y Y Y Y Y Y
Data on normal usage of and exposure to 
tattoo inks Y
Y                   
(particularly 
amount applied)
Y Y Y Y Y
Development and harmonization of analytical 
methods Y Y Y Y
Y                  
(1-heavy 
metals, 2-
AA, 3-PAH 
and BaP)
Y Y
Guidelines for risk assessment Y Y Y Y Y Y Y Y
Risk assessment of ingredients
Absorption level, distribution, metabolism and 
excretion (ADME) of ingredients Y Y Y
Y                            
(top priority) Y
Derivation of No Adverse Effect Level (NOAEL) Y Y Y Y
Phys-chem properties of ingredients
Purity Y Y Y Y Y
Impurities Y Y Y Y Y
Auxiliary ingredients Y Y Y Y
Stability Y Y Y Y
Cleavage products Y Y Y Y Y
Toxicological data on ingredients
Corrosion Y Y Y Y
Irritation Y Y Y Y
Phototoxicity Y Y Y Y
Immunotoxicity Y Y Y Y
Genotoxicity in vitro Y Y Y Y
Photo-genotoxicity Y Y Y
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Kluger [68], in its paper on tattoos, inks and cancer concluded that, based on the 
literature review, the association between tattoos and skin tumours seems to be 
coincidental, as no direct cause/effect relationship could be established. At the same 
time, they noted the lack of large-scale studies of clinical and epidemiological factors and 
pointed out the necessity of in-vivo data on the skin concentrations of tattoo ingredients, 
impurities and by-products, both in the cancer area and in an unaffected area of the 
tattoo that contains the same colour. Similar opinions were expressed by Mataix [43] 
and the Belgian Superior Health Council [71] and by a number of experts of the CSN-
STPM. 
The need to investigate more the fate of tattoo ingredients in the skin and in the body in 
general, also under solar and laser light was mentioned by several authors (for example, 
[52, 71]) and experts during the meetings of the CSN-STPM. 
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4. Conclusion 
The conclusions of the third Work Package of the EC project "Tattoos - Permanent Make-
up" are described in the following paragraphs.  
Adverse health effects linked to tattoo/PMU applications 
As the popularity of tattoos and PMU has increased over the last decades, a wide range 
of health effects are nowadays encountered by physicians. The real incidence of tattoo 
reactions is currently unknown. The difficulty of precise counting stems also from the 
lack of differentiation between serious complications and mild discomfort "complaints", 
experienced by a highly variable proportion of tattooed individuals, up to 67% due to the 
subjectivity of the matter. 
Adverse effects can been subdivided into the following categories: acute aseptic 
inflammation, infectious risks (bacterial and viral) and non-infectious risks, including 
allergic/hypersensitivity and autoimmune type reactions and other secondary effects.  
At short term, together with the inevitable wound healing process taking place already 
during the tattoo session, immediate complications may arise within days in the case of 
skin bacterial infection, or within weeks, for allergic reactions. In the long run persistent 
inflammatory reactions and delayed hypersensitivity with chronic dermatosis may 
appear, sometimes after years or decades.  
Transmissible diseases through tattoo/PMU application involve mainly inoculation of 
bacteria or more rarely viruses. The frequency of cutaneous infections by pathogenic 
germs remains unknown, though it has been estimated at up to 5% of the tattoo-
recipients, and even rarer in case of PMU applications, which usually take place in 
professional settings. Skin infections can generally be avoided by improving inks sterility 
and hygiene conditions of tattoo parlours. 
The vast majority of tattoo/PMU complications are allergic reactions and poorly 
understood coincidental diseases implying autoimmunity, which are by definition 
unpredictable, except in susceptible patients, and which may show long latency (up to 
decades) after having placed the tattoo/PMU. So far, the risk of (skin) tattoo-induced 
tumours has been neither proved nor excluded. For both of these groups of diseases no 
straightforward causal relationship has been so far established with regard to ink 
composition and further studies, i.e. epidemiological screenings, would be needed to fill 
the data gaps. 
Tattoos may interfere with medical procedures, such as PET and MRI. Sustained 
cutaneous reaction (“burn”) has been reported in patients going through Magnetic 
Resonance Imaging possibly due to the presence of ferromagnetic metallic compounds in 
tattoo pigments. Epidural anaesthesia could be complicated in case of tattoos in the 
spinal area. 
Patients with prior cardiac, blood or autoimmune pathologies should be prevented from 
tattooing in order to avoid potential severe complications. 
Adverse health effects linked to tattoo/PMU removal 
Nowadays, the most commonly used technique for tattoo/PMU removal is based on the 
use of Q-switched lasers, which underwent significant technological improvements in the 
last decades. Despite this progress, temporary and permanent side effects still occur, 
especially when incorrect parameters are applied. Among these, acute aseptic 
inflammations, blistering, crusting, erythema and pinpoint bleeding have been described 
in the literature. At the same time, other risks such as allergic reactions and pigmentary 
disorders (hypo/hyperpigmentation and paradoxical darkening) have also been reported. 
The potential toxicity of the photo degradation products of ink ingredients and 
impurities, in particular of pigments, have been highlighted by several authors as 
possible cause of adverse reactions, also systemic, even though no clear cause/effect 
link has been proved so far. Correct information about possible side-effects and 
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impossibility to completely remove certain tattoos, because of colours and/or skin type, 
should be provided to the patients before initiating the removal treatment and possibly 
even before applying the tattoo. 
Henna-based temporary tattoos: outline and side effects 
Even though henna-based temporary tattoos are not made by injection, but the henna 
based preparation is applied on the skin surface, they may entail some risks, especially 
the ones made with black henna, such as contact dermatitis and hypertrophic/keloid 
scars. P-phenylenediamine, which is contained in black henna, is a powerful antigen 
potentially inducing immediate and/or delayed allergy type reactions. 
Experience with the CoE ResAP(2008)1 
The majority of the respondent national authorities considered that based on their 
experience the recommendations of the CoE ResAP(2008)1 should be updated to 
improve the level of safety of tattoo/PMU inks and practices. Practical suggestions 
regarding chemical, labelling, hygiene/sterility and other requirements were collected 
through the answers to a questionnaire and discussions during the meetings of the 
Consumer Safety Network Subgroup Tattoos and Permanent Make-up. Proposals ranged 
from the inclusion in the negative lists of additional substances, like aromatic amines, 
colorants and impurities, to the request of adding the period of maximum durability after 
opening and the indication of the ink sterilisation method on the label, to the 
establishment of a compulsory register of complications. 
Additional proposals by Member States' authorities included the need of establishing 
Good Manufacturing Practices for tattoo/PMU inks, of controlling products sold on the 
internet, of establishing compulsory training for tattooists. Moreover, suggestions to 
enhance the collaboration among manufacturers and authorities and to ban “backyard” 
tattooing were also mentioned by several Member States. 
Risk perception and communication 
Concerning risk communication, among the respondents, nine Member States reported 
that information campaigns had been organised either at national or at local level in their 
countries. There was a general consensus on the benefit of additional information 
campaigns targeted to tattoo artists, potential clients and general public, with a 
particular emphasis on the young population. Similar conclusions can be found in the 
literature.  
Currently the information on risk perception comes from the tattooist (possibly via an 
informed consent form), or is received through parents or friends, or read in mass media 
and internet. A number of surveys targeting students evidenced a general knowledge of 
infectious risks related to body art practices (considering both piercing and tattooing) in 
the range 36-90%, which decreased to 3.5-60% when more specific questions about 
transmittable agents were asked. Similarly, non-infectious risks associated to body art 
practices were indicated by 26-65% of students, with only 2-5% having a more precise 
knowledge of them. 
Data gaps and research needs 
The following data gaps and research needs were identified by the majority of experts:  
• guidelines for risk assessment of tattoo/PMU products;  
• harmonised analytical methods;  
• data on normal usage of and exposure to tattoo inks;  
• better knowledge of inks' physical-chemical properties, chemical composition, 
purity, and ingredients' concentration. 
Experts also noted that to successfully carry out a toxicological assessment of 
tattoo/PMU inks, several data are missing, such as the ones on absorption level, 
distribution, metabolism and excretion (ADME) of ingredients, including pigments 
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migration in the body and photo-degradation, No Adverse Effect Level (NOAEL), as well 
as chemical and toxicological properties of ingredients. 
Moreover, many authors suggested conducting prospective cohort studies in order to 
investigate the correlation between tattoos and skin carcinogenesis. 
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List of abbreviations and definitions  
Abbreviations 
AA Aromatic Amines 
ADME Absorption, Distribution, Metabolism and Excretion 
BCC Basal Cell Carcinoma 
BfR German Federal Institute for Risk Assessment 
CoE Council of Europe 
CMR carcinogenic, mutagenic and reprotoxic 
CSN Consumer Safety Network 
EFTA European Free Trade Association 
EC European Commission 
EU European Union 
GMP Good Manufacturing Practices 
HBV Hepatitis B Virus 
HCV Hepatitis C Virus 
HIV Human Immunodeficiency Virus  
HPV Human Papilloma Virus 
KA Keratoacanthoma 
MCV Molluscum Contagiosum Virus 
MRI Magnetic Resonance Imaging 
MRSA Methicillin-Resistant Staphylococcus Aureus 
MS Member States 
NDELA N-nitrosodiethanolamine 
NOAEL No Adverse Effect Level 
NTM Non Tuberculosis Mycobacteriae 
PAA Primary Aromatic Amines 
PAH Polycyclic Aromatic Hydrocarbons 
PAO Period of maximum durability After Opening 
PEH Pseudoepitheliomatous Hyperplasia 
PET Positron Emission Tomography 
PIRL picosecond infrared laser 
PG Pyoderma Gangrenosum 
PMU Permanent Make-Up 
PPD Para-phenylendiamine 
ResAP Resolution (Council of Europe) 
STPM Subgroup Tattoos and Permanent Make-up 
QS laser Quality Switched laser 
SCC Squamous Cell Carcinoma 
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TIME Tattoo Ink Manufacturers in Europe 
 
Definitions 
Basal Cell Carcinoma (BCC) is the most common form of skin cancer. More than two 
million cases of this skin cancer are diagnosed in the United States each year. This skin 
cancer usually develops on skin that gets sun exposure, such as on the head, neck, and 
back of the hands. People who use tanning beds have a much higher risk of getting BCC. 
They also tend to get BCC earlier in life. This type of skin cancer grows slowly, and rarely 
spreads to other parts of the body, if untreated. (from American Academy of 
Dermatology) 
Eczema (called also atopic dermatitis) is an inflammation causing symptoms such as 
itchy, red, and dry skin. The treatment may require oral or topical corticosteroids and 
light therapy. (from Web MD) 
Granulomatous reactions are sub-classified into about four types. They can be 
tuberculoid, sarcoidal, pallisading or infectious (suppurative). Various diseases present 
as different types of granulomas. Foreign body material can cause any type of 
granuloma but usually it is sarcoidal. The sarcoidal granuloma is sometimes called the 
naked granuloma because there is just a collection of histiocytes without any 
surrounding lymphocytes or neutrophils. The tuberculoid granuloma contains histiocytes 
but also some central caseous necrosis. In the pallisading granuloma the cells are 
surrounding denatured collagen which goes under the name of necrobiosis or sometimes 
there is mucin or foreign body material at the centre of a pallisading granuloma. A 
suppurative granuloma has centrally numerous neutrophils and they are part of an 
infected abscess. The granuloma is the body's immune attempt at isolating this infective 
or inflammatory process. The most common granulomatous diseases encountered by 
dermatologists are ruptured follicular cyst, sarcoidosis, granuloma annulare, actinic 
granuloma, necrobiosis lipoidica, tuberculosis of the skin and leprosy. (from 
"Dermatopathology Made Simple", the teaching website of the Australian Institute of 
Dermatology) 
Keratoacanthoma is a relatively common low-grade tumour that originates in the 
pilosebaceous glands and closely resembles squamous cell carcinoma (SCC). In fact, 
strong arguments support classifying keratoacanthoma as a variant of invasive SCC. In 
most pathology/biopsy reports, dermatopathologists refer to the lesion as "squamous 
cell carcinoma, keratoacanthoma-type." Keratoacanthoma is characterized by rapid 
growth over a few weeks to months, followed by spontaneous resolution over 4-6 
months in most cases. Keratoacanthoma may progress rarely to invasive or metastatic 
carcinoma. Whether these cases were SCC or keratoacanthoma, the reports highlight the 
difficulty of distinctly classifying individual cases (from Medscape) 
Lichenoid reaction pattern implies histological changes at the dermal/epidermal 
junction due to an immune attack of lymphocytes at the dermal/epidermal junction. 
Classic conditions in this category include lichen planus, lupus erythematosis and 
erythema multiforme. There are variants on this such as fixed drug reaction, graft 
versus host reaction and some of the other collagen diseases that also are associated 
with damage to the dermal/epidermal junction and the greater that degree of damage 
the more it influences the clinical picture. (from "Dermatopathology Made Simple", the 
teaching website of the Australian Institute of Dermatology) 
Molluscum Contagiosum virus (MCV) is a common disease of childhood transmitted 
by skin-to-skin contact or by contact with fomites. Molluscum may represent a sexually 
transmitted disease. It can also present as widespread lesions in the setting of 
immunodeficiency (AIDS) [57].  
Pseudoepitheliomatous Hyperplasia: a benign marked increase and downgrowth of 
epidermal cells, observed in chronic inflammatory dermatoses and over some dermal 
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neoplasms and nevi; microscopically, it resembles well-differentiated squamous cell 
carcinoma. (from: Farlex Partner Medical Dictionary © Farlex 2012) 
Sarcoidosis is an idiopathic, multisystemic, granulomatous disease characterised 
histologically by non-caseating epithelioid granulomas. Lung disease, the most common 
systemic manifestation of sarcoidosis, is present in 90% of patients. (Ali [65] citing 
Howard A, White CR. Non-infectious granulomas. In: Bolognia JL, Jorizzo JL, Rapini RP, 
editors. Dermatology. London: Mosby;2003. p. 1455- 69). 
Squamous Cell Carcinoma: a malignant neoplasm derived from stratified squamous 
epithelium, but that may also occur in sites such as bronchial mucosa where glandular or 
columnar epithelium is normally present; variable amounts of keratin are formed, in 
relationship to the degree of differentiation, and, if the keratin is not on the surface, it 
may accumulate in the neoplasm as a keratin pearl; in instances in which the cells are 
well differentiated, intercellular bridges may be observed between adjacent cells. (from: 
Farlex Partner Medical Dictionary © Farlex 2012) 
Tattoo Complaints: any unusual condition, sensation or visible reaction in the tattooed 
skin that differs from normal skin of the same person. Usually mild, and treated ”at 
home” [14]. 
Tattoo Complications: more serious adverse reactions in tattoos associated with 
objective, clinical pathologies of the tattoo in combination with major subjective 
symptoms and significant discomfort, i.e. events that would typically make the patient 
consult a doctor [14].  
Uveitis: eye inflammation affecting the middle layer of tissue in the eye wall 
(uvea).Uveitis warning signs often come on suddenly and get worse quickly. They 
include eye redness, pain and blurred vision. The condition can affect one or both eyes, 
primarily in people ages from 20 to 50. Possible causes of uveitis are infection, injury, or 
an autoimmune or inflammatory disease. Many times a cause can't be identified. Uveitis 
can be serious, leading to permanent vision loss. Early diagnosis and treatment are 
important to prevent the complications of uveitis. (Definition by Mayo Clinic Staff) 
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Minutes of the meeting of the Consumer Safety Network Subgroup Tattoos and 
Permanent Make-up (Ispra (VA), Italy – 9th November 2015) 
 
The agenda and list of participants are reported in Tables A and B, respectively. 
 
Welcome and adoption of the agenda 
Mrs Piccinini, chair of the meeting and project responsible, EC DG JRC IHCP, welcomed 
the country delegates and stakeholders. She reminded all present the aims and different 
Work Packages of the project. After each participant's introduction, the agenda of the 
meeting was approved as written, with the addition of a presentation from Mr. Michel, 
TIME, in case the schedule would allow it under data gaps and research needs. 
Mrs Blass Rico, EC DG JUST, informed about the EC decision of not going ahead with an 
emergency measure for tattoo/PMU inks under Article 13 of the General Product Safety 
Directive (GPSD) 2001/95/EC. She explained that the Commission has decided to 
address the chemical safety of tattoo inks under the chemical legislation and stressed 
the high expectations from the output of this project, which is still very important and 
will be considered for any future actions. She acknowledged the work of this group and 
thanked all for their support, reminding that the final conclusions from the project shall 
be very well supported and solid. 
 
Adoption of the minutes 
The minutes of the meeting of the Consumer Safety Network Sub-group Tattoos and 
Permanent Make-up, held on 20th April 2015, were adopted without any modification. 
 
The spectrum of clinical complications of tattoos in Europe (Jørgen SERUP, 
Bispebjerg University Hospital, DK) 
Mr Serup summarised the various types of health concerns linked to tattoos/PMU in a 
pyramide scheme containing in decreasing order of severity and increasing order of 
frequency: 1) disablement, death; 2) medical complications; 3) the complaints (for 
which generally people do not see a doctor); and 4) the absence of any problem, which 
represents the majority (+/- regrets). An impressive photo gallery of complications 
coming from his professional experience very well illustrated the various range and 
grade of tattoo complications that have been observed and treated. 
In studies [16, 17] of a tattooed sample of 298 people, the prevalence of mild tattoo 
symptoms or complaints reached 42% (with 44% concerning photosensitivity). Mr Serup 
reported similar medical complications based on his recent statistical data from the 
”Tattoo Clinic”: 405 patients with 493 tattoo complications between October 2008 - June 
2015. The diagnoses showed the hereunder distribution: 
• 12% infections 
• 57% non infectious 
• 9% psycho-social 
• 16% miscellaneous 
• 6% techniques and treatment failures  
Mr Serup concluded by noting that the majority of the complications (40.5%) were 
multiple and by mentioning that, in his opinion, tattoo inks cause not more than 9-15% 
of the observed problems. He also put forward the question of determining to what 
extent a possible regulation could change the pyramid distribution levels. 
 
Literature - Adverse health effects linked to tattoo/PMU Practices (Sazan 
PAKALIN, EC DG JRC) 
Mr Pakalin summarised the data published in the literature from 2004 on by briefly 
introducing the methodology followed and by describing the following complications. 
Infections: these types of complications depend on human and technical factors 
(hygiene), the bacterial infections are mainly local, they include skin infections and non-
tuberculous mycobacterial infections. 
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Allergy: allergic reactions are the most common reaction to tattoo pigments and occur 
predominantly with red inks; they can provoke acute inflammation (heals within 1-3 
weeks), delayed hypersensitivity reactions and eczema or allergic contact dermatitis. 
Coincidental diseases: this group includes reactivation of underlying dermatoses within a 
tattoo (isomorphic phenomenon), sarcoidosis (autoimmune disease) and 
cancers/malignancy risks possibly due to the potential carcinogenicity of some ink 
contaminants (AA, PAH, heavy metals), and photo degradation products of ingredients, 
such as pigments. It was highlighted that the casual link between tattooing and the 
development of malignant tumours has not been proven. 
Mr Pakalin also mentioned the possible disruption of diagnosis and medical procedures 
by tattoo applications and the possible adverse health effects of tattoo removal.  
 
Questionnaires - Adverse health effects linked to tattoo/PMU practices (Laura 
CONTOR, EC DG JRC) 
Mrs Laura Contor described the two questionnaires developed for competent authorities 
and dermatologists and reported back on the responses. 5 Member States answered to 
the health effects section of the questionnaires and 19 dermatologists reported on the 
health complications. Among these, 15 dermatologists see less than 15 patients/year 
showing tattoo complications and 4 examine up to 150. This low number of replies limits 
the interpretation of the results of the exercise. 
The outcome showed that some common pre-conditions affecting complications include 
metal allergy and atopic or contact dermatitis. The top three skin symptoms ranked as 
being frequent/common and severe were reported as being skin ulceration, swelling and 
pain. Removals were reported as involving pain as common reported effect. The 
respondents also agreed that adverse effects were more frequently encountered in black 
and red colours. 
 
Questionnaires - Proposals to improve the safety of tattoo/PMU practices 
(Paola PICCININI, EC DG JRC) 
Mrs. Piccinini reviewed the questionnaire responses of the competent authorities 
regarding the experience with the CoE ResAP(2008)1. 14 replies were received. To 
improve the safety of tattoo/PMU inks and practices, some modifications of the 
recommendations laid down in the CoE ResAP(2008)1were considered necessary. 
Member states proposed some modifications to the negative lists of chemicals in the CoE 
ResAP(2008)1.  
These changes covered aromatic amines (AA), such as adding aniline, 2-ethoxyaniline 
and N-isopropyl-N'-phenyl-1,4-phenylendiamine, and introducing concentration limits for 
AA. A number of pigments were suggested to be added to the negative list of colorants. 
Proposals for establishing a limit value for nickel and modifying limits for 
benzo[a]pyrene, Ni, As, Co, Pb and Sb were also put forward. Regarding labelling 
requirements, a number of respondents agreed on adding the period of durability after 
opening (PAO), the quantitative composition of inks and the storage conditions. A 
register of complaints was felt necessary, as well as compulsory training for tattooists. 
 
Questionnaires – Data gaps and research needs (Paola PICCININI, EC DG JRC) 
Among the proposals provided in the questionnaires, Mrs Piccinini highlighted the most 
cited data gaps: data on normal usage of and exposure to tattoo inks, guidelines for risk 
assessment of tattoo/PMU products, data needed to carry out the risk assessment and 
development and harmonisation of analytical methods. 
 
Literature and questionnaires – Risk communication and perception (Paola 
PICCININI, EC DG JRC) 
Mrs Piccinini reviewed the questionnaires responses on risk communication and 
perception. Nine countries informed that they had organised information campaigns, 
either at national or local level, using means such as brochures, newspapers/magazines 
and internet/social networks to communicate with tattoo artists, potential clients, the 
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general public, young people, students, physicians and school teachers. Respondents 
agreed on the fact that additional information campaigns would be beneficial. 
In the opinion of national authorities and several authors in the literature, risk 
perception seems to be based on the information received by the tattooist, another 
person (either parents or friends), the informed consent, or what is available in the 
media and internet. In addition, some papers estimated the level of knowledge of 
possible health risks among students. In general, infectious risks were better known that 
non-infectious ones, even though the level of knowledge was in many cases only 
superficial. These evidences support the need of further additional information 
campaigns. 
 
Discussions on health effects 
Cancer 
Discussions took place around the levels of evidence for skin cancer and/or systemic 
cancer. Mr Fiala (ANEC) recommended being cautious before stating there is evidence 
that tattoos do not cause cancer. Ms. De Cuyper, Belgium Superior Health Council, noted 
that 50 cases of skin cancer related to tattoos were reported, but no data exists 
regarding systemic cancer. Mr Serup highlighted that in the last century black pigments, 
probably containing PAH, were used and no problems were evidenced. Mrs Blume, BfR 
(DE), commented that carcinogenic substances in tattoo inks might induce cancer inside 
the body if they become systematically available; that it could be difficult, however, to 
demonstrate a causal link between a given tattoo ink ingredient and internal cancer, 
because the human body is exposed to a variety of carcinogenic substances throughout 
lifetime. Mr Pakalin noted that some substances do not have a safe threshold. 
Hepatitis 
Mr Renzoni, Superior Health Institute (IT), mentioned that Italy shows the highest 
prevalence of hepatitis in the Mediterranean area. In an epidemiological study performed 
by the Italian Surveillance System (SEIEVA), between 2010-2014, in the age group of 
15 to 54 years old, 10.3% of patients newly infected with HCV, and 4.8% of those 
infected with HBV had placed a tattoo within 6 months prior to the hepatitis onset.  
The report indicates a strong association, albeit no formal causal relationship, between 
the two events. Mr Bergström, Sweden Registered Tattoo artists, informed that in 
Sweden public health inspectors had identified 40 cases of hepatitis related to tattoo 
practices during the last 3-4 years, all from home tattooing, probably due to low hygiene 
conditions. Mr Serup noted that it might be worth to have a specialist in infectious 
diseases examine this matter further.  
Colours 
According to Mrs De Cuyper, the health effects related to the red colour were under 
reported in the literature. Mr Michel, TIME (DE), considered that nowadays the 
complications related to the red colour are not due to the presence of mercury as in the 
past, but to some organic pigment, especially photo reactive pigments. 
Regulations 
Mrs Bjerregaard Lerche, Danish EPA, supported by Mr Fiala, commented that two worlds 
co-existed: the clinical world with the physicians and the regulatory world with a more 
preventive approach where regulations are based on effects in animals. Both need to be 
considered and mentioned in this description; at present the clinical side is very big 
while the other approach is not so well covered. According to Mrs. De Cuyper, it is 
needed to divide the issues in 1) procedures (infections) and materials (sterility) to be 
addressed by the CEN guidelines and 2) toxicity, carcinogenicity, allergy to be addressed 
by this CSN subgroup to identify the problematic ingredients and impurities that could be 
taken into account by regulatory action to eliminate the risky substances.  
Data collection 
This tattoo health effect field is new for dermatologists and clinicians, no prior education 
exists, and no solid diagnosis can be made due to the lack of knowledge and limited 
experience. Mr Serup stated that the replies to the questionnaires collected and the 
literature review are not enough to reflect the real picture. In his opinion, infections by 
staphylococcus are far more common than the Köbner phenomenon or the mycobacteria. 
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Mrs. De Cuyper added that usually minor symptoms are dealt with by the client himself, 
the pharmacist, the tattooist or the general practitioners. The number of consulted 
dermatologists does not provide a reliable picture of all complications. 
Mr Baeumler, University of Regensburg (DE), believed that the data acquisition was the 
problem, more information is needed from dermatologists and physicians and data from 
more than 1000 patients should be collected to have reliable statistics. Focus should be 
put on infections, allergies and foreign body reactions and the identification of the right 
questions would be challenging. Currently, not enough reliable information is available 
and there is the need of a reliable reporting system. 
Mr Serup agreed with the existence of data gaps and lack of knowledge and considered 
important to focus on clinical problems more than on ink composition. He would be in 
favour of a registry where doctors would be obliged to report tattoo complications like 
what already exists in Sweden regarding cancer and occupational diseases. He 
considered that this is a Member States task and that the RAPEX system does not collect 
adverse health reactions but actions taken by the Member States on dangerous inks on 
the market.  
The registry of adverse reactions should be made mandatory to be effective according to 
Mrs Lerche. Mrs Verdier, French National Safety Agency of medicine and health products, 
complemented this information explaining the vigilance system put in place in France 
since 2008. A notification form is filled in when adverse health effects are observed, 
however, despite this obligation adverse health effects are usually under reported and 
the register does not allow any client-ink traceability. So far, 37 side-effects were 
reported and many questions about the process or the removals were raised.  
Mr Bäumler believed that the reporting system should concentrate on a short list of most 
common problems and focus on hospitals/dermatologists that would volunteer to 
complete an on-line questionnaire for input in a data base, thus forming a reporting 
network. The advantages would be the voluntary/dedicated basis of the exercise, the 
reduction of under-reporting, and a professional outcome with a medical diagnosis, 
avoiding self-reporting and biased reports.  
In Mr Bäumler's opinion, it will probably take some years before a reliable information 
collection system on adverse health effects could be put in place, therefore he 
considered that, in parallel, attention should be paid to what can be addressed already, 
i.e. black inks without PAH, ban the red pigment 22 that causes most of the adverse 
effects among the 20-25 red pigments available, ensure hygiene and sterility measures. 
German and Danish experts agreed that there are enough data and information to act, 
as shown by the Member States where there are national legislation on tattoo inks; that 
the focus should be on further collaboration and each part involved in the tattoo 
activities assuming their responsibility towards safety. 
Allergy 
Mr Serup proposed a possible study using the skin sample collection he has gathered 
from the allergic patients. The skin samples could be tested for the identification of inks 
ingredients that could be linked to the triggering of the allergic reaction. Mr Serup asked 
the possibilities for EU funding of such study. The limitation of this proposal, highlighted 
by Mrs Lerche, was that allergies are very-much individual-dependant. Nevertheless, Mrs 
Lerche supported the need for further data on released substances after cleavage and on 
removal products, as well as investigation of the biopsies in allergic skins. 
 
Discussions on safety improvements 
Chemicals 
Experts were in favour of specifying concentration limits for the aromatic amines that 
should not be contained in tattoo/PMU products according to the CoE ResAP(2008)1 and 
some proposed to include additional AAs in the negative lists. Similarly, various 
pigments were mentioned as possible candidates for the negative list. In the opinion of 
the manufacturers' representatives, pigment green 7 should not be prohibited as there 
are not better substitutes available. It was pointed out that some of the candidates for 
the negative lists should already not be used in tattoo/PMU products as they are 
classified as CMRs in the CLP regulation or they are listed either in Annexes II or IV 
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(column g) of the cosmetic regulation. It was generally agreed that any change in the 
list of substances or on the recommended limits should be based on solid data and duly 
justified. 
When the proposal for a positive list of colorants was discussed, Mr Renzoni noted that 
such a list requires preparing accurate risk assessment dossiers. 
Adverse effect/complaint registers 
Experts agreed on the usefulness of a register of complaints. Mrs Kisacova, Public Health 
Authority of the Slovak Republic, believed that this register would improve the public and 
tattooist knowledge. 
Pre-marketing 
In the questionnaires, pre-marketing authorisation of inks was supported by 5/9 
countries. Germany considered that compulsory safety assessment should be made by 
manufacturers, importers or the person responsible for placing the product on the 
market. For the manufacturers and tattooists associations, it is very important to ensure 
that the ingredients reported on the bottle are reliable and complete.  
Hygiene practices 
The participants were briefed about the activities of the European Committee for 
Standardization (CEN)/Technical committee 435 on tattooing services, which is preparing 
guidelines on hygiene for tattooists (including tools) and clients. The document, to be 
completed in 2016, will address topics such as sterilisation of tools, disinfection of 
premises, possible vaccination of tattooists, informed consent form, training 
programmes, age limits, etc. Tattooists associations, together with dermatologists and 
other stakeholders are involved in the exercise. 
The validation of the sterilisation method for inks was considered; however it was 
highlighted that it would be difficult as it depends on the packaging, product, etc. Mr 
Michel (TIME) agreed to share a proposal they developed to avoid contamination. Mr 
Renzoni considered that it is necessary to identify an effective sterilisation method, as 
the results of microbiological analyses performed show that sealed inks, marketed as 
sterile, are actually contaminated. Hence, Italy proposed to set up a working group to 
validate ink sterilisation methods. 
 
Discussions on regulations options 
Mrs Piccinini reminded all participants that the aims of this meeting are to come up with 
recommendations to improve the safety of tattoo/PMU inks and practices based on the 
lessons learned and experience from the MS. How the conclusions and recommendations 
would be taken up by the legislator is beyond the remit of this group. The project should 
establish the state of play, identify the problems and provide suggestions to improve the 
safety. Mrs Blass Rico reminded that the recommendations in the CoE ResAPs as 
benchmark used by the Member States to draft their national legislations have been 
revised by the experts. A representative of the Council of Europe is member of the group 
although Council of Europe activities are of course beyond the scope of this project. The 
CoE representative in the meeting acknowledged the usefulness of the discussions and 
informed that at the next meeting of the Steering Committee on Consumer Safety 
Products (February 2016) a point to consider the new data made available by this 
project could be included on the agenda.  
Mrs Blass Rico explained that some circumstances have evolved since the project was 
originally designed in principle linked to a possible emergency measure. A detailed 
impact assessment is needed for any new legislative proposal: including what is the 
problem and its size, data on the health costs, what is the prevalence in the population, 
what are the costs for the manufacturers, etc. 
She stressed that pragmatic recommendations and concrete proposals from this project 
are still very relevant to improve the safety of tattoo and PMU inks.  
Germany, Denmark and Belgium experts considered that an EU harmonised measure 
was needed. 
Mr Bergström (Tattoo artists) stressed that the main safety problems are linked to the 
existence of "black market" of tattoo artists who do not respect hygiene and good 
practices. The project should recommend addressing the "illegal" practice at EU level. Mr 
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Michel agreed that national laws will not be sufficient to tackle the problem of home 
scratchers. He also stressed the difficulties for manufacturers to comply with different 
national regulations in each country. 
Mr Fiala noted that a key outcome of this project could be a recommendation to 
establish limits, to identify the key PAHs, to gather basic information on toxicity of 
colorants, to harmonise the classification of sensitisation and, as a next step, establish a 
positive list. Building on this, Mr Michel – supported by Mrs Hrzenjak, National 
Laboratory of Health Environment and Food (SI) and Mr Serup – added the need to 
clarify which limits should be addressed and with which analytical methods. 
Mr Bäumler mentioned that the real challenge is to identify the problem, determine its 
size and increase the awareness. Mr Serup added that manufacturers will not be able to 
solve the data weaknesses; in the meantime, if the absence of regulation the illegal 
market will increase. The focus should be to produce solid figures with good research.  
During the meeting the majority of participants voiced support for the preparation of a 
stand-alone legislation on tattoo inks in the EU. 
 
Discussion on data gaps and recommendations 
Analytical methods for limit setting 
As suggestions were made to modify or set more limits, Mrs Piccinini reminded the lack 
of analytical methods developed for tattoo inks. Mrs Josefa Barrero, EC DG JRC, added 
that the limit values needed also to be harmonised and agreed upon. 
Guidelines for risk assessment 
Mrs Amela Saracevic, Council of Europe (FR), informed the participants that the CoE has 
finalised a document on guidelines for risk assessment that should be ready during the 
first quarter of 2016. 
Risk perception 
The public, in particular the young population, need to be aware of the risks of taking a 
tattoo and the possible consequences of opting for a backyard tattooist compared to a  
professional working under good hygienic conditions. 
Informed consent 
Mr Serup stressed the need for informing the customer in writing, preferably the day 
before the procedure and including the data regarding possible interfering pre-
conditions. Mrs Meisner noted that this step would also protect the tattooist. In addition, 
according to Mr Serup and Mr Bergström, not only the customers should be registered 
but also the inks used, to allow tracing back in case of adverse health effects.  
Training of tattooists 
Mr Bergström considers that most of the infections occur outside the parlour after the 
tattoo is performed; if both the tattooist and the client are aware of aftercare rules half 
of the infections would be avoided. The group agreed on the need for training for 
tattooists at EU and /or national level on hygiene, cross-contamination, storage, inks, 
adverse effects, skin/body elements but not the artistic/aesthetic part. This is being 
addressed by the CEN/TC 435. 
 
Follow-up 
Participants were invited to:  
• send in writing further suggestions regarding recommendations 
• comment on presentations, missing points 
• identify relevant items to be addressed  
• as soon as available, review the report on WP2: State of play and trends in tattoo 
practices – (a) statistics about practices, (b) ink ingredients & their fate and (c) 
RAPEX notifications & market surveillance. 
The 1st draft of WP3 was expected by the end of 2015: (a) adverse health effects linked 
to tattoo/PMU applications and removals, (b) assessment and update of the ResAP 
(2008)1, (c) risk perception and communication and (d) data gaps and research needs. 
 
Next meeting 
The final meeting of the project would be held during the first quarter of 2016. 
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Table A: Agenda of the meeting of the CSN-STPM held on 9th November 2015 at the DG 
JRC in Ispra (VA), Italy. 
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Table B: List of participants (meeting of the CSN-STPM on 9th November 2015). 
 
 
 
 
 
 
 
 
  
Country National Expert Affiliation
Belgium  DE CUYPER Christa Belgian Superior Health Council
Denmark LERCHE Dorte B. Danish Environmental Protection Agency
France VERDIER Cécile 
Agence Nationale de sécurité du Médicament 
et des produits de santé
BLUME Annegret Bundesinstitut für Risikobewertung
MEISNER Anke Federal Ministry of Food and Agriculture
Italy RENZONI Alberto Istituto Superiore di Sanità
DE VRIES-HLAVACOVA 
Mariana
Nederlandse Voedsel- en Warenautoriteit
JANSSEN Pjcm
Netherlands National Institute for Public Health 
and the Environment
Slovak Republic KISACOVA Janka Public Health Authority of the Slovak Republic
Slovenia HRŽENJAK Vesna 
National laboratory of health- environment and 
food
Spain VIDAL Areses 
Agencia Española de Medicamentos y 
Productos Sanitarios
Sweden CRONA Magnus Medical Product Agency
Switzerland HOHL Christopher Kantonales Laboratoirum Basel-Stadt
United Kingdom AXFORD Ian LGC LTD
Country Stakeholders Affiliation
Austria FIALA Franz ASI Consumer Council
Denmark SERUP Jørgen Bispebjerg University Hospital
France SARACEVIC Amela 
European Directorate for the Quality of 
Medicines & HealthCare- 
Council of Europe
BAUMLER Wolfgang University of Regensburg 
KEMNER Sina Tattoo Ink Manufacturers in Europe (TIME)
MICHEL Ralf Tattoo Ink Manufacturers in Europe (TIME)
WERNER Alexander 
H-A-N Haus der Angewandten 
Naturwissenschaften GmbH
Italy GIUSEPPIN Eliseo Associazione tatuatori.it
Italy ZOPPETTI Marco Associazione tatuatori.it 
Sweden BERGSTROM Jens Sweeden Registered Tattoo artists (SRT)
European 
Commission
Directorate General Institute and Unit
BARRERO Josefa
BIANCHI Ivana 
BLASS RICO Ana 
Maria 
EC DG Justice and 
Consumers 
Dir. E Product and Service Safety
CONTOR Laura 
PAKALIN Sazan 
PICCININI Paola 
Joint Research Centre
Institue for Health and Consumer Protection, 
Chemical Assessment and Testing Unit (Dir I.1)
Germany
Netherlands
Germany
Joint Research Centre
Institue for Health and Consumer Protection, 
Chemical Assessment and Testing Unit (Dir I.1)
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Table A: Questionnaires on adverse health effects for dermatologists. 
 
SKIN
 Bleeding
 Swelling 
 Itching 
 Pain
SKIN
 Burning
 Crusts
 Redness 
 Skin ulceration
SKIN 
 Skin ulceration
 Wounds 
 Sun-related lesion (photosensitivity)
 Scar tissue
 Numbness
SYSTEMIC
 Fever
 Dizziness
 Headache
 Nausea
 Behavioral changes
ATOPIC OR CONTACT DERMATITIS HISTORY
 allergy to metals (e.g. nickel, cobalt, chromate)
 allergy to para-phenylendiamine (PPD)
 allergy to latex
ATOPIC OR CONTACT DERMATITIS HISTORY
 allergy to preservatives
 allergy to medical drugs
OTHER SKIN DISEASES
 urticaria
 wart (verruca)
 vitiligo
ALLERGIC SKIN REACTIONS
 Contact dermatitis
 Plaque elevation 
 Hyperkeratosis 
 Ulceration/necrosis 
  General rash (in allergy to nickel or 
preservatives)
NON-ALLERGIC INFLAMMATORY 
REACTIONS 
 Papulo-nodular inflammatory reactions (typical in 
black tattoos)
 Nodules and granulomas including cutaneous 
sarcoidosis
 tattoo general sarcoidosis
CUTANEOUS INFECTIONS 
 Bacterial (streptococcus, staphylococcus, 
pseudomonas, mycobacterium,...)
 Viral (herpes papilloma, molluscum etc 
 Fungal: (Candida albicans, Cutaneous Tinea 
infection, zygomycosis, sporotrichosis, …) 
REGIONAL INFECTIONS 
 Erysipelas
  Abscess
SYSTEMIC INFECTIONS 
 hepatitis B/C
 AIDS
 septicaemia
OTHERS 
 Hypo/hyper pigmentation
 Photosensitivity
 Urticaria 
 Lymphoedema and lymph node reaction
TATTOO RELATED TUMOURS 
 Benign tumours 
1. Hyperplastic scar or keloid 
2. Keratoacanthoma
3. Other tissue reactions
 Malignancies
1. Basal cell carcinoma 
2. Squamous cell carcinoma 
3. Melanoma 
4.  Lymphoma 
HISTOPATHOLOGICAL DIAGNOSIS
 Inflammation only 
 Lichenoid reaction
 Granulomatous reaction
 Sarcoid reaction or sarcoidosis
 Pseudolymphoma
 Pseudoepitheliomatous hyperplasia
 Other histologic diagnosis (specify)
1.6 Amongst all your patients having consulted for tattoo/PMU complications, what proportion had previous known allergies and/or skin diseases' history
1.7 - 1.8 Amongst all your patients having consulted for tattoo complications, how frequently did you establish the following diagnosis and what was the main 
histopathologic diagnosis
1. COMPLICATIONS FOLLOWING TATTOO/PMU APPLICATION
1.1 Are you a dermatologist interested in complications linked to tattoos/PMU and do you perform tattoo removals
1.2 How many patients do you see in a year and how many of them have tattoo complications
1.3 What was the interval between the tattoo/PMU application and the onset of symptoms: infectious and non-infectious complications (1 week - > 1 year)
1.4 - 1.5 Amongst all your patients having consulted for tattoo/PMU complications, how frequently did you observe the following cases and how severe were these 
symptoms: 
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ACUTE SYMPTOMS (<1 MONTH)
 pain
 blistering
 pinpoint bleeding
 crusting
 urticarial
 other (specify)
DELAYED SYMPTOMS (>1 MONTH)
 (photo) allergic reactions
 scars
 hyper- and hypopigmentation
 ink retention and darkening
 other (specify)
 <150 
 151 – 300
 301 – 900
 >900 
 black
 red
 orange
 violet/purple
 henna colours
 blue/green/turquoise
 brown
 white
 yellow
 multi-coloured
 Legs
 Arms
 Trunk
 Head/neck
 Genitals
 Multiple locations
 Performed by registered/official tattooist
 Perfomed by amateur/scratcher tattooist
 Performed by cosmetic professional
 Henna application
 Traumatic tattoo
 Iatrogenic tattoo (e.g. nipple reconstruction)
2. COMPLICATIONS FOLLOWING TATTOO/PMU REMOVAL
4 OTHER INFORMATION THAT COULD BE RELEVANT FOR THE PURPOSE OF THIS SURVEY
2.1 How many patients do you see in a year and how many of them have tattoo/PMU  removal complications
2.2 How frequent are the following health issues (acute/chronic) amongst your patients having undertaken tattoos/PMU removals
2.3 What was the technique/instrumentation used for the removal
3. CORRELATIONS BETWEEN HEALTH COMPLICATIONS AND CERTAIN TATTOO CHARACTERISTICS/PARAMETERS
3.1 Amongst the patients that consulted you for medical complications, how frequent were the number of tattoos/patient: 1, 2, 3, 4, 5 or >5
3.2 What was the prevalence of the tattoo' sizes: Total tattooed area (cm²)
3.3 How frequent were the different gender/age characteristics of these patients
3.5 Which localisations of the tattoo/PMU applications were most frequent
3.6 How frequent were the various tattoo/PMU procedures having provoked the health complications 
3.4 What was the frequency of the various colours of their tattoos/PMU
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Table B: Questionnaires for National Authorities. 
 
Skin Acute side-effects (<1 month)
 infections
 allergic reactions
 edema
 itching
 numbness
 wound healing problems
Skin Persistent side-effects (> 1 
month) 
 eczema
 psoriasis
 scars
 scleroderma
 photosensitivity
 granulomas 
 tumours
Systemic Acute side-effects (<1 
month)
 fever
 infections
 dizziness
 headache
 nausea
 behavioural changes
Systemic Persistent side-effects 
(> 1 month)
 infections
 hepatitis
 AIDS
 psychic problems
Immediate skin reactions (< 1 month)
 pain
 blistering
 pinpoint bleeding
Immediate skin reactions (< 1 
month)
 crusting
 urticarial
Delayed symptoms (> 1 month)
 (photo) allergic reactions
 local
 systemic
Delayed symptoms (> 1 month)
 scars
 hyper- and hypopigmentation
 ink retention and darkening
 number of tattoos (single vs 
multiple)
 size of the tattoo 
 gender differences (men vs women)
 customer's age at the time of 
tattooing (adults vs under18 years 
old)
 colour of the tattoo 
 localisation of the tattoo (limbs, 
trunk, head/neck, genitals)
 localisation of the tattoo (limbs, 
trunk, head/neck, genitals)
 type of tattooist (professional, 
scratcher,…)
1. HEALTH EFFECTS
1.1 How frequent are the different health issues amongst people having undertaken tattoos/PMU procedures in your country
1.2 How frequent are the different health issues amongst people having undertaken tattoos/PMU removals in your country
1.3 Were the following factors correlated to higher frequency of medical complications
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CoE ResAP(2008)1
 CoE ResAP(2008)1, Table 1
 CoE ResAP(2008)1, Table 2
 CoE ResAP(2008)1, Table 3
 Requirements for further 
organic impurities for colorants 
used in foodstuffs and cosmetic 
products as set out in Directive 
95/45/EEC
 Ingredients mentioned in Annex 
II to EC Regulation 1223/2009 on 
Cosmetics
 Colorants specified in Annex IV, 
column g of EC Regulation 
1223/2009 on Cosmetics
 CMR substances classified 
under categories 1A, 1B and 2 in 
Table 3.1 of Annex VI to EC 
Regulation 1272/2008 on 
Classification, Labelling and 
Packaging
Other proposals on chemical 
requirements
 Establish positive lists of 
colorants
 Single lists of chemicals (e.g. 
colorants, aromatic amines, 
impurities) instead of cross 
references lists
 Harmonise analytical methods 
for testing hazardous chemicals
 PAO (period of durability after 
opening)
 Quantitative composition of inks 
(decreasing order of concentration for 
each ingredient)
 Date of production
 Conditions of storage
 Type of product: tattoo colour / 
permanent make-up ink
 Address of distributor
 Health warnings
 Sterilization method
 Specify the sterilisation method for 
inks
 Specify the sterilisation method 
for tattooing tools
 Specify the sterilisation method 
for parlour premises
 Use of single dose containers 
vs multidose packaging
 Control products sold on web
 Enhance collaboration between 
manufacturers and authorities
 Ban backyard tattooing
 Establish a list of recognised 
tattooists
 Compulsory training for 
tattooists
 Set up Good Manufacture 
Practices for inks
2. EXPERIENCE WITH THE COUNCIL OF EUROPE RESOLUTION (2008)1
2.1 Chemicals 
Do you have suggestions on what changes in the chemical recommendations would improve the safety of tattoo and PMU inks 
compared to those currently listed in the CoE ResAP(2008)1
2.2 Labelling
Do you have suggestions on what changes in the labelling recommendations would improve the safety of tattoo and PMU inks 
compared to those currently mentioned by the CoE ResAP(2008)1
2.3.1 Do you think a register of complaints/side effects would improve the safety of tattoo/PMU inks
2.3.3 How should the safety assessment be performed
2.3.4 In your opinion would a pre-marketing authorisation for tattoo/PMU inks be necessary to improve the safety
2.3 Safety assessment
2.4 Hygiene/sterility
Do you have suggestions on what changes in hygiene/sterility recommendations would improve the safety of tattoo and PMU inks
2.5 Other suggestions
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Audience
 National
 Local
Audience
 Targeted:
- tattoo artists/studios
- students
- military staff
- sports clubs
- music concerts participants
Means used
Printed material:
- Brochures
- Posters
- Advertisements
- Commercials
- Mix
Media coverage:
- Newspapers/Magazines
- Radio
- Television
Events held
Internet and social networks
 Addressed to tattoo artists
 Addressed to potential clients
 Media campaigns for general 
public
 Addressed to tattoo artists
 Addressed to potential clients
 Media campaigns for general 
public
 Awareness of prior aggravating 
medical condition
 Awareness of possible risks
 Awareness of risks of infection and 
disease transmission
 Risks related to the choice of 
tattooists (professional or not)
 Safety of premises and tools 
(sterility and hygiene)
 Permanency and risks 
associated to removal options 
What main sources of information 
was their perception based on:
 Parents
 Friends
 Media
What main sources of information 
was their perception based on:
 Internet
 Tattooists
 Physicians
 Inquiry about client's health status
 Information on risks, possible 
complications
 Post-treatment instructions
 Knowledge on what to do in 
case of problems
 Information on removal 
treatments, including their risks
3. RISK COMMUNICATION AND PERCEPTION
3.4 In your country, do the clients of tattoo parlours have to sign a prior informed consent
3.1 Did you carry out any information campaigns on tattoo/PMU practices in your country
3.2 Do you think an (additional) information campaign would help to improve the safety of tattoo/PMU
3.3 Do you have any information as to how the risk on tattoo/PMU procedures is perceived by the general public, or by the tattooed 
population
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 Better knowledge of inks' chemical 
composition and purity, ingredients' 
concentration
 Better knowledge of inks physical-
chemical properties (stability, shelf-
life)
 Data on normal usage of and 
exposure to tattoo inks (surface of 
application, body area, colour, 
population group)
 Guidelines for risk assessment
 Risk assessment of ingredients:
- Data on physical-chemical 
properties of ingredients (purity, 
impurities, auxiliary ingredients, 
stability, cleavage products)
 Risk assessment of ingredients:
- Toxicological data on ingredients 
(corrosion, irritation, phototoxicity, 
immunotoxicity, genotoxicity in 
vitro including test of cleavage 
products, photo-genotoxicity
- Absorption level, distribution, 
metabolism and excretion 
(ADME) of ingredients, including 
pigments migration in the body 
and photo-degradation
- Derivation of No Adverse Effect 
Level (NOAEL)
 Development and 
harmonization of analytical 
methods for tattoo/PMU inks 
(please indicate priority)
4.1 In your opinion what are the data gaps that deserve further research or technical development in order to improve the safety of 
tattoo/PMU inks and practices
4. DATA GAPS IDENTIFICATION
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Table A: Frequency of health issues amongst people having undertaken tattoo/PMU. 
 
Frequency: N= never, E= exceptional, R= rare, C= common, F= frequent na: not available 
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frequency
BE R R F C E R na E E R N C E N na E E R R R E na E na na na No data if viral infections are tattoo related
BG Only studios are controlled, not able to answer.
CZ na
DK No systematic official registration of negative 
effects from tattoos.
ES N N N N
FI R R N/E N/E
FR X X F X C X F
IT No register of complaints/side effects thus no data 
available on frequency.
NL F C E F R E R R C N R C R E E N N N N E N N E
RO na
SE R No requirements in legislation to report side-effects 
coupled to tattooing. 
SK
No information in this area. Only market 
surveillance for Tattoos notified through RAPEX - 
according national law.
HEALTH EFFECTS/TATTOO APPLICATION Q 1.1
Local Systemic
Acute side-effects Persistent side-effects Acute side-effects Persistent side-effects 
 76 
 
Table B: Frequency of health issues amongst people having undertaken tattoo/PMU removal. 
 
Frequency: N= never, E= exceptional, R= rare, C= common, F= frequent na: not available 
MS
p
a
i
n
b
l
i
s
t
e
r
i
n
g
p
i
n
p
o
i
n
t
 
b
l
e
e
d
i
n
g
c
r
u
s
t
i
n
g
u
r
t
i
c
a
r
i
a
l
o
t
h
e
r
f
r
e
q
u
e
n
c
y
l
o
c
a
l
 
(
p
h
o
t
o
)
 
a
l
l
e
r
g
i
c
 
r
e
a
c
t
i
o
n
s
s
y
s
t
e
m
i
c
 
(
p
h
o
t
o
)
 
a
l
l
e
r
g
i
c
 
r
e
a
c
t
i
o
n
s
s
c
a
r
s
h
y
p
e
r
-
 
a
n
d
 
h
y
p
o
p
i
g
m
e
n
t
a
t
i
o
n
i
n
k
 
r
e
t
e
n
t
i
o
n
 
a
n
d
 
d
a
r
k
e
n
i
n
g
o
t
h
e
r
 
f
r
e
q
u
e
n
c
y
BE C R C R E
All symptoms are 
considered as acceptable 
after laser tattoo removal
R E C C C/R
CZ na na
DK
No systematic official registration 
of negative effects from tattoos or 
removal from tattoo.
ES X N X Keloid R
FI na
In two cases reported 
scars and skin burns 
after applying do-it-
yourself-removalcream 
(Verruxin)
na
FR
No information. More and more 
questions regarding the status of 
tattoo removal products (and 
laser). Real problem because not 
under the scope of French 
legislation on tattoos. Real need for 
a harmonization and a common 
European status for these 
products.
NL F N E C N E E E C C E
SE na na
SK na na
HEALTH EFFECTS/TATTOO REMOVAL Q 1.2
Immediate skin reactions Delayed symptoms
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Table C: Correlation between health issues and tattoo characteristics. 
 
na: not available 
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BE Yes Yes na na YesRED
Yes
Exposed 
areas
Yes
Poor quality 
tattoos and 
scarring
Little 
tattooing 
under the age 
of 18!
CZ na
FI na X na na na na na
FR Yes
Strong 
suspicions 
concerning 
bad practices 
of tattooist
NL
Women; propably 
because women 
are currently more 
frequently tattood
Red 
(following 
black, blue, 
yellow)
Possibly 
sunlight-
exposed 
areas.
na
Sunlight 
exposure
SE na
SK na
HEALTH EFFECTS/CORRELATION Q 1.3
 Are the following factors correlated to higher frequency of medical complications?
MS
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Table D: Experience with the Council of Europe Resolution (2008)1 – Chemicals. 
 
 
Suggestion Rationale Suggestion Rationale Suggestion Rationale
DE Add Solvent Yellow 14
DK yes + aniline
and limit value of 10 ppm
The limit values are unnecessarily restrictive (low). 
For lead we suggest 10 ppm and for Bap 0,2 
ppm.
ES Revision Update: Add aniline Revision
Evaluate the following dyes, 
already mentioned for their 
possible toxicity: 45170.2 CI, 
CI 11741, CI 12390. CI 
73360, CI 12490, CI 11680.
Revision Update: Nickel content limit.
FI Should be taken into account Should be taken into account Should be taken into account
IT
Determination of further dangerous aromatic 
amines: qualitative screening revealed that 
other aromatic amines were not carcinogenic 
but toxic (aniline CAS n° [62-53-3], 2-
etoxianiline CAS n° [94-70-2] and IPPD CAS 
n° [101-72-4]) were found in certain samples. 
Extension of aromatic amines list in 
Resolution ResAP 
Introduction of concentration limits for AA in 
table 1 as provided for Benzo(a)Pyrene in 
table 3
Table 1 is not complete for 
different aspects
The use of the following colorants, in addition 
to the 35 listed in the CoE ResAP (2008)1, 
should be avoided: Pigment Violet 1; 
Pigment Yellow 74; Pigment Red 17; 
Pigment Red 181; Pigment Blue 15; Pigment 
Green 7; Pigment Red 5; Pigment Yellow 1.
Nowadays there aren’t 
enough evidences for the 
effective hazard of these 
colorants listed in the 
suggestion box.
The introduction of these 
colorants should be done 
after a verification study
• “Copper (Cu) soluble” to be defined.  
• Fix a maximum allowed concentration for Ni 
•Base actual limit on toxicological study
• Amend concentration limits for: As: 0.2 ppm; Co: 
5.0 ppm (labelling: ‘Contains cobalt; may cause 
an allergic reaction’); Pb: 1.0 ppm; Sb: 1.0 ppm; 
Ni: 0.5 ppm
• As use & quantities different, tattoo colours and 
PMU inks limits should be differentiated.
• Clarify list of single PAH classification for hazard 
or cancer risk, as provided for BaP 
(Benzo(a)pyrene).
Some unclear aspects in ResAP 
lead to controversy and are a 
problem for producers, importers, 
retailers and control authorities. 
General PAHs index does not 
clarify mixtures composition that 
need to be classified in terms of 
hazards and cancer risk.
NL
Nickel
PAH
Barium
• Nickel's allowed concentration to 
be clarified as different countries 
and labs give their own 
interpretation of this item. When 
Fe oxides used as pigments, Ni 
concentration higher. 
• Specify which PAH have to be 
chosen. 
• Barium – in art. 2 BaSO4 
specified; not in accordance with 
Ba requirement of 50 mg/kg.
SI Nickel (Ni)
Setting maximum allowed 
concentration based on risk 
assessment and technical ability
EXPERIENCE WITH THE COUNCIL OF EUROPE RESOLUTION (2008/1) Q 2.1a
CoE ResAP(2008)1, Table 1 CoE ResAP(2008)1, Table 2 CoE ResAP(2008)1, Table 3
Chemicals
MS
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Suggestion Rationale Suggestion Rationale Suggestion Rationale Suggestion Rationale
DE Yes
DK Yes
ES
Include 
updated 
website 
CMR 
substances 
in list
To facilitate knowledge 
and consultation of 
manufacturers and 
authorities.
FI
Should be 
banned in 
tattoo colours 
Is continuously changing. 
Same level of safety should 
be required when 
chemicals are injected into 
the skin as with chemicals 
on the skin.
Not relevant as risk is 
assessed only for skin 
contact and not inside skin. 
Should be 
banned
The CLP-classification 
as a CMR substance 
triggers a lot of 
consequences in other 
legislations and should 
be taken into account in 
restrictions on tattoo inks
FR Yes
IT Yes Yes
NL (Yes)
EXPERIENCE WITH THE COUNCIL OF EUROPE RESOLUTION (2008/1) Q 2.1b
MS
Chemicals
Colorants specified in Annex IV, 
column g of EC Regulation 1223/2009 
on Cosmetics
CMR substances classified under 
categories 1A, 1B and 2 in Table 3.1 
of Annex VI to EC Regulation 
1272/2008 on Classification, 
Labelling and Packaging
Requirements for further 
organic impurities for 
colorants used in 
foodstuffs and cosmetic 
products as set out in 
Directive 95/45/EEC
Ingredients mentioned in Annex II to 
EC Regulation 1223/2009 on 
Cosmetics
 80 
 
  
 
 
Suggestion Rationale Suggestion Rationale
BE Yes Safety garantee Yes Easier
DE Yes Best way to ensure consumer protection; negative lists cannot be 
exhaustive. No
Cross references lists mirror the actual state of regulation; otherwise 
changes in other areas would have to be regularly incorporated into 
tattoo regulation.
FI
Not easy to establish. Would be 
good to establish but needs time 
and ressources
Wide number of ingredients can be carcinogenic according to the 
WHO
FR Yes
Positive lists ideal and more understandable for operators. But needs 
updating according to other regulations evolution. Given lack of human 
resources, this option is impossible to follow.
IT
Italy would favourably consider 
positive lists of colorants, but there 
are positive elements and 
negative elements to be taken into 
account (see Rationale column).
A positive list of colorants means that each substance is 
associated with a very accurate risk assessment dossier that would 
be stable over time. But random tests would be needed to check 
the composition of inks. It is easier that substances not properly 
investigated, could result to further study toxic or carcinogenic. So 
the negative list should be periodically updated. Negative lists 
speed up controls: check label to assess ink composition and 
absence of banned components. Negative lists allows producer to 
avoid components that should not be present in the ink formulation. 
Yes
NL
The Netherlands is in favour of an 
exhaustive list of substances 
proved safe for this use under  
specified conditions 
List should be supported by safety assessments from competent 
bodies and harmonised at the European level.
SE
A EU-COM scientific committé 
performs the examination of 
colorants and safe colorants are 
listed on a positive list 
• Easier for companies to check the ingredient list/documentation 
to make sure their tattoo colors only contain permitted colorants. 
• The companies would have to invest less time choosing  colorants 
and evaluating their safety, however they must ensure that their 
tattoo color do not exceed limitations for contaminants found in 
table 3 Resap2008.
No. Instead we suggest a single 
positive list of colorants in tattoo 
legislation  instead of reference to 
appendix IV colorants in  
regulation (EU) nr 1223/2009 on 
cosmetics
Companies can easily check forbidden colorants in table 2 Resap2008. 
But with the current cross reference to appendix IV regulation (EU) nr 
1223/2009, such company could be tempted to choose those colorants 
and think that they are automatically safe to use in tattoo colours. But 
these colorants are evaluated for cosmetic use and not for injection 
through the skin. Furthermore, there are no requirements that 
substances listed in this appendix IV should be re-evaluated once they 
have been put in such annexes.
SI Yes Positive list of colorants based on risk assessment provides more 
safety Yes Would be easier
SK positive list of colorants Positive list of colorants better to increase consumer safety
Establish positive lists of colorants Single lists of chemicals (e.g. colorants, aromatic amines, impurities) instead of cross references lists
Chemicals
MS
EXPRIENCE WITH THE COUNCIL OF EUROPE RESOLUTION (2008)1 Q 2.1c
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Suggestion Rationale Suggestion Rationale
BE Absolutely
All products forbidden in cosmetics should be 
banned from tattoo inks and all products (ea 
preservatives) in tattoo inks should have the same 
limits of concentration as drugs used for injection 
in the body
It is logical that products injected in the 
body should be as safe as food or 
products in contact with the skin
DE Yes Better comparability of results. Guidance values for technically unavoidable 
amounts.
Guidance for manufacturers and market 
surveillance authorities.
DK Yes We recommend a safety assessment
ES Agree Need to have harmonized analytical methods to compare results.
FR
Establishing a European consensus on the status 
of tattoo removal products.
IT
More information strongly needed for Table 3 
elements: 
• sample preparation (maximum allowed 
concentrations for product as such or dry 
substance; or analysis of part or entire amount of 
an element present in sample)
• can the microwave-assisted acid digestion be 
applied
• How to make extraction for “Copper (Cu) 
soluble”
• PAH and BaP 
• AA (because the concentration of sodium 
dithionite (the reductive agent) could influence the 
AA cleavage from the pigment).
The described unclear aspects in the ResAP 
are a great problem for producers, importers, 
retailers and control authorities
NL The method of NVWA
According the resolution 2008(1) preservatives 
should only be used after a safety assessment. 
Therefore a positive list of conservatives is 
SE
There would be optimal for the analysis of the 
hazardous chemicals in tattoo inks (powders and 
solutions) if there are harmonized methods, 
aimed for this group of product. Further, methods 
for the determination of the impurities (eg primary 
aromatic amines, residual organic solvents, 
softeners like phthalate, heavy metals) of the 
tattoo inks that are relevant for the safe use of 
tattoo inks should, if possible, also be 
harmonized.
The analytical methods that are commonly 
used for the qualitative and quantitative 
determination of the hazardous chemicals, 
mainly aromatic amines, in tattoo inks  (eg EN 
14362, part 1 , 2 and 3) are aimed for azo 
colorant in textiles, while the determination of 
PAHs are often carried out by the ZEK 01.2-
08 method GC-MS, which is harmonized by 
GS - "Geprüfte Sicherheit" mark bodies.
SI Yes Comparability
SK
Harmonise analytical methods for testing tattoos 
and PMU
Harmonisation of methods will be helpful for 
market control activities
Chemicals
Harmonise analytical methods for testing hazardous chemicals Other
EXPERIENCE WITH THE COUNCIL OF EUROPE RESOLUTION (2008/1) Q 2.1d
MS
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Table E: Experience with the Council of Europe Resolution (2008)1 – Labelling. 
 
Suggestion Rationale Suggestion Rationale Suggestion Rationale Suggestion Rationale
BE As for cosmetics Yes Yes Yes
DE Yes
Sterility is difficult 
to maintain after 
opening; PAO 
indicates period 
of safe use after 
opening. 
No
Qualitative 
composition 
should be given to 
inform consumers 
(as suggested by 
ResAP 2008).
No
Date of minimum 
durability suffices 
(as suggested by 
ResAP 2008).
Yes
If specific storage 
conditions are 
necessary.
DK Yes
Yes
List to begin with "Ingredients"; 
listed in descending order 
according to weight when 
added to ink; concentration < 
1% not listed (unless classified 
as skin sensitiser); use 
international nomenclature 
(INCI, EINECS or ELINCS ) - if 
substance not found then ISO 
or IUPAC names; for dyes use 
Colour Index (CI) Constitution 
Numbers and the container’s 
nominal amount (nominal mass 
or nominal volume)
Yes
Wording "May not be used after ..." 
should be placed before the expiry date 
clearly stating either 'month and year' or 
'day, month and year'.
If necessary, the conditions under 
which the shelf life can be 
maintained may be stated.
ES
In addition to the PAO, include the 
following sentence: "the sterility of the 
contents is guaranteed for X 
applications"
For more safety. Yes
For added safety 
and information 
for users and 
authorities.
yes Yes
FI Yes Yes Yes Yes
FR Present in national legislation Present in national legislation Present in national legislation
IT Yes Yes Yes Yes
NL Yes Datasheet with concentration of 
all relevant parameters Yes
SI Yes
Should be 
supplemented by 
an indication of 
conditions which 
must be satisfied 
to guarantee the 
stated PAO
Yes
To provide safe 
storage after 
opening
SK PAO for non-single-use packaging
Irrelevant for 
single-use 
packaging
Not required
It depends of form 
of labelling date of 
durability, please 
see Other
Required It is required for 
safety of products
LABELLING Q 2.2a
PAO (period of durability after opening) Quantitative composition of inks (decreasing 
order of concentration for each ingredient) Date of production Storage conditions
MS
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Suggestion Rationale Suggestion Rationale Suggestion Rationale Suggestion Rationale Suggestion Rationale
BE Yes Yes Yes Yes
DE Yes
Consumer information. 
However, technical 
differences are small.
No
Name and address of 
manufacturer, importer 
or person responsible for 
placing on the market 
should be given (as 
suggested by ResAP 
(2008)1)
Yes Useful in case of allergy, if known No
Guaranteed sterility (as 
suggested by ResAP 
2008).
DK
The manufacturer's and 
the importer's (if for 
resale) company name 
and address.
The batch number of 
manufacture or reference  
to identify the tattoo ink.
ES Yes
Yes
Address of distributor in 
the EU and manufacturer 
if a third country.
Yes
It is not necessary to 
indicate the 
manufacturing method
FI Yes Yes
Identification of the 
manufacturer and a 
batch number
FR Present in national legislation
IT The products could be labelled differently
Considering the different 
use and injected 
quantities, the products 
could be separated in 
two different categories
Address of the person 
responsible for placing 
the product on the 
market 
They may be included in 
a separate document
The declaration of 
sterility should specify 
the sterilization method 
and be accompanied by 
technical/ analytical 
documents
It is a useful tool for 
surveillance authorities
The label should be 
written in the language of 
the country in which it is 
marketed
The label must be easily 
understood by the final 
client.
NL Preferably phone 
number 
SE
Such labeling 
requirements could help 
avoid the usage of inks 
that is not supposed to 
be injected like drawing 
inks
Sweden has noticed that 
drawing inks are 
sometimes used by 
tattooist’s for injection 
even though such colors 
should not be injected 
because it endangers 
consumers health
The Swedish legislation 
on tattoo colors requires 
name and address of the 
manufacturer if outside 
Sweden
Name and address of 
the manufacturer is 
useful during market 
surveillance (if help is 
needed from authorities 
abroad) and when 
performing Rapex-
notification
The Swedish legislation 
says that a tattoo color is 
considered sterile if it 
fulfils European 
Pharmacopeia about 
sterility
The Swedish legislation 
requires that the tattooist 
gives the following 
information (printed form 
or electronically using e-
mail) to the consumer 
immediately after being 
tattooed:
• Name of the tattoo 
colour
• Ingredient list
• Batch-number
• Name and address of 
distributor or 
manufacturer in Sweden 
+ name and address of 
foreign manufacturer
If doctors / patient / 
consumers know which 
colours had been used 
for injection, they could 
inform authorities or 
doctors in the case of 
side-effects that would 
then help researchers 
studying health effects.
SI Yes
About possible allergic 
reactions, phototoxicity, 
other health effects 
(infection, keloid,..)
SK Not required Not required
Information only relevant 
for specialists. No list of 
sterilisation methods for 
tattoos and PMU.
Date of minimum 
durability- can be used 
symbol (sand-glass) 
which is used for 
cosmetics and 
medicines.
For simplification
MS Type of product: tattoo colour/PMU ink Address of distributor
LABELLING Q 2.2b
Health warnings Sterilization method Other
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Table F: Experience with the Council of Europe Resolution (2008)1 – Safety assessment. 
 
MS A register of complaints/side effects would improve the safety of 
tattoo/PMU inks?
How should the safety assessment be 
performed?
Would a pre-marketing authorisation for tattoo/PMU inks be 
necessary to improve the safety?
BE
1.It would give a better view on the number of side effects and offer more info for 
researcher to focus on specific problems.
2. It would give the authorities a better view on the weak points in tattoo parlors, 
border control, distribution etc
 
If the requirements are clear and sufficient to guarantee safety  and if they 
are respected by the producers premarketing authorisation is not 
necessary
CZ
Yes
It should be based on the resolution resap(2008)1
DE
Yes
A “tattoovigilance” system would be helpful to track undesirable effects and take 
appropriate measures. 
For each ingredient (helpful, if effect can be 
traced back to a specific ingredient) and for the 
final product
A pre-marketing authorisation would guarantee a high level of consumer 
protection. However, there are still data gaps that need to be filled. A 
compulsory safety assessment to be commissioned by manufacturers, 
importers or persons responsible for the placing on the market and 
performed by qualified persons is a step towards safer products. 
ES
Through a form that that could be filled by dermatologists, users, professionals or 
those responsible for the placing on the market. Final product
Yes
In Spain a process of authorization is required prior to marketing, which 
includes an evaluation of the safety of products and of labels.
FI
Similar kind of notifications as in Article 23 of the Cosmetics Regulation (SUE 
notifications) Final product NA
FR
Yes
Vigilance of tattoo products not specifically addressed by the CoE ResAp 2008. 
France has established a national vigilance system of tattoo products in 2008 to 
monitor the risk of side effects from the use of tattoo products that are available on 
the market.
In the French notification form, it is requested to 
indicate the composition of the colorants in the 
product.
No
The spirit of the resolution of the Council of Europe and the French 
legislation, is that the responsibility to place tattoo products on the market 
is supported by the responsible person.
IT
Yes
A register of complaints/side effects is a useful tool to acquire information about 
the extent and the frequency of complications and side effects. It could be 
correlated with the inks used, to provide traceability.
Each and final ingredients.
The simultaneous presence of more ingredients 
may give an amplified or a different effect 
compared to the single ingredient one.
Yes
It would improve the safety: the long contact time of the ink in the body 
could be considered similar to that of implantable devices.
NL
• Stimulation from the consumer side for ‘good work practices’ 
• Side effects/complaints should be included in an ‘informed  consent’ form people 
should sign before taking a tattoo.
Final product YesIt will probably improve the transparency
SE
• Requirements for reporting side-effects should be discussed before a discussion 
about a register. 
• Side-effects could be caused by for example hygiene issues or a harmful tattoo 
colour. 
• Even if the tattoo colour fulfils the legislation the consumer might react to the tattoo 
colour getting a side-effect. 
• Even if the side-effect is reported it is not easy for the authority to decide what 
have caused the side effect. 
• In Sweden also different authorities control the tattoo colours and the hygiene at 
the tattooist.
Final product
No
Authorities should guide companies on how to fulfil the legislation. An pre-
marketing approval of tattoo colours would demand a lot of resources, but 
such authorisation could be financed through fees from the companies.
SI
No
But a register of complaints/side effects would improve public and tattoo artist 
awareness about health risks.
Both (if a register would be set) YesIf a tattoo/PMU ink is not safe, it is not placed on the market
SK
Reports about serious undesirable effect of inks (e.g. the same way like SUE of 
cosmetics, can be used IC SMS system (The internet-supported information and 
communication system for the pan-European market surveillance)
Final product Yes
SAFETY ASSESSMENT Q 2.3
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Table G: Experience with the Council of Europe Resolution (2008)1 – Hygiene/sterility. 
 
Inks Tools Studio Dose Other
BE
1.Materials should be sterile. The sterilisation 
method should be adapted to the material. (ea 
ink and tools will be sterilised in a different way)
2. single dose units (although the best guarantee 
for sterility) are utopy and not practical for 
tattooist; Sterile products and limited duration of 
use (PAO) is more realistic.
DE
Or multi use containers with a 
design that ensures that the 
contents will not be contaminated 
during the period of use. 
DK Yes Yes
ES Yes Yes
In Spain the use of single-dose 
containers is recommended to 
ensure the sterility of each 
application. Multidose containers 
are accepted for a maxiumum 
content of 30ml , guaranteeing the 
sterility of each application.
In Spain  tattoo/PMU parlors are regulated by the 
regional authority. In particular, methods of 
disinfection and sterilization of instruments are 
listed .
FI No
FR Yes Yes Yes Yes
IT
It is necessary to identify 
the most effective 
sterilizing method for inks.
It could be referred to 
the harmonized 
standards concerning 
the validation of 
sterilization methods 
applicable to medical 
devices.
Regarding "parlor 
premises" it should be 
more appropriate 
referring to sanitization 
and disinfection.
preferentially single use, if 
technically possible.
SE
The Swedish legislation 
says that a tattoo color is 
seen sterile if it fulfils 
European Pharmacopeia 
about sterility
SI
hygiene and sterility 
recommendations are good, but 
use of single dose containers 
should be enhanced because of 
difficulties in keeping ink sterility 
after opening
SK Yes Yes Yes e.g. Good Application Practices for tattoo artists
Do you have any suggestion on how to improve safety of tattoo/PMU inks?
YES
HYGIENE Q 2.4
NOMS
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Table H: Experience with the Council of Europe Resolution (2008)1 – Other suggestions. 
 
 
 
 
 
 
 
 
 
 
Suggestion Rationale Suggestion Rationale Suggestion Rationale Suggestion Rationale Suggestion Rationale Suggestion Rationale Suggestion Rationale
BE Absolutely
Fakes and 
unsafe 
origin
Yes Yes Yes Yes Yes Border control
Import in one EU 
country means free 
transport allover EU
CZ More comprehensive 
and binding 
DE Yes
Market 
surveillance 
should 
include web 
sales.
In Germany the need 
for dual vocational 
training must be 
presented to the 
Federal Ministry for 
Economic Affairs 
Yes
Production 
conditions 
are essential 
for safe 
products.
ES Yes To improve 
safety Yes
In Spain there is 
a close 
collaboration 
with 
manufacturers 
to register tattoo 
inks and 
permanent 
Yes
They should 
be banned as 
they do not 
guarantee the 
proper 
sanitary 
conditions
Yes
A certificate issued 
by regional 
authorities is 
required in Spain
Yes
To improve 
manufacturin
g conditions
FI
Difficult due to 
the limits of 
jurisdictions 
and powers of 
the authorities. 
Can be done 
on national 
level only.
Yes
Qualified yes - 
Finland already 
has legislation on 
safety of the 
consumer 
services. Though 
surveillance of 
homemade 
tattoos is nearly 
impossible.
na na Yes
OTHER SUGGESTIONS Q 2.5a
MS Control web sales Collaboration Ban backyard List of recognised Compulsory training for tattooists Set GMP for inks Other
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Suggestion Rationale Suggestion Rationale Suggestion Rationale Suggestion Rationale Suggestion Rationale Suggestion Rationale Suggestion Rationale
FR
In France, the regulation 
indicates that tattoo artists 
should attend training in 
hygiene and sanitary. An 
order of the Minister of 
Health determines the 
categories of institutions 
and organizations 
authorized by the State 
representative in the region 
to deliver this training, and 
the contents thereof and 
diplomas accepted by the 
equity method.
Yes
In France, there 
is an order 
regarding the 
GMP for tattoo 
products (Arrêté 
du 15 
septembre 
2010)
IT
Harmonisation 
of surveillance 
procedures 
within the EU 
in order to 
prevent the 
sale of fake 
inks
Problems related 
with the presence of 
fake inks of 
unknown origin on 
the market.
Yes See next item
Definition of a 
uniform professional 
profile for  tattooists.
Institution of a 
national register of 
licensed tattooists 
on the basis of an 
European standard
Protect 
clients, 
preventing 
illegal 
tattooist 
and 
backyard 
tattoing
Harmonize 
tattooist training, 
with the aim to 
guarantee the 
same performance 
and reliability all 
over EU.
Ensure a minimum level of 
skill.
Ensure uniform criteria for 
the definition of the 
professional requirements 
for tattooists.
Yes
Sterilisation: As the scientific 
literature on the subject is insufficient, 
Italy proposes a working group to 
validate ink sterilization methods and 
procedures. It is necessary to identify 
an effective sterilization method.There 
is no common regulation about age 
limits.  
An age limit should be seriously 
considered at European level. It 
should be forbidden to perform 
tattoos under the age of 14. 
Performing tattoos under the age of 
eighteen would be possible only with 
the informed consent of the parents or 
guardian.
Microbiological  
analysis show that 
some sealed  inks, 
marketed as sterile on 
the label, are 
contaminated. These 
results elicit doubts 
about che 
effectiveness of the 
sterilization 
procedures. Minors do 
not have a full 
awareness of the 
risks. 
SE
In Sweden 
tattoists/PMU-artists 
have to notify their 
business to the local 
authorities. Lists of 
such companies 
may be extracted 
from our 290 local 
authorities
Sweden think 
obligatory training 
regarding hygiene 
is a good 
suggestion
SI Yes
A the moment there 
are no control 
measures for web 
sales
Most problematic 
tattoo inks and 
permanent make-up 
colorants are 
probably sold via 
web sites
Yes Pre - 
autorisation Yes
Most health 
problems are 
probably 
associated 
with backyard 
tattooing
Better control 
of hygiene 
and sterility 
Yes Better 
control Yes
Better knowledge of 
tattooists about safe 
practices
Yes
Good 
manufacture 
practices would 
improve the 
safety of tattoo 
and PMU inks
SK prepare EN 
standard
OTHER SUGGESTIONS Q 2.5b
MS
Control web sales Collaboration Ban backyard List of recognised tattooists Compulsory training for tattooists Set GMP for inks Other
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Table A: Complication following tattoo/PMU application. 
 
 
 
 
 
 
<1w 1w-1m 1m-1y >1y Uncertain <1w 1w-1m 1m-1y >1y Uncertain
BE-1 yes yes 50 6000 <1% <1% <1% 10% 10% 20-30% >30%
BE-2 yes no 1 5000
BE-3 yes yes 10 2700 50% 50% 30% 30% 30%
BE-4 yes yes 2 200
DE-1 yes no 10 1200 80% 80%
DE-2 yes no 2-6 6000 50% 50% 50% 50%
DE-3 yes yes 0 30-50
DE-4 yes no 3 6000 70% 30% 50% 50%
DE-5 yes yes 15/300 6000 35% 20% 45% 10% 15% 25% 20% 30%
DK-1 yes no 1-2 10000 X X
DK-2 yes 0-1 1200 X X
DK-3 yes yes 5 50 X
DK-4 yes yes 2-5 50 50% 50% 100%
DK-5 yes yes 150+ 5000 90% 10% 5% 25% 40% 25% 5%
FI-1 yes no na na 80-90%10-20% 10%
NL-1 yes no 4-5 ? 50% 50% 10% 70% 20%
NL-2 no no 2 3500 100%
NL-3 yes no 75 7500 30% 60% 10%
SE-1 yes no 4 2000 50% 50%
90%
Interval between application and onset of symptoms
Infectious complications Non-infectious complicationsMS
Number of 
tattoo 
complications
Interest in 
tattoos/PMU 
complications
Removals 
performed
Number 
patients/year
COMPLICATIONS Q 1.1-1.3
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Frequency (F): N= never, E= exceptional, R= rare, C= common, F= frequent. Grade (G): L=light M=moderate S=severe. na: not applicable 
 
 
 
 
s
c
a
l
i
n
g
h
y
p
e
r
k
e
r
a
t
o
s
i
s
u
r
t
i
c
a
r
i
a
a
l
l
e
r
g
i
c
 
r
a
s
h
f
l
u
 
i
t
c
h
F G F G F G F G F G F G F G F G F G F G F G F G F G F G F G F G F G F G F G F G F G F F F G F G F
BE-1 E L C M F S E M R L R L C M E M F F R E E L N N N N
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Frequency: N= never, E= exceptional, R= rare, C= common, F= frequent 
 
 
 
 
 
 
 
 
NA
Pollen Sarcoidosis Eczema
BE-1 R C N N N E R N N N
BE-2 N N N N N N N N N N N
BE-3 R E
BE-4 E N N N N N E E N N N
DE-1 F F F R R R C N R E
DE-2 C C E N N E E N R N
DE-3
DE-4
DE-5 C R E E E E E E E E
DK-1 X C N N N N N N N N N
DK-2
DK-3
DK-4 R E R N N N N E R N
DK-5 C C E E R E R R R N R
FI-1 E X
NL-1 R R E R E E R R E E
NL-2 N N N N N N N N N N N N
NL-3 R N N R N C  N NA R R
SE-1 R R E R R 50% of 
cases 
Other
Other skin 
diseases
COMPLICATIONS 1.6
Vitiligo
Other diseases
Previous known allergies/skin diseases
Allergy
MS
Wart 
OtherAtopic or 
contact 
dermatitis
Allergy to 
metals 
Allergy to 
para-
phenylen
diamine
Allergy to 
latex
Allergy to 
preservatives
Allergy to 
medical 
drugs
Urticaria
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Frequency: N= never, E= exceptional, R= rare, C= common, F= frequent 
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COMPLICATIONS Q 1.7-1.8
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Table B: Complication following tattoo/PMU removal. 
 
Frequency: N= never, E= exceptional, R= rare, C= common, F= frequent. na: not available 
  
 
 
 
 
Infection
BE-1 20 6000 C E R E E R C E QS Lasers (ND-Yag 1064,532, Alexandrite 755)
BE-2 0 5000
BE-3 20 2700 E E E E N N N N N N Q Switched 1064/532 nm
BE-4 2 200 R E E E E N R E R E Trivantage Alexandriet 1064/755 2mm/3mm
DE-1 na na na na na na na na na na na
DE-2 na na na na na na na na na na na
DE-3 0 30-50 C E R CR E 0 0 0 0 Revlite si cynosure (ND:YAG laser)
DE-4 na na na na na na na na na na na Rubin Laser
DE-5 5/300 6000 F R C C N N R R E N ERB YAG - LASER
DK-1 0 10000
DK-2 0 0
DK-3 5 5 na N N N N F F
DK-4 2-3 600 F C R R E E C C E ND:YAG laser
DK-5 3 20 F F C C R R N F F C
Some Q-switched Yag but most 
complications come from low cost 
lasers. In the hospital only apply Q-
switched Yag.
FI-1 0 0
NL-1 ? ? C R C C R E R R E na
NL-2
NL-3 5 7500 C N N N N N C N N
SE-1 0 2000
Other
2. COMPLICATIONS FOLLOWING A TATTOO/PMU REMOVAL Q 2.1-2.3
MS
Acute symptons Delayed symptons
UrticalCrustingPin-point bleedingBlisteringPain
ink 
retention 
and 
darkening
Other
Technique/instrument used
Number 
patients/y
ear
Number of 
complications 
linked to 
tattoo 
removals
(photo) 
allergic 
reactions
Scars hyper- and hypopigmentation
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Table C: Correlation between health complications and tattoo characteristics. 
 
Frequency: N= never, E= exceptional, R= rare, C= common, F= frequent 
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BE-2 F R E N E C E C F F E C E R R R C C C R N C
BE-3 F C E N N N F F R E E F E F F R N E E E N N N R R C F E N E F F F R R E E
BE-4 X X X F R E R R R E N R R R F R E N R X
DE-1 C C C C C C E N E E E N E R C C C E E E N
DE-2
DE-3 X F F F R E F R F F C E C E F E E R F F F F R E R X
DE-4 F F F
DE-5 F F F C R R F F C R F R F F R F F F R F F C R E C C F F F R E F R F F F C R
DK-1 C C N C N C C C C C N C N N C C R C C R E C C R R E R R
DK-2 X X X X C C C X
DK-3 R C R C C N C N C C R R R R C X
DK-4 R R C C F R C C C F R C C R C R F C F E R R C F F R N F F C N F E N
DK-5 R C C C C R C C R R F C F F C F F F R R R F R F F F F F F F E F F R R C R C
FI-1 X F N N N C C C C F F R C N R N N F X F R
NL-1 C C E E E E E E C E C C E E
NL-2 1 1 1 1 1 1 F C N C R C N R C C C C R N C X
NL-3 C C C R E E F C E N F E F C E F F F E E E C E E R F E F R E N F F C R N N N
SE-1 C C R C C R C C R C C R R C R R
MS
Procedure
3. CORRELATIONS BETWEEN HEALTH COMPLICATIONS AND CERTAIN TATTOO CHARACTERISTICS/PARAMETERS Q 3.1-3.6
Number of tattoos Tattoo size Gender/age Colours Localisation
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Table A: Adverse health effects: allergy/inflammation. 
 
[55], [107], [108], [18], [109], [43], [65], [110], [69], [111], [112] 
  
Reference Country 
of study Sample size
Study 
covered 
years
Age range 
(Years)
Time of onset after 
tattooing
Colour/Location/
Gender Incidence rate Minor symptoms <3 months
2015, Hutton-Carlsen DK 40 (34 Females, 6 Males)
Sept-Nov 
2012
Mean age: 
33
2015, Høgsberg DK 19 2009-2011 18-52 Average 3 months
Red nuances (red, 
pink, purple, 
bordeaux)
2012, Fors SE 2000-2004 15-23
2010, Klügl DE 3411 (Internet 
survey)
July 2007-
March 
2008 
Immediately to 4 weeks 
after tattooing
67.5% transitory skin problems; "moderate” in 10% 
of cases and “intense” to “very intense” in 1.8%. 4 
weeks after tattooing, 9% still had health problems, 
6% persistent skin effects: oedema, itching, papules 
and scarring; 6.6% systemic 
reactions:dizziness,headache, nausea or fever;  
1.3% reported burning and itching of tattooed skin 
when exposed to sun. 3% stated psychic problems 
and light sensitivity of  tattoo
Bleeding, crusts, itching edema and pain, followed by 
burning sensation, blister formation  
2010, Wenzel DE 6 weeks to several months
Pigment Red 181 
(CI73360). 
Female, PMU
2009, Mataix Multi
Delayed allergic 
reactions:weeks-years after 
tattooing (difficult to 
classify); they may last 
years despite treatment
Acute inflammation lasting for 1 to 2 weeks.
2008, Ali Saba US 1 31
10 years after tattooing 
(incubation period=3-20 
years)
2008, De Cuyper Multi Rare Swelling and crusting may persist for a few days; 
swelling or burning when undergoing MRI
2007, Kazandjieva BG 234
Overall prevalence of skin complications = 2.1% (5 
of 234 cases), including infections and 
allergic/granulomatous complications
Immediate (after few hours) inflammatory reaction 
always appears;  transient symptoms at the site of 
tattoo (swelling, heating,skin irritation) in small n° of 
patients (< 10) after magnetic resonance imaging
2006, Teixeira 1 30 1 day
PMU: black 
eyelash and 
eyebrow dye
2003, Bhardwaj US 1 38 Red (Patchy red 904A)
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LIC+ECZ: Lichenoid and eczematous reaction. SRC+FBD: Cutaneous Sarcoidosis and Foreign body reaction 
[55], [107], [113], [44], [108], [18], [109] 
Reference
LIC+ECZ (linked 
to SRC & 
Granuloma)
SRC+FBD  (linked to 
Granuloma)
Systemic 
sarcoidosis
Pseudolymphomatous 
reactions Contact Dermatitis 
Plaque 
Elevation
Ulceration/
Necrosis
Papulo-
nodular 
inflammatory 
Reactions  
(non specific)
Anaphylactic 
reaction
Fibro-
Scleroderma 
(scars)
Reactivation of 
Underlying 
Dermatoses
Dermatofibroma Other
2015, Hutton-
Carlsen
Quality of life evaluation according to the Itch Severity 
Scale (ISS) and the Dermatology Life Quality Index 
(DLQI). The ISS has been used to evaluate patients 
with pruritus, genital pruritus and nephrogenic pruritus 
as well as atopic dermatitis, psoriasis and urticaria, 
which revealed ISS scores from 7.4-13.4. Patients 
with tattoo reactions revealed an average ISS score 
of 7.2. The DLQI has also been utilized on patients 
with hand eczema, pruritus and neurodermatitis with 
scores from 8-13.3. Tattooed patients DLQI score 
was 7.4 
2015, Høgsberg
6 cases; The 
granulomatous 
pattern has been 
found on a 
background of 
interface dermatitis
14/19 cases of interface 
dermatitis. 1/19 cases 13/19 cases
14/19 Patients were patch tested with European 
standard because suspected to be allergic. 5/14 
resuted allergic towards potassium dichromate, 
fragrance mix, hydrocyisohexyl-3-cyclohexene-carbon-
xaldehyd, sorbic acid, cobalt chloride and nickel 
sulphate. 11/19 were patch tested with a textile series 
consisting of 42 dispersed dyes. Two reacted with 
reactions to red and orange dyes.
13/19 patients were patch tested with a selection of 
eight problematic stock tattoo ink products. One 
patient reacted against the red and yellow inks.
2014, Huynh
2013, Juhas Reported Reported  Reported Reported Reported Reported Less common 
Koebner 
phenomenon in 
preexisting 
psoriasis, 
systemic lupusand 
sarcoidosis 
Following trauma or 
coincidence Vasculitis 
2012, Fors
The study is not directly 
related  to adverse effect of 
tattooing practice. It tries to 
correlate the effect of 
lifestyle (for instance the 
presence of a tattoo) with 
nickel allergy by patch 
testing some volunteers. 
Conclusion is that in 
comparison with not 
tattooed people, tattooed 
boys showed a 3-fold and 
girls almost 2-fold increase 
in Nikel allergy by patch test. 
2010, Klügl
0.7% (n=3411) 
complained of 
“elevated skin"
0.4% (n=3411) 
complained of 
“skin papules”
2010, Wenzel
3/4 resulted positive to prick 
test of both PMU colorant 
and CI 73360 (red). 1 
patient declined prick test. 
Patch test negative in all 
cases. 
Granulomatous, lychenoid and pseudolymphomatous reactions represent the most common 
dysimmune reaction and may be the direct result of the tattooing practice.
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[114], [115], [43], [65], [110], [69], [111], [112] 
Reference LIC+ECZ (linked to SRC & Granuloma)
SRC+FBD  (linked to 
Granuloma)
Systemic 
sarcoidosis Granuloma
Pseudolymphomatous 
reactions Contact Dermatitis Photoallergy
Plaque 
Elevation
Papulo-
nodular 
inflammatory 
Reactions  
(non specific)
Fibro-
Scleroderma 
(scars)
Reactivation of 
Underlying 
Dermatoses
Other
2009, Bocca
Granulomatous reaction can be 
induced by pigments containing 
Al and Ti
Reported a case of skin 
hypersensitivity caused by the 
presence of Co in the blue ink 
used for tattoo; Hg contained 
in some tattoo red dyes is 
reported to produce a delayed 
hypersensitivity reaction
2009, Forte
Granulomatous reaction can be 
induced by pigments containing 
Al and Ti; Sarcoid granulomas 
developed in a black area of a 
tattoo; patch test positive to Ni, 
Co, Cd. Analysis of pigment 
revealed the presence of Ni 
and Co. Acute dermatitis 
overlaying a granuloma has 
been reported at the site of a 
violet tattoo.
Eryhemathous 
papules 
scattered within 
a black area
2009, Mataix
Lichenoid reactions 
are the most 
common type of 
tattoo reaction, with 
lesions that are 
clinically and 
histologically similar 
to lichen planus.
Granulomatous reactions 
reported in association with 
chromium, mercury, cobalt,and 
magnesium; Less common, 
sarcoid granulomas may be 
non specific but can also be an 
early  manifestation of 
systemic sarcoidosis.
Indurated, erythematous, 
violaceous nodules 
confined to the tattoo, 
mainly described for red 
pigment tattoo but also  for 
green and blue pigments.
Eczematous lesions confined 
to the tattooed area, with 
occasional secondary spread; 
patch test inconclusive;
UV-induced 
erythematous oedema 
most often caused by 
yellow and red Cd-
containing
pigments.
Koebner 
phenomenon in 
association with 
sarcoidosis, 
pyoderma 
gangrenosum, 
and cutaneous 
lupus 
erythematosus.
2008, Ali Saba
Intermittent swelling, blistering, 
burning, confined to brown 
areas of tattoo;
edematous papules with 
surrounding erythema 
Known hilar 
lymphadenopathy
2008, De 
Cuyper
Foreign body 
epitheloid granuloma 
after cosmetic 
eyebrow tattooing. 
Frequent
Eyelid necrosis, 
loss of eyelashes, 
and secondary 
cicatricial
ectropion, 
hypertrophic scars, 
and keloids 
2007, 
Kazandjieva
Lichenoid reactions 
more often to the red 
pigment.
Single cases (Days to months) Single cases (Days to months) Always in the red areas of the tattoo Single cases (Days to weeks)
Single cases: After 
sun exposure and 
cadmium in sufficient 
amount in tattoo dye 
(yellow)
Single cases: 
Psoriasis (10 d-
30 y) 
Lichen planus, 
Lupus 
erythematosus 
chronicus 
discoides (always 
in the red areas of 
the tattoo)
2006, Teixeira
Positive patch results to: p-
phenylendiamine both at 0,1 
and 1%, Disperse red 17, 
disperse red 1, disperse 
orange 3, disperse orange 1 
and dye as it has been used. 
Allergy manifested as intense 
itching, erythema, swelling and 
exudation.
Important: the 
permanent eyelash 
used contained p-
phenylendiamine.
2003, Bhardwaj
Patch test positive for "Patchy 
Red 904A" both on normal 
skin and on scar tissue after 
tattoo removal
Swelling 
and itching 
confined to 
the red 
areas
 99 
 
Table B: Correlations among tattoo characteristics and adverse health effects. 
 
[55], [107], [44], [18], [114], [115], [43], [110], [69] 
 
 
 
 
Reference BLK COLOR RED OR VL BG WH Trunk Head
2015, Hutton-
Carlsen 5 1
2015, Høgsberg 1
2013, Juhas Anaphylactic 
reaction
Pseudolymphomatous  
lichenoid and 
granulomatous 
reactions
Pseudolymph
omatous  
reactions
Pseudolymphomatous  
reactions
2010, Klügl
Slightly more 
short-term skin 
or systemic 
reactions
2009, Bocca
Cinnabar and Vermilion 
contain Hg which is 
known to produce 
delayed hypersensitivity
Al and Ti were detected by 
microscopic examination 
of excised tumor in the 
violet areas of a tattoo.
Co containing tattoo ink caused 
skin hypersensitivity
2009, Forte
Sarcoid granulomas developed in a 
black area of a tattoo; patch test 
positive to Ni, Co, Cd. Analysis of 
pigment revealed the presence of 
Ni and Co; erythema tous papules 
originating from "India Ink"
Cinnabar and Vermilion 
contain Hg which is 
known to produce 
delayed 
hypersensitivity. In the 
preent work Cr is the 
predominant metal in 
ink composition wile 
other metals reported 
giving strong allergic 
reaction (Hg, Ni and 
Cd) did not reach µg/g 
level.
Al and Ti were detected by 
microscopic examination 
of excised tumor in the 
violet areas of a tattoo. 
Large amount of Mn was 
fount in the biopsy 
specimen of a granuloma 
at the site of a violet tattoo. 
In the present work Mn 
was not analysed, but 
analysis of violet ink 
revealed high contents of 
Cr and Ni
Co contained as component or 
impurity is reported to cause 
urticaria; Ti (linked to 
granulomatous reactions) found 
in a commercial available blue 
ink: Co, when present in blue 
dyes, is reported being cause 
of deep granulomas and 
urticarial syntomps. Green may 
contain Cr which is deemed to 
cause eczemathous reactions. 
Hg and Cr have been found at 
high concentration in the 
present work.
From Ti or ZnO. In 
the present work, 
Ni was the 
prevailing metal 
followed by Cd. 
Traces of Cr and 
Co were 
observed.It could 
potentially contain 
other metallic 
derivatives. µg/g 
concentartion was 
never reached. 
2009, Mataix
Red inks, particularly if 
containing Hg, are the 
most common causes 
of delayed
allergic reactions.
2008, De Cuyper
Red inks, containing 
Hg, cause
lichenoid reactions.
2007, Kazandjieva
 case of sarcoid granulomas 
developing
in blue-black tattoo reported
 Case of sarcoid granulomas 
developing
in blue-black tattoo reported
M
34
12
6
7
GENDERCOLOUR LOCATION
Extremities
35
18 (arms=6, legs=11, 
foot=1)
Crusts, itching, edema and systemic 
health problems directly after tattooing 
slightly more frequent in females.
After 4 weeks,health problems were 
graded as more severe by females; 7.3% 
(n=3411) reported persistent skin 
problems. Solar sensitization and psychic 
problems more frequent in young people 
(not gender related)
4.2 % (n=3411) reported 
persistent skin problems. Solar 
sensitization and psychic 
problems more frequent in young 
people (not gender related)
F
 100 
 
Table C: Adverse health effects: infections. 
 
[98], [116], [117], [118], [119], [42], [120], [121], [46], [122], [123], [18], [72], [110], [69], [124], [125] 
2015, Mudedla Multi 114 2003 -2013 Within 4 to 6 weeks (majority of 
cases), up to 6 months after tattoo 
2014, Gulati US 1 48 Female, tattoo on the back Home made tattoo
2013, Falsey 3 Jan-Mar 2012
First papules appeared 7-21 day after 
tattoo placement. New papules 
developed in the subsequent 1-4 
months
2012, Kennedy Rochester, NY. US 19 Oct-Dec 2011 18-48 Within 3 weeks Premixed grey ink
2012, Morbidity and 
Mortality weekly report 
(CDC)
US: New York (refers to 
2012, Kennedy), 
Washington. Iowa and 
Colorado
Washington, cluster 1: 27  
Washington, cluster 2: 4 
Iowa:2 Colorado: 1
2011-2012
Washington, cluster 1: Black  
Washington, cluster 2: Grey 
Iowa:Back Colorado: Black
2012, Tohme Multi 1994-2011
2011, Giulieri CH 12 2009-2010 56 Range 2-7 weeks Female, with PMU
2011, Rodriguez-Blanco ES 5 (plus 2 suspected but not 
analysed)
Sept 2008-April 
2009 18-23 3 to 30 days Grey
2011, Urbanus NL 375 tattoed persons among total 434 interviwed. 23-37
2010, Bechara FR (Brazilian man) +internet 
review 1 + review (36 patients) 51
10 days after tattoo (review: 1 w.- 3 
months)
2010, Drage US 6 Oct 2007-May 2008 20-49 1-2 weeks
Grey (by water dilution of 
black ink)
2010, Klügl DE 3411 (survey)
2010, Pérez-Cotapos
Depends on the hygienic 
conditions under which the 
procedure was carried out, 
and the expertise of the 
tattooist
2008, De Cuyper LASER/PMU
2007, Kazandjieva BG 234
Overall prevalence of skin 
complic. = 2.1% (5 / 234 
cases), including infections 
and 
allergic/granulom.reactions
2006, Morbidity and 
Mortality weekly report 
(CDC)
US
34 primary cases, 10 
secondary cases. The 
persons with secondary 
cases were exposed to 
persons with primary cases 
by direct contact because 
they were living in the same 
house or had close personal 
contact. 
Jun 2004- Aug 
2005 15-42 4-22 days among all 34 primary cases
73% male, 27% female. 
Outbreaks was reported in 
three different states: 
Kentucky, Ohio and Vermont
During interviews, 13 
unlicenced tattooist were 
identified. 7 tattoist were 
located and interviewed. 
Adherence to some infection 
control measures were not 
practiced. 
2005, Porter NZ 2 45 and 29 years old within 2 days
Both cases of Samoan 
tattoing, performed in 
unlicensed premises by 
temporary tattooist
Colour/Location/Gender Tattoo ApplicationReference Country of study Sample size Study covered years
Age range 
(Years) Time of onset after tattooing
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[98], [126], [116], [113], [117], [118], [37], [42], [120], [121], [46] 
Incidence rates Pyogenic NTM Other Hepatitis B and C Other
2015, Mudedla unknown
Unspecific erythematous papules, 
pustules, and nodules, predominantly 
within the borders of tattoos, generally the 
gray part; Chelonae  most common 
cause; contamination occurs through 
unsterile instrumentation or tap water 
used for diluting tattoo ink.
2014, Fowler
This paper cites a number of reports of 
cutaneous Mycobacterium Chelonae 
infections in immunocompetent hosts due 
to subcutaneous inoculation with 
contaminated tattoo ink
2014, Gulati
Same ink and equipment were used by 
her husband who also developed IPA due 
to Staphylococcus aureus.  
Iliopsoas abscess due to Staphylococcus 
aureus 
2014, Huynh
A predominance of warts among a 
variety of opportunistic infections may 
result from a local immune 
disregulation (rather than from direct 
inoculation or coincidence) caused by 
tattooing practice.
2013, Falsey
2 different inks (A and B), from 2 different 
companies (A and B) arose concerns. 
Company A reported receiving 35 
complaints of unusual skin reactions to 
brand A ink. Company A had identified a 
single batch of ink that was associated 
with these complaints and voluntarily 
issued a recall. Company B declined to 
provide ingredients or sources of inks, 
and denied receiving any complaints. 
Nevertheless, no NTM was recovered 
from brand A ink samples; brand B ink 
samples obtained from the tattoo artist 
grew M. chelonae indistinguishable from 
patient 1’s
An health alert was sent out  and an investigation 
was initiated.  2 tattoo artists involved were 
contacted and interviewed. This investigation 
revealed  2 unlinked clusters of NTM infections. 
Cluster A comprised 27 infections, all tattooed by 
the same artist by using the same bottle of brand 
A black ink. Three of these infections were 
confirmed by biopsy and culture; the remaining 
infection swere suspected. Cluster B comprised 4 
infections (2 confirmed through biopsy and 
culture), all of whom were tattooed by using the 
same bottle of brand B gray wash ink. No 
infections were identified among either artist’s 
clients tattooed with previous or subsequent 
bottles of ink.
Tissue culture grew nontuberculous 
mycobacteria (NTM) in all cases. 
Speciation from patient 1 revealed 
Mycobacterium chelonae; speciation in 
patients 2 and 3 revealed Mycobacterium 
abscesuss
2012, Kennedy Premixed grey ink from 1 company
14 confirmed                                                                  
4 probable                                                                  1 
suspected
chelonae, giving the pathologic evidence 
as papules, pustules
2012, Morbidity and 
Mortality weekly report 
(CDC)
Total of 3 companies. Washington cl 2 
and Iowa cases used ink from the same 
company.
Washington, cl 1: 3 confirmed and 24 possible                
Washington, cl 2: 2 confirmed and 2 possible 
Iowa: 2 confirmed  Colorado: 1 confirmed 
Washington, cl 1: Abscessus                
Washington, cl 2: Chelonae              Iowa: 
Chelonae  Colorado: Chelonae  Always 
giving the pathologic evidence as 
papules, pustules
2012, Tohme (included 
in 2013,Carney)
No evidence for an increased risk of HCV infection in 
professional parlors.
2011, Giulieri
All procedures were performed by the 
same artist. Microbiological investigation 
of oil and cold sterilising agents were 
negative. Direct examination of 18 inks 
resulted negative. Nevetheless 6/18 
samples, broad-spectrum PCR resulted 
positive for Mycobacterium haemophilum
Index patient presented with skin lesion 
of the eyebrow and ipsilateral 
lymphadenitis. Mycobacterium 
haemophilum was identified by 
sequencing. 11 additional patients with  
lesion of the eyebrow and ipsilateral 
lymphadenitis were identified. 10/12 had 
microbiological diagnosis of M. 
Haemphilum. For the remaining 2 
diagnosiswas based on clinical 
presentation.
2011, Rodriguez-
Blanco
Chelonae giving the pathologic evidence 
as skin lesions
2011, Urbanus
375 people bearing at least one tattoo (median number 
5, median body surface 18%) have been tested for anti-
HBc and HCV. The study population included both 
tattoo related variables (number of tattoos, % of body 
tattoed, being a tattoo artist, have had a tattoo in a 
HBV endemic country) and tattoo-unrelated variables ( 
HBV vaccination, being born in HBV endemic country,  
residence, snorting drugs). NONE OF THE TATTOO-
RELATED VARIABLES WERE SIGNIFICANTLY 
ASSOCIATED WITH HBV. As for HCV, only 1 
participant resulted infected. The participant was a 
tattoo artist who received a tattoo more than 100 times 
and reported several other risk factors, including 
needel-stick accidents. 
375 people bearing at 
least one tattoo 
(median number 5, 
median body surface 
18%)
Reference % contaminated inks Bacterial Viral
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[122], [123], [18], [72], [43], [110], [69], [124], [125] 
 
 
 
 
 
Incidence rates Pyogenic NTM Other Hepatitis B and C AIDS Other
2010, Bechara 
RGM rarely documented after tattoo, 
but in progression; M.abscessus :1st 
case published
M.abscessus:
 erythematous papulo-
pustula, limited to the colored
parts of tattoo;symptoms:pruritus, 
tenderness 
2010, Drage Grey ink used by the same artist at a 
single establishment
5 confirmed                                                           
1 suspected
chelonae, giving the pathologic evidence 
as papules, pustules
2010, Klügl 0,50% Bacterial skin infections (pus-filled skin 
areas)
2010, Pérez-Cotapos
Bacterial infections are more 
common following piercing than 
tattooing procedures. The most 
frequent are local bacterial infections 
at the site of the procedure.
1) Often Streptococcus pyogenes and 
Staphylococcus aureus
2) Severe secondary infections have 
been reported such as erysipelas, 
cellulitis, sepsis, and spinal abcesses, 
either due to Streptococcus pyogenes 
, Staphylococcus aureus , or 
Pseudomonas species 
3) outbreak of Mycobacterium 
chelonae infection in 6 patients 
tattooed by same tattooist
Different types of viral 
infections can be 
transmitted. Papiloma 
virusinduced warts , 
Mollusca contagiosa, 
herpes simplex , blood-
transmitted diseases 
such as hepatitis and 
HIV
2009, Mataix Incidence diicult to determine Relatively common 
Isolated cases of skin 
infection caused by the 
human papilloma virus 
and molluscum 
contagiosum
Increase in 
systemic 
infections due to 
bacteria that gain 
access to the 
body via tattoos.
2008, De Cuyper Bacterial superinfection is
rare
Through nonsterile
equipment and needles
2007, Kazandjieva 
Impetigo, Acne varioliformis, Ecthyma: 
Usually located in tattooed area (First few 
days)
Historical: Tetanus, 
Chancroid,Tuberculosis cutis, Lepra, 
Syphilis (onset from weeks to years) 
Reported Reported
Only few cases: 
Verruca, Molluscum 
contagiosum 
(Incubation: weeks to 
months)
Single cases: 
Zygomycoses 
(After years), Tinea 
cutis glabrae (After 
weeks)
Toxic shock 
syndrome 
2006, Morbidity and 
Mortality weekly report 
(CDC)
A primary case of tattoo-associated 
Methicillin-resistant Staphylococcus aureus 
(MRSA) skin infection was defined as a skin 
infection consistent with staphylococcal 
infection (e.g., boil, folliculitis, erythema, or 
abscess) that occurred near or at the site of 
a recent tattoo in a person from whom a 
culture from that site yielded MRSA. A 
secondary case was defined as a skin 
infection consistent with staphylococcal 
disease that occurred in a person who had 
not received a recent tattoo but had been in 
close contact with an MRSA patient who had 
received a tattoo. A total of 34 primary 
cases and 10 secondary cases were 
identified in the three states.
2005, Porter
Samoan tattoo equipement was analised 
in one case and grew various quantities 
of mixed Gram + organisms.Most 
extensive growth came from ink and 
yellow pigment.
Streptococcus pyogenes and 
Staphylococcus aureus were  grew in both 
cases. In one case Preudomonas 
aeruginosa was grew as well. Tissue 
cultures also grew Corynebacterium species 
and Klebisella oxtoca in the second case.
Bacterial infection caused skin 
necrosis septic shock that led to death 
in one case. 
Septic shock 
registered in both 
cases
Septicaemia
Epidemiologically, the risk factor of HIV/ hepatitis C virus e 
transmission through tattoo  is not  statistically relevant.
Reference % contaminated inks Bacterial Viral Fungal
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Table D: Adverse health effects: tumours. 
 
[107], [127], [18], [128], [129], [130], [131], [69], [132], [70] 
 
 
 
 
 
 
 
Reference Country of 
study Sample size
Study 
covered 
years
Age range 
(Years)
Time of onset after 
tattooing Colour/Location/Gender
2015, Høgsberg DK 19 2009-2011 18-52 Average 3 months Red nuances (red, pink, purple, bordeaux)
2014, Soran US 1 73
2010, Klugl DE 3411 (survey)
2009, Dos Santos Gon BR 1 60 4 months woman
2009, Kürle DE 1 22
Female. Tattoos on the 
right ankle, right groin and 
coccyx.
2009, Lee KR 1 (plus 7 already 
reported in the past)
60 (other 
cases from 
28 to 74) 
3 years (other cases from 
1 to 46 years)
Black PMU on left 
eyebrow. Woman
2008, Goldenberg US 1 38 1 month
2007, Kazandjieva BG 234
2006, Birnie 28 6 years Black,/central back/Female
2005, Baker UK 1 35 7 years
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[107], [113], [127], [18] 
 
 
 
 
 
 
 
 
 
 
 
Frequency Keratocanthoma (KA) 
Pseudolymphoma 
(PSL) Frequency
Basal cell 
carcinoma (BCC) 
Squamous cell 
carcinoma (SCC) Melanoma (MEL) Other
2015, Høgsberg
6 cases: 
pseudolymphomato
us infiltration pattern  
has been found on a 
background of 
interface dermatitis
2014, Huynh
2014, Soran
2010, Klugl 0.1% (all male, n=3411)
Tattooing   causes difficulties in assessing a sentinel lymph node 
biopsy specimen because the pigment can mimic metastatic 
disease and thus provide a challenge for surgeons and pathologists. 
Sentynel limph node biopsy was performed to stage a ductal 
carcinoma in situ (NOT NECESSARILY RELATED TO THE 
PRESENCE OF THE TATTOO). Intra-operatively four colored nodes 
were harvested, labeled and sent separately for histopathology. The 
first and third nodes were hot with technetium 99 and contained blue 
dye staining, the second node was blue in color and the fourth axillary 
SLN was palpable only. The pathology report of the lymph nodes 
revealed that all  axillary SLN were free of tumor. In addition, the 
second axillary SLN which was grossly blue/black in color 
haextracellular anthracotic pigmentation and pigment-laden 
macrophages. 
Reference
Benign tumours Malignancies
Lymph nodes
BCC, SCC and MEL may result from the local dysimmune reactions 
triggered by tattooing
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[128], [129], [130], [43], [131], [69], [132], [70] 
  
Frequency Keratocanthoma (KA) 
Pseudolymphoma 
(PSL) Other tissue reactions Frequency
Basal cell 
carcinoma (BCC) 
Squamous cell 
carcinoma (SCC) Melanoma (MEL)
2009, Dos Santos Gon
Keratocanthoma 
confirmed by 
histological 
analysis
2009, Kürle
Noticed at first as 
brownish-black skin 
lesion noticed in the 
region of the right 
thigh, then confirmed 
by hisological 
analysis.
Black pigmented  lymph node found 
negative at histological analysis.   
2009, Lee 8 cases reported in the literature over 33 years
Confirmed by 
histopatologic 
findings
2009, Mateix Purely coincidental 5 cases cited 7 cases cited 3 cases cited 12 cases cited
2008, Goldenberg
The case reports a 
superficially invasive 
squamous cell 
carcinoma, 
keratocanthoma type 
(in the form of 
erythematous 
hyperkerathotic 
papules)
2007, Kazandjieva 5 cases reported 
Single cases (no 
proof for a link with 
tattoo)
6 cases reported
2006, Birnie
Basal cell carcinoma 
of no special type 
confirmed by 
hystology, 
manifesting as 
asymptomatic nodule
2005, Baker
This is reported as the first 
case of 
dermatofibrosarcoma 
protuberans occurring in a 
decorative tattoo
Dermatofobrosarcoma 
protuberans has an 
intermediate grade of 
malignancy. It is 
reported being locally 
aggressive and rarely 
methastatic. In this case 
it manifested as 
cutaneous nodule.
Reference
Benign tumours Malignancies
Lymph nodes
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